0000357097-16-000179.txt : 20160804 0000357097-16-000179.hdr.sgml : 20160804 20160804080615 ACCESSION NUMBER: 0000357097-16-000179 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 63 CONFORMED PERIOD OF REPORT: 20160630 FILED AS OF DATE: 20160804 DATE AS OF CHANGE: 20160804 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Fibrocell Science, Inc. CENTRAL INDEX KEY: 0000357097 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 870458888 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-31564 FILM NUMBER: 161805864 BUSINESS ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 484-713-6000 MAIL ADDRESS: STREET 1: 405 EAGLEVIEW BOULEVARD CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: ISOLAGEN INC DATE OF NAME CHANGE: 20020320 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /DE DATE OF NAME CHANGE: 19960330 FORMER COMPANY: FORMER CONFORMED NAME: AMERICAN FINANCIAL HOLDING INC /CO DATE OF NAME CHANGE: 19921008 10-Q 1 fcsc063016form10q.htm FORM 10-Q Document


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549 
 ___________________________________________________________________
FORM 10-Q
 
x Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended June 30, 2016
 
OR
 
o         Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 ___________________________________________________________________

Commission File Number 001-31564
Fibrocell Science, Inc.
(Exact name of registrant as specified in its Charter)
Delaware
 
87-0458888
(State or other jurisdiction of incorporation)
 
(I.R.S. Employer Identification No.)
405 Eagleview Boulevard
Exton, Pennsylvania 19341
(Address of principal executive offices, including zip code)
(484) 713-6000
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for any shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes ý  No o
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
    Yes ý  No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer o
 
Accelerated filer o
 
 
 
Non-accelerated filer  o
 
Smaller reporting company  x
(Do not check if a smaller reporting company)
 
 
 
Indicate by check mark whether the registrant is shell company (as defined in Rule 12b-2of the Exchange Act)     Yes o  No ý
As of July 29, 2016, there were 43,898,785 outstanding shares of the registrant’s common stock, par value $0.001.
 



TABLE OF CONTENTS
 
 
 
 
PAGE
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
_____________________________

Unless the context otherwise requires, all references in this Form 10-Q to the “Company,” “Fibrocell,” “we,” “us,” and “our” include Fibrocell Science, Inc. and its subsidiaries.

Trademark Notice
Fibrocell®, Fibrocell Science®, the Fibrocell logo and LAVIV® are trademarks of Fibrocell Science, Inc. (Exton, PA). All other trademarks, service marks or trade names appearing in this Form 10-Q are the property of their respective owners.



NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Form 10-Q contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, among others, statements relating to:
•
our expectation that our existing cash resources will be sufficient to enable us to fund our operations into the fourth quarter of 2016;
•
our plans to address our capital requirements and the consequences of failing to do so;
•
our expectation to dose the first subject in the Phase I portion of our Phase I/II clinical trial of FCX-007 at the end of 2016 and to have three-month data for the adult subjects in the Phase I portion of the trial in the second half of 2017, as well as six-month data for a cohort of this group;
•
the anticipated submission of an Investigational New Drug application (IND) for FCX-013 to the United States Food and Drug Administration (FDA) in 2017;
•
expected costs associated with the wind-down of azficel-T (including LAVIV) operations at our Exton, PA facility including future cash expenditures to decommission our azficel-T manufacturing facility and to terminate and wind-down our contractual and other obligations relating to our azficel-T operations, as well as potential non-cash charges related to future impairments of the carrying values of inventory and equipment used in our azficel-T operations;
•
future expenses and capital expenditures;
•
our product development goals under the collaboration that we entered into with Intrexon Corporation (Intrexon) in December 2015;
•
the potential benefits of orphan drug and pediatric rare disease designations; and
•
the potential advantages of our product candidates and technologies;
as well as other statements relating to our future operations, financial performance and financial condition, prospects, strategies, objectives or other future events. Forward-looking statements appear primarily in the sections of this Form 10-Q entitled “Item 1—Financial Statements,” and “Item 2—Management’s Discussion and Analysis of Financial Condition and Results of Operations.” In some cases, you can identify forward-looking statements by words such as “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing,” “scheduled” and similar expressions, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based upon current expectations and assumptions and are subject to a number of known and unknown risks, uncertainties and other factors that could cause actual results to differ materially and adversely from those expressed or implied by such statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in this Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015 (2015 Form 10-K) and in particular, the risks and uncertainties discussed under the caption “Item 1A—Risk Factors”. As a result, you should not place undue reliance on forward-looking statements.

Additionally, the forward-looking statements contained in this Form 10-Q represent our views only as of the date of this Form 10-Q (or any earlier date indicated in such statement). While we may update certain forward-looking statements from time to time, we specifically disclaim any obligation to do so, even if new information becomes available in the future. However, you are advised to consult any further disclosures we make on related subjects in the periodic and current reports that we file with the Securities and Exchange Commission (SEC).

This Form 10-Q also contains estimates, projections and other information concerning our industry, our business, and the markets for certain diseases, including data regarding the estimated size of those markets, and the incidence and prevalence of certain medical conditions. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances reflected in this information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from reports, research surveys, studies and similar data prepared by market research firms and other third parties, industry, medical and general publications, government data and similar sources.

1

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
Fibrocell Science, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
($ in thousands, except share and per share data)

 
June 30,
2016
 
December 31, 2015
Assets
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
8,161

 
$
29,268

Inventory, net
109

 
482

Prepaid expenses and other current assets
636

 
1,244

Total current assets
8,906

 
30,994

Property and equipment, net of accumulated depreciation of $1,401 and $1,242, respectively
1,546

 
1,582

Intangible assets, net of accumulated amortization of $0 and $2,204, respectively
—

 
4,136

Other assets
64

 
—

Total assets
$
10,516

 
$
36,712

Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
553

 
$
499

Related party payable
924

 
10,720

Accrued expenses
1,253

 
1,779

Deferred revenue
408

 
457

Warrant liability, current
5

 
1,910

Total current liabilities
3,143

 
15,365

Warrant liability, long term
759

 
6,365

Deferred rent
785

 
779

Total liabilities
4,687

 
22,509

Stockholders’ equity:
 

 
 

Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares outstanding as of June 30, 2016 and December 31, 2015
—

 
—

Common stock, $0.001 par value; 150,000,000 shares authorized, 43,898,785 shares issued and outstanding as of June 30, 2016; 100,000,000 shares authorized, 43,898,785 shares issued and outstanding as of December 31, 2015
44

 
44

Additional paid-in capital
162,555

 
161,330

Accumulated deficit
(156,770
)
 
(147,171
)
Total stockholders’ equity
5,829

 
14,203

Total liabilities and stockholders’ equity
$
10,516

 
$
36,712

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


2

Fibrocell Science, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
($ in thousands, except share and per share data)

 
Three Months
Ended June 30,
 
Six Months
Ended June 30,
 
2016
 
2015
 
2016
 
2015
Revenue from product sales
$
73

 
$
55

 
$
85

 
$
168

Collaboration revenue
14

 
82

 
18

 
163

Total revenue
87

 
137

 
103

 
331

Cost of product sales
392

 
77

 
409

 
221

Cost of collaboration revenue
—

 
85

 
1

 
88

Total cost of revenue
392

 
162

 
410

 
309

Gross (loss) profit
(305
)
 
(25
)
 
(307
)
 
22

Research and development expense
2,352

 
2,567

 
4,954

 
4,814

Research and development expense - related party
925

 
1,127

 
2,249

 
2,867

Selling, general and administrative expense
2,540

 
3,640

 
5,280

 
6,564

Intangible asset impairment expense
3,905

 
—

 
3,905

 
—

Restructuring costs
292

 
—

 
292

 
—

Operating loss
(10,319
)
 
(7,359
)
 
(16,987
)
 
(14,223
)
Other income (expense):
 
 
 

 
 
 
 
Warrant revaluation income (expense)
2,254

 
602

 
7,511

 
(1,061
)
Other expense
(31
)
 
—

 
(31
)
 
—

Interest income
4

 
1

 
8

 
3

Loss before income taxes
(8,092
)
 
(6,756
)
 
(9,499
)
 
(15,281
)
Income tax benefit
—

 
—

 
—

 
—

Net loss
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
 
 
 
 
 
 
 
 
Per Share Information:
 
 
 
 
 
 
 
Net loss:
 
 
 
 
 
 
 
     Basic
$
(0.18
)
 
$
(0.17
)
 
$
(0.22
)
 
$
(0.37
)
     Diluted
$
(0.18
)
 
$
(0.17
)
 
$
(0.26
)
 
$
(0.37
)
Weighted average number of common shares outstanding:
 

 
 

 
 
 
 
     Basic
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

     Diluted
43,898,785

 
40,889,732

 
43,934,819

 
40,875,704

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


3

Fibrocell Science, Inc.
Condensed Consolidated Statement of Stockholders’ Equity
(unaudited)
($ in thousands, except share data) 

 
Common Stock
 
Additional paid-in capital
 
Accumulated deficit
 
Total Equity
 
Shares
 
Amount
 
 
 
Balance, December 31, 2015
43,898,785

 
$
44

 
$
161,330

 
$
(147,171
)
 
$
14,203

Cumulative effect from adoption of new accounting standard (Note 3)
—

 
—

 
100

 
(100
)
 
—

Stock-based compensation expense
—

 
—

 
1,125

 
—

 
1,125

Net loss
—

 
—

 
—

 
(9,499
)
 
(9,499
)
Balance, June 30, 2016
43,898,785

 
$
44

 
$
162,555

 
$
(156,770
)
 
$
5,829

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


4

Fibrocell Science, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
($ in thousands) 
 
Six Months Ended June 30,
 
2016
 
2015
Cash flows from operating activities:
 

 
 

Net loss
$
(9,499
)
 
$
(15,281
)
Adjustments to reconcile net loss to net cash used in operating activities:
 

 
 

Stock-based compensation expense
1,125

 
1,044

Warrant revaluation (income) expense
(7,511
)
 
1,061

Depreciation and amortization
391

 
346

Provision for (recovery of) doubtful accounts
(12
)
 
(1
)
Inventory reserve
151

 
—

Intangible asset impairment
3,905

 
—

Loss on disposal or impairment of property and equipment
65

 
—

Decrease (increase) in operating assets:
 

 
 

Accounts receivable
12

 
2

Inventory
222

 
87

Prepaid expenses and other current assets
728

 
549

Other assets
(64
)
 
—

Increase (decrease) in operating liabilities:
 
 
 
Accounts payable
(3
)
 
1,061

Related party payable
(9,796
)
 
(338
)
Accrued expenses and deferred rent
(518
)
 
599

Deferred revenue
(49
)
 
84

Net cash used in operating activities
(20,853
)
 
(10,787
)
Cash flows from investing activities:
 

 
 

Purchase of property and equipment
(143
)
 
(111
)
Net cash used in investing activities
(143
)
 
(111
)
Cash flows from financing activities:
 

 
 

Payment of deferred offering costs
(109
)
 
—

Proceeds from the exercise of stock options
—

 
255

Principle payments on capital lease obligations
(2
)
 
(2
)
Net cash (used in) provided by financing activities
(111
)
 
253

Net decrease in cash and cash equivalents
(21,107
)
 
(10,645
)
Cash and cash equivalents, beginning of period
29,268

 
37,495

Cash and cash equivalents, end of period
$
8,161

 
$
26,850

 
 
 
 
 
 
 
 
Supplemental Cash Flow Disclosures:
 
 
 
Non Cash Investing and Financing Activities:
 
 
 
Property and equipment in accounts payable
$
46

 
$
—

Deferred offering costs in accounts payable
$
11

 
$
—

 
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


5
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)


Note 1. Business and Organization

Organization

Fibrocell Science, Inc. (as used herein, “we,” “us,” “our,” “Fibrocell” or the “Company”) is the parent company of Fibrocell Technologies, Inc. (Fibrocell Tech). Fibrocell Tech is the parent company of Isolagen International, S.A., a company organized under the laws of Switzerland (Isolagen Switzerland). The Company’s international activities are currently immaterial.

Effective April 1, 2016, Fibrocell Science Hong Kong Limited (“Fibrocell Hong Kong”), a company organized under the laws of Hong Kong and former subsidiary of Fibrocell, was dissolved. As this entity had no historical financial or operational activities, the impact of the dissolution did not, and is not expected to have, a material impact on the Company’s present or future consolidated financial statements.

Business Overview

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. The Company is focused on discovering and developing therapies for the localized treatment of diseases affecting the skin and connective tissue. All of the Company’s product candidates incorporate its proprietary autologous fibroblast technology. The Company’s research and development efforts focus on gaining regulatory approvals of its product candidates in the United States.

Liquidity and Financial Condition

The Company expects to continue to incur losses and will require additional capital to advance its product candidates through development to commercialization. As of June 30, 2016, the Company had cash and cash equivalents of approximately $8.2 million and working capital of approximately $5.8 million. The Company believes that its cash and cash equivalents at June 30, 2016 will be sufficient to fund operations into the fourth quarter of 2016. The Company will require additional capital to fund operations beyond that point. To meet its capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. These conditions raise substantial doubt about its ability to continue as a going concern. Consequently, the audit report prepared by the Company’s independent registered public accounting firm related to its Consolidated Financial Statements for the year ended December 31, 2015 included a going concern explanatory paragraph.
Note 2. Basis of Presentation

General

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (2015 Form 10-K), filed with the Securities and Exchange Commission (SEC). The Company’s significant accounting policies are described in the Notes to Consolidated Financial Statements in the 2015 Form 10-K and updated, as necessary, in Note 3 in this Form 10-Q. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year.

All intercompany accounts and transactions have been eliminated in consolidation. The Company's international operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.

6
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 2. Basis of Presentation (continued)

Reclassifications

The prior year Condensed Consolidated Financial Statements presented in this Form 10-Q contain certain reclassifications made to the Condensed Consolidated Statement of Operations and the Condensed Consolidated Statement of Cash Flows to conform to the current year’s presentation. Specifically, related party payables were reclassified from accounts payable and accrued expenses as of June 30, 2015.
Note 3. Summary of Significant Accounting Policies

Intangible Assets

Intangible assets are research and development assets related to the Company’s primary study on azficel-T that were capitalized on the balance sheet upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identifiable intangible assets was $6.3 million. Azficel-T had two current or target indications: the Company's FDA-approved product LAVIV® and a clinical development program for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Effective January 1, 2012, the Company launched LAVIV and as a result, the research and development intangible assets related to the Company’s primary study were considered to be finite-lived intangible assets and began amortizing over 12 years, the estimated useful life of the assets which is analogous with the exclusivity period granted to the Company under the BLA.

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews the estimated remaining useful life of its intangible assets on an annual basis with any changes, if applicable, accounted for prospectively. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Impairment or Disposal of Long-Lived Assets, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In June 2016, based on its failure to achieve primary efficacy endpoints for its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring, the Company determined to wind-down its azficel-T operations as more fully described in Note 9. As a result, management concluded that the Company’s intangible assets had become fully impaired. Accordingly, a non-cash impairment charge of approximately $3.9 million was recorded during the three months ended June 30, 2016 and is included in the Condensed Consolidated Statement of Operations.

Stock-Based Compensation

The Company follows ASC 718, Compensation – Stock Compensation (ASC 718), or ASC 505-50, Equity – Equity Based Payments to Non-Employees, where applicable. The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. In addition, the Company accounts for stock-based compensation to non-employees in accordance with the accounting guidance for equity instruments that are issued to entities or persons other than employees. The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected term of the options. The value of the award that is ultimately expected to vest based on the achievement of a performance condition (i.e., service period) is recognized as expense on a straight-line basis over the requisite service period. See Note 7 for additional details.

Previously, ASC 718 required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. In the first quarter of 2016, the Company adopted FASB Accounting Standards Update (ASU) 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures when they occur. In connection with the adoption of this ASU, the Company made an accounting policy election to account for forfeitures as they occur and applied this change in accounting policy on a modified retrospective basis. As a result, the Company recorded a cumulative-effect adjustment to retained earnings which resulted in an increase to accumulated deficit of $0.1 million with an offsetting

7
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 3. Summary of Significant Accounting Policies (continued)

increase to additional paid-in capital (zero net total equity impact) as of the date of adoption, principally related to additional stock compensation expense that would have been recognized on unvested outstanding options unadjusted for estimated forfeitures.

Restructuring Costs

Restructuring charges are primarily comprised of severance costs related to workforce reductions, contract termination and wind-down costs, asset impairments and costs of decommissioning the Company’s azficel-T manufacturing facility. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company recognizes restructuring charges when the liability has been incurred, except for one-time employee termination benefits that are incurred over time. Generally, one-time employee termination benefits (i.e. severance costs) are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments. Other costs, including but not limited to, contract termination and wind-down costs and manufacturing facility decommissioning costs, will be recorded as incurred. Asset impairment charges have been, and will be, recognized when management has concluded that the assets have been impaired in accordance with ASC 360-10-35, Impairment or Disposal of Long-Lived Assets, or other applicable authoritative guidance. See Note 9 for additional details.

Income Taxes
    
In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.  For the six months ended June 30, 2016 and 2015, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses.  The Company has not recorded its net deferred tax asset as of either June 30, 2016 or December 31, 2015 because it maintains a full valuation allowance against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of June 30, 2016 and December 31, 2015, the Company had no uncertain tax positions.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had or is expected to have a material impact on the Company’s present or future consolidated financial statements.
Note 4. Inventory
    
Inventories consist of raw materials and work in process intended for use in the manufacture of LAVIV, which was approved by the FDA in 2011 for the improvement of nasolabial fold wrinkles in adults. However, raw materials may be used for clinical trials and are charged to research and development (R&D) expense when consumed for such activities.
Inventories consisted of the following as of:
 
($ in thousands)
June 30, 2016
 
December 31, 2015
 
 
Raw materials (LAVIV and product candidates)
$
71

 
$
338

 
Work in process (LAVIV)
189

 
144

 
Total inventory, gross
260

 
482

 
Less: Reserve for work in process expiration
(151
)
 
—

 
Total inventory, net
$
109

 
$
482


8
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 4. Inventory (Continued)

In connection with the wind-down of the Company’s azficel-T operations, as more fully described in Note 9, the Company recognized inventory write-downs of approximately $0.2 million in cost of goods sold and recorded a reserve for work in process expiration of approximately $0.2 million during the second quarter of 2016. With respect to LAVIV, the Company is no longer accepting new prescriptions.
Note 5. Warrants

The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. As of June 30, 2016 and December 31, 2015, all of the Company’s outstanding common stock warrants were classified as derivative liabilities and accounted for based on the guidance in ASC 815, Derivatives and Hedging as the warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and hence were determined not to be indexed to the Company’s own stock. The warrants will continue to be classified as a liability, regardless of the likelihood that such instruments will ever be settled in cash, until they are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.

The following table summarizes outstanding liability-classified warrants to purchase common stock:
 
Number of Warrants
 
 
 
 
Liability-classified warrants
June 30, 2016
 
December 31, 2015
 
Exercise
Price
 
Expiration
Dates
Issued in March 2010 financing
—

 
319,789

 
$
6.25

 
Mar 2016
Issued in June 2011 financing
—

 
6,113

 
$
22.50

 
Jun 2016
Issued in Series B and D Preferred Stock offerings
1,970,594

 
1,970,594

 
$
6.25

 
Jul 2016 - Dec 2016
Issued in August 2011 financing
565,759

 
565,759

 
$
18.75

 
Aug 2016
Issued to placement agents in August 2011 financing
50,123

 
50,123

 
$
13.635

 
Aug 2016
Issued in Series E Preferred Stock offering
60,000

 
60,000

 
$
2.50

 
Dec 2017
Issued with Convertible Notes
1,125,578

 
1,125,578

 
$
2.50

 
Jun 2018
Issued in Series E Preferred Stock offering
1,568,823

 
1,568,823

 
$
7.50

 
Dec 2018
Total
5,340,877

 
5,666,779

 
 

 
 
    
The table below is a summary of the Company’s warrant activity during the six months ended June 30, 2016:
 
Number of
warrants
 
Weighted-
average
exercise
price
Outstanding at December 31, 2015
5,666,779

 
$
7.14

Granted
—

 
—

Exercised
—

 
—

Expired
(325,902
)
 
6.55

Outstanding at June 30, 2016
5,340,877

 
$
7.18


Accounting for Liability-classified Warrants

The foregoing warrants were recorded as derivative liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income or expense in the Company’s Condensed Consolidated Statements of Operations in each subsequent period. The change in the estimated fair value of the warrant liability for the three and six months ended June 30, 2016 resulted in non-cash income of approximately $2.3 million and $7.5 million, respectively. The change in the estimated fair value of the warrant liability for the three and six months ended June 30, 2015 resulted in non-

9
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 5. Warrants (continued)

cash income of approximately $0.6 million and non-cash expense of approximately $1.1 million, respectively. The Company utilizes a Monte Carlo simulation valuation method to value its liability-classified warrants.

Assumptions Used in Determining Fair Value of Warrants

The estimated fair value of warrants is determined using Level 2 and Level 3 inputs.  Inherent in the Monte Carlo simulation valuation method are the following assumptions:

Volatility. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected remaining life of the warrants.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the valuation date commensurate with the expected remaining life assumption.

Expected remaining life. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.

Dividend rate. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.

Scenarios.  The probability of complex features of the warrants being triggered is subjective (no observable inputs or available market data) and based on internal and external information known to management at the valuation date.

The following table summarizes the calculated aggregate fair values, along with the inputs and assumptions utilized in each calculation:      
($ in thousands except per share data)
June 30, 2016
 
December 31, 2015
Calculated aggregate value
$
764

 
$
8,275

Weighted average exercise price per share
$
7.18

 
$
7.14

Closing price per share of common stock
$
1.15

 
$
4.55

Volatility
97.2
%
 
85.2
%
Weighted average remaining expected life
1 year, 3 months

 
1 year, 8 months

Risk-free interest rate
0.49
%
 
0.98
%
Dividend yield
—

 
—

Note 6. Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis
    
The Company follows the guidance in ASC 820, Fair Value Measurement, to account for financial assets and liabilities measured at fair value on a recurring basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The guidance requires fair value measurements be classified and disclosed in one of the following three categories within the hierarchy:
•
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
•
Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.

10
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 6. Fair Value Measurements (continued)

•
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period.

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 
June 30, 2016
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
8,161

 
$
—

 
$
—

 
$
8,161

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
764

 
$
764

 

 
December 31, 2015
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
29,268

 
$
—

 
$
—

 
$
29,268

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
8,275

 
$
8,275


Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis - Common Stock Warrants

The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:
 
Warrant
($ in thousands)
Liability
Balance at December 31, 2015
$
8,275

Expiration of warrants (1)
(62
)
Change in fair value of warrant liability
(7,449
)
Balance at June 30, 2016
$
764


(1)
Represents the fair value as of the beginning of the year for warrants expiring during the year and has been recorded to warrant revaluation income or expense in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2016.

Effect of Fibrocell’s Stock Price and Volatility Assumptions on the Calculation of Fair Value of Warrant Liabilities

The fair value of the warrant liability is based on Level 3 inputs. As discussed in Note 5, the Company uses a Monte Carlo simulation valuation method to value its liability-classified warrants. The determination of fair value as of the reporting date is affected by Fibrocell’s stock price as well as assumptions regarding a number of subjective variables that do not have observable inputs or available market data to support the fair value. These variables include, but are not limited to, expected stock price volatility over the term of the warrants and the risk-free interest rate. The primary factors affecting the fair value of the warrant liability are the Company’s stock price and volatility as well as certain assumptions by the Company as to the likelihood of provisions to the underlying warrant agreements being triggered. The methods described above and in Note 5 may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values.

11
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 6. Fair Value Measurements (continued)

Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.

Fair Value of Certain Financial Assets and Liabilities

The Company believes that the fair values of the Company’s current assets and liabilities approximate their reported carrying amounts. There were no transfers between Level 1, 2 and 3 during the periods presented.
Note 7. Stock-Based Compensation

2009 Equity Incentive Plan

The Company’s Board of Directors (the Board) adopted the 2009 Equity Incentive Plan (as amended to date, the Plan) effective September 3, 2009.  The Plan is intended to further align the interests of the Company and its stockholders with its employees, including its officers, non-employee directors, consultants and advisers by providing equity-based incentives.  The Plan allows for the issuance of up to 7,600,000 shares of the Company’s common stock.  In addition, there are 25,000 options outstanding that were issued outside the Plan to consultants in 2013.

The types of awards that may be granted under the Plan include options (both non-qualified stock options and incentive stock options), stock appreciation rights, stock awards, stock units and other stock-based awards.  The term of each award is determined by the Compensation Committee of the Board at the time each award is granted, provided that the terms of options do not exceed ten years.  Vesting schedules for stock options vary, but generally vest 25% per year over four years for employee options and on the one-year anniversary date for non-employee director options. The Plan had 3,365,103 shares available for future grants as of June 30, 2016.

Accounting for Stock-Based Compensation

The Company recognizes non-cash compensation expense for stock-based awards based on their grant date fair value, determined using the Black-Scholes option-pricing model. During the six months ended June 30, 2016 and 2015, the weighted average fair market value for options granted was $1.53 and $3.57, respectively.

Total stock-based compensation expense recognized using the straight-line attribution method and included in operating expenses in the Condensed Consolidated Statements of Operations was approximately $0.6 million and $0.8 million for the three months ended June 30, 2016 and 2015, respectively, and approximately $1.1 million and $1.0 million for the six months ended June 30, 2016 and 2015, respectively.

Assumptions Used in Determining Fair Value of Stock Options

Inherent in the Black-Scholes option-pricing model are the following assumptions:

Volatility. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected term of the stock options.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.

12
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 7. Stock-Based Compensation (continued)

Forfeitures. The Company accounts for forfeitures when they occur. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

The fair market value of these stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the six months ended:
 
June 30, 2016
 
June 30, 2015
Expected term
6 years, 1 month

 
6 years, 1 month

Interest rate
1.40
%
 
1.56
%
Dividend yield
—

 
—

Volatility (1)
92.4
%
 
103.3
%
(1)
For the six months ended June 30, 2016, the Company estimated expected volatility based on the historical volatility of its own common stock on a stand-alone basis. Prior to January 1, 2016, including the six months ended June 30, 2015, the Company estimated expected volatility based on the historical volatility of a peer group.

Stock Option Activity
    
The following table summarizes stock option activity for the six months ended June 30, 2016:
($ in thousands except share and per share data)
Number of
shares
 
Weighted-
average
exercise
price
 
Weighted- average
remaining
contractual
term
 
Aggregate
intrinsic
value
Outstanding at December 31, 2015
3,134,094

 
$
6.23

 
8 years
 
$
1,630

Granted
1,091,000

 
2.01

 
 
 
 
Exercised
—

 
—

 
 
 
 
Forfeited
(29,256
)
 
4.61

 
 
 
 
Expired
(188
)
 
4.24

 
 
 
 
Outstanding at June 30, 2016 (1)
4,195,650

 
$
5.15

 
8 years
 
$
43

Exercisable at June 30, 2016
1,954,190

 
$
7.50

 
6 years, 11 months
 
$
—

(1)
Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.

The total fair value of options vested during the six months ended June 30, 2016 was approximately $1.6 million. Additionally, as of June 30, 2016, there was approximately $4.7 million of unrecognized compensation expense related to non-vested stock options which is expected to be recognized over a weighted-average period of 2.8 years.
Note 8. Related Party Transactions

The Company and Intrexon Corporation (Intrexon) are parties to two distinct exclusive channel collaboration agreements including the Exclusive Channel Collaboration Agreement entered into in October 2012 and amended in June 2013 and January 2014 (as amended, the 2012 ECC) and the Exclusive Channel Collaboration Agreement entered into in December 2015 (the 2015 ECC). Pursuant to these agreements, the Company engages Intrexon for support services for the research and development of product candidates covered under the respective agreements and reimburses Intrexon for its cost for time and materials for such work.

For the three months ended June 30, 2016 and 2015, the Company incurred total expenses of $0.9 million and $1.1 million, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, no expenses were

13
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)
 
Note 8. Related Party Transactions (continued)

incurred for work performed under the 2015 ECC. Of the $0.9 million incurred during the 2016 period, $0.3 million related to direct expenses for work performed by Intrexon and $0.6 million related to pass-through costs. Of the $1.1 million incurred during the 2015 period, $0.8 million related to direct expenses for work performed by Intrexon and $0.3 million related to pass-through costs.

For the six months ended June 30, 2016 and 2015, the Company incurred total expenses of $2.2 million and $2.9 million, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, no expenses were incurred for work performed under the 2015 ECC. Of the $2.2 million incurred during the 2016 period, $0.8 million related to direct expenses for work performed by Intrexon and $1.4 million related to pass-through costs. Of the $2.9 million incurred during the 2015 period, $1.7 million related to direct expenses for work performed by Intrexon and $1.2 million related to pass-through costs.

As of June 30, 2016 and December 31, 2015, the Company had outstanding payables to Intrexon of $0.9 million and $10.7 million, respectively. In connection with the 2015 ECC, in consideration for the license and the other rights that the Company receives under the agreement, the Company paid Intrexon an up-front technology access fee of $10 million in cash in January 2016.
Randal J. Kirk is the chairman of the board and chief executive officer of Intrexon and, together with his affiliates, owns more than 50% of Intrexon’s common stock. Affiliates of Randal J. Kirk (including Intrexon) own approximately 38% of our common stock. Additionally, two of our directors, Julian Kirk (who is the son of Randal J. Kirk) and Marcus Smith, are employees of Third Security, LLC, which is an affiliate of Randal J. Kirk.
Note 9. Restructuring Costs

In June 2016, the Company determined to wind-down its azficel-T operations at the Company’s Exton, PA facility and to reduce the workforce that supports such operations. This decision enables the Company to focus its resources towards pre-clinical and clinical research and development of its gene-therapy product candidates.

Restructuring-related charges for both the three and six months ended June 30, 2016 totaled approximately $0.3 million and were comprised of approximately $0.3 million of employee severance and benefit related charges and less than $0.1 million of asset impairments.

The restructuring and asset impairment activity for the six months ended June 30, 2016 was as follows:
($ in thousands)
 
Employee Severance and Benefits
 
Asset Impairments
 
Total
Accrued restructuring balance as of December 31, 2015
 
$
—

 
$
—

 
$
—

Additional accruals
 
258

 
34

 
292

Cash payments
 
—

 
—

 
—

Non-cash settlements
 
—

 
(34
)
 
(34
)
Accrued restructuring balance as of June 30, 2016
 
$
258

 
$
—

 
$
258


The restructuring-related charges incurred during the three and six months ended June 30, 2016 related to employee severance and benefits resulting from the reduction-in-workforce and the impairment of property and equipment. In connection with the reduction-in-workforce, 25 positions were eliminated, primarily in the areas of manufacturing and quality operations, representing approximately 50% of the Company's employees. The accrued restructuring balance as of June 30, 2016 relates to employee severance and benefits which are expected to be paid in the third quarter of 2016 and is recorded as a current liability within accrued expenses in the Condensed Consolidated Balance Sheet. Additionally, the Company recognized inventory write-downs in cost of goods sold related to the wind-down of its azficel-T operations as described in Note 4.


14
Fibrocell Science, Inc.
Notes to Consolidated Financial Statements
(unaudited)
 
Note 9. Restructuring Costs (continued)


The Company expects to incur additional charges in the future for employee severance and benefits, contract termination and wind-down costs, assets impairments and costs to decommission the Company’s azficel-T manufacturing facility, but cannot estimate them at this time.
Note 10.  Loss Per Share
    
Basic loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during that period.  The diluted loss per share calculation gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money common stock equivalents based on the average market price during the period.  Common stock equivalents have been excluded where their inclusion would be anti-dilutive.
    
Details in the computation of basic and diluted loss per share are as follows:
 
Three months ended  June 30,
 
Six months ended  June 30,
($ in thousands, except share and per share data)
2016
 
2015
 
2016
 
2015
Loss per share - basic:
 

 
 

 
 

 
 

Numerator for basic loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Basic loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.22
)
 
$
(0.37
)
Loss per share - diluted:
 

 
 

 
 

 
 

Numerator for diluted loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Adjust: Warrant revaluation income (expense) for dilutive warrants
—

 
—

 
1,958

 
—

Net loss attributable to common share
$
(8,092
)
 
$
(6,756
)
 
$
(11,457
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Plus: Incremental shares underlying dilutive warrants outstanding
—

 
—

 
36,034

 
—

Denominator for diluted loss per share
43,898,785

 
40,889,732

 
43,934,819

 
40,875,704

Diluted net loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.26
)
 
$
(0.37
)
     
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive: 
 
Three months ended  June 30,
 
Six months ended  June 30,
 
2016
 
2015
 
2016
 
2015
“In the money” stock options
216,000

 
1,482,614

 
545,500

 
1,518,957

“Out of the money” stock options
3,979,650

 
1,654,200

 
3,556,497

 
1,442,200

“In the money” warrants
—

 
1,201,698

 
—

 
1,201,698

“Out of the money” warrants
5,340,877

 
4,831,352

 
4,751,145

 
4,831,352

 
 
 
 
 
 
 
 
Other securities excluded from the calculation of diluted loss per share:
 
 
 
 
 
 
 
Stock options with performance condition
—

 
100,000

 
—

 
100,000


15
Fibrocell Science, Inc.
Notes to Condensed Consolidated Financial Statements
(unaudited)



Note 11. Equity

Common Stock - Shares Authorized

In July 2016, the Company amended its Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock that the Company is authorized to issue from 100,000,000 to 150,000,000. The amendment was approved by stockholders in June at the Company’s 2016 Annual Meeting of Stockholders.

Common Stock - “At-The-Market” Equity Program

In January 2016, the Company entered into a Controlled Equity Offering™ Sales Agreement (the ATM Agreement) with Cantor Fitzgerald & Co. (Cantor Fitzgerald) to implement an "At-The-Market" (ATM) equity program under which the Company, from time to time, may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million (the Shares) through Cantor Fitzgerald.

Subject to the terms and conditions of the ATM Agreement, Cantor Fitzgerald will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the ATM Agreement or terminate the ATM Agreement. Cantor Fitzgerald will be entitled to a fixed commission of up to 3.0% of the gross proceeds from Shares sold. Through June 30, 2016, no Shares have been sold through the ATM equity program.

16

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis should be read in conjunction with:
•
our unaudited Condensed Consolidated Financial Statements and accompanying notes included in Part I, Item 1 of this Form 10-Q; and
•
our audited Consolidated Financial Statements and accompanying notes included in our Annual Report on Form 10-K for 2015 (2015 Form 10-K), as well as the information contained under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our 2015 Form 10-K.
Overview

We are an autologous cell and gene therapy company focused on translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Our approach to personalized biologics is distinctive and the foundation of our personalized biologics platform is our proprietary autologous fibroblast technology. Fibroblasts are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen and other growth factors, that provide structure and support. Because fibroblasts naturally reside in the localized environment of the skin and connective tissue, they represent an ideal delivery vehicle for proteins targeted to these areas. We target the underlying cause of disease by using fibroblast cells from a patient's skin to create localized therapies with genetic modification that are compatible with the unique biology of the patient (i.e., autologous).

We are focused on discovering and developing localized therapies for diseases affecting the skin and connective tissue, where there are high unmet needs, to improve the lives of patients and their families. In that regard, we commit significant resources to our research and development programs. Currently, all of our research and development operations and focus are on gaining regulatory approvals to commercialize our product candidates in the United States; however, we may seek to expand into international markets in the future.

Our current pipeline consists of the following product candidates which we are developing in collaboration with Intrexon Corporation (Intrexon):


Development Programs

FCX-007 for Recessive Dystrophic Epidermolysis Bullosa

Recessive dystrophic epidermolysis bullosa (RDEB) is the most severe form of dystrophic epidermolysis bullosa (DEB), a congenital, progressive, devastatingly painful and debilitating genetic disorder that often leads to death. RDEB is caused by a mutation of the COL7A1 gene, the gene which encodes for type VII collagen (COL7), a protein that forms

17

anchoring fibrils. Anchoring fibrils hold together the layers of skin, and without them, skin layers separate causing severe blistering, open wounds and scarring in response to friction, including normal daily activities like rubbing or scratching. Children who inherit this condition are often called “butterfly children” because their skin can be as fragile as a butterfly’s wings. We estimate that there are approximately 1,100 - 2,500 RDEB patients in the U.S. Currently, treatments for RDEB address only the sequelae, including daily bandaging (which can cost a patient in excess of $10,000 per month), hydrogel dressings, antibiotics, feeding tubes and surgeries.
    
Our lead product candidate, FCX-007, is in clinical development for the treatment of RDEB. In addition to having orphan drug designation from the U.S. Food and Drug Administration’s (FDA) Office of Orphan Products Development (OOPD), FCX-007 also was granted pediatric rare disease designation. FCX-007 is a genetically-modified autologous fibroblast that encodes the gene for COL7 for localized treatment of RDEB and is being developed in collaboration with Intrexon. By genetically modifying autologous fibroblasts, ex vivo, to produce COL7, culturing them and then treating blisters and wounds locally via injection, FCX-007 offers the potential to address the underlying cause of the disease by providing high levels of COL7 directly to the affected areas, thereby avoiding systemic treatment. In addition, we believe the autologous nature of the cells, localized delivery, use of an integrative vector and the low turnover rate of the protein will contribute to long-term persistence of the COL7 produced by FCX-007.

Phase I/II Trial of FCX-007 for RDEB

The primary objective of this open-label trial is to evaluate the safety of FCX-007 in RDEB subjects. Additionally, the trial will assess (i) the mechanism of action of FCX-007 through the evaluation of type VII collagen expression and the presence of anchoring fibrils and (ii) the efficacy of FCX-007 through intra-subject paired analysis of target wound area by comparing FCX-007 treated wounds to untreated wounds in Phase I and to wounds administered with sterile saline in Phase II. Six adult subjects are expected to be treated with FCX-007 in the Phase I portion of the trial and six pediatric subjects in the Phase II portion of the trial. Prior to enrolling pediatric subjects, we are required to obtain allowance from the FDA and submit evidence of FCX-007 activity in adult subjects and final data from an ongoing toxicology study.

We are actively recruiting adult subjects for the Phase I portion of this trial and currently have 2 subjects enrolled. We expect to dose our first subject at the end of 2016. Additional adult subjects will be dosed after a required 90-day waiting period following the dosing of the first subject. This required waiting period is to provide time to assess the safety of the first dose of the new gene therapy. We expect to have three-month post-treatment data for safety, mechanism of action and efficacy for the adult subjects in the Phase I portion of the trial in the second half of 2017, as well as six-month data for a cohort of this group.

FCX-013 for Linear Scleroderma

Linear scleroderma, a form of localized scleroderma, is a chronic autoimmune skin disorder that manifests as excess production of extracellular matrix, specifically type I collagen and type III collagen, resulting in thickening of the skin and connective tissue. The localized areas of skin thickening may extend to underlying tissue and muscle in children which can impair growth and development. Lesions appearing across joints can be painful, impair motion and may be permanent. Current treatments for linear scleroderma, which include systemic or topical corticosteroids, UVA light therapy and physical therapy, only address the symptoms of the disorder. We estimate the U.S. population of patients who have linear scleroderma over a major joint and exhibit severe joint pain to be approximately 40,000.

Our second gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. FCX-013 incorporates Intrexon’s proprietary RTS® switch, a biologic switch activated by an orally administered compound to control future protein expression once the initial fibrosis has been resolved. FCX-013 is designed to be injected under the skin at the location of the fibrosis where the genetically-modified fibroblast cells will produce a protein to break down excess collagen accumulation. The patient takes an oral compound to facilitate protein expression. Once the fibrosis is resolved, the patient will stop taking the oral compound which will stop further production of the subject protein by FCX-013.

We have successfully completed a proof-of-concept study for FCX-013 in which the primary objective was to determine whether FCX-013 had the potential to reduce dermal thickness in fibrotic tissue. In this study, FCX-013 was evaluated in a bleomycin-induced scleroderma model utilizing severe combined immunodeficiency (SCID) mice. Data from the study demonstrated that FCX-013 reduced dermal thickness of fibrotic tissue to levels similar to that of the non-treated control and further reduced the thickness of the sub-dermal muscle layer. Based upon these data and the FDA’s feedback to our pre-IND briefing package, we are advancing FCX-013 into a pre-clinical dose-ranging study to be followed by a toxicology/biodistribution study. In April 2016 we received orphan drug designation from the OOPD for FCX-013 for the treatment of localized scleroderma. We expect to submit an IND application for FCX-013 to the FDA in 2017.

18

Gene Therapy Research Program for Arthritis and Related Conditions

Arthritis is a broad term that covers a group of more than 100 different types of diseases that affect the joints, as well as connective tissues and organs, including the skin. According to the Centers for Disease Control and Prevention, arthritis—characterized by joint inflammation, pain and decreased range of motion—is the United States’ most common cause of disability affecting more than 52 million adults as well as 300,000 children at a cost exceeding $120 billion.

Our third gene-therapy program is focused on the treatment of arthritis and related conditions. Our goal is to deliver a protein therapy locally to the joint to provide sustained efficacy while avoiding key side effects typically associated with systemic therapy.

Intrexon Collaborations

We collaborate with Intrexon Corporation, a related party, through two distinct exclusive channel collaboration agreements consisting of the Exclusive Channel Collaboration Agreement entered into in October 2012 and amended in June 2013 and January 2014 (as amended, the 2012 ECC) and the Exclusive Channel Collaboration Agreement entered into in December 2015 (the 2015 ECC). Pursuant to these agreements, we engage Intrexon for support services for the research and development of product candidates covered under the respective agreements and reimburse Intrexon for its cost for time and materials for such work. We are developing FCX-007 and FCX-013 under the 2012 ECC and we are in the research phase for a gene-therapy treatment for arthritis and related conditions under the 2015 ECC. For additional details, see Note 8 in the accompanying Notes to the Condensed Consolidated Financial Statements included in this Form 10-Q and additional disclosures included in our 2015 Form 10-K.
Wind-down of azficel-T Operations

In June 2016, we reported that the primary efficacy endpoints were not met in our Phase II clinical trial of azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. As a result, we determined to wind-down azficel-T (including LAVIV) operations at our Exton, PA facility in order to focus our efforts and resources on our gene-therapy portfolio of product candidates. In connection with this wind-down, we eliminated 25 positions, primarily in the areas of manufacturing and quality operations, representing approximately 50% of our employees. We have incurred one-time termination costs in connection with the reduction in workforce, which include severance, benefits and related costs, of approximately $0.3 million for the quarter ended June 30, 2016 and expect to incur an additional $0.1 million for the quarter ended September 30, 2016. We have incurred approximately $0.3 million and less than $0.1 million, respectively, for non-cash impairment charges against the carrying values of inventory (including reserves) and equipment used in our azficel-T operations for the quarter ended June 30, 2016. Additionally, we expect to incur other cash expenditures to decommission our azficel-T manufacturing facility and to terminate and wind-down our contractual and other obligations relating to our azficel-T operations, as well as potential non-cash charges related to future impairments of the carrying values of inventory and equipment used in our azficel-T operations, but cannot estimate them at this time. Please refer to Note 9 in the accompanying Notes to the Condensed Consolidated Financial Statements contained in this Form 10-Q for further details including the financial statement impact this restructuring has had, and is expected to have, on our results of operations.

With the focus now on our gene-therapy portfolio, we are actively seeking an acquiror for azficel-T.

19

Financial Condition, Liquidity and Capital Resources

Financial Condition
    
We have experienced losses since our inception. As of June 30, 2016, we had an accumulated deficit of $156.8 million. The process of developing and commercializing our product candidates requires significant research and development efforts and clinical trial work, as well as significant manufacturing and process development. These activities, together with our selling, general and administrative expenses, are expected to continue to result in significant operating losses for the foreseeable future.

Our financial condition is summarized below as of the following dates:
 
June 30, 2016
 
December 31, 2015
 
Change
($ in thousands)
 
 
$
%
Cash and cash equivalents
$
8,161

 
$
29,268

 
$
(21,107
)
(72.1
)%
Working capital:
 
 
 
 
 
 
Total current assets
$
8,906

 
$
30,994

 
$
(22,088
)
(71.3
)%
Total current liabilities
(3,143
)
 
(15,365
)
 
12,222

(79.5
)%
Net working capital
$
5,763

 
$
15,629

 
$
(9,866
)
(63.1
)%

Liquidity and Capital Resources
    
Our principal sources of liquidity are cash and cash equivalents of $8.2 million as of June 30, 2016. As of June 30, 2016, we had net working capital of $5.8 million. Net working capital decreased approximately $9.9 million, or 63.1%, from December 31, 2015 to June 30, 2016. This decrease is primarily the result of net consumption of cash used in operations to further our development programs (for which future funding requirements are described below). We believe that our existing cash and cash equivalents will be sufficient to fund our operations into the fourth quarter of 2016; however, changing circumstances may cause us to consume capital faster than we currently anticipate, and we may need to spend more money than currently expected because of such circumstances. We will require additional capital to fund operations beyond that point and prior to our business achieving significant net cash from operations. Our future capital requirements may be substantial, and will depend on many factors, including, but not limited to:
•
the cost of clinical activities and outcomes related to our Phase I/II clinical trial for FCX-007;
•
the costs of pre-clinical activities and outcomes related to FCX-013, for which we expect to file an IND with the FDA in 2017;
•
the costs to wind-down our azficel-T (including LAVIV) operations including, without limitation, the costs to decommission our azficel-T manufacturing facility and to terminate and wind-down our contractual and other obligations relating to our azficel-T operations;
•
the cost of additional clinical trials in order to obtain regulatory approvals for our product candidates;
•
the cost of regulatory submissions, as well as the preparation, initiation and execution of clinical trials in potential new clinical indications; and
•
the cost of filing, surveillance around, prosecuting, defending and enforcing patent claims.

To meet our capital needs, we are considering multiple alternatives, including but not limited to equity financings, debt financings, corporate collaborations, partnerships and other strategic transactions and funding opportunities. If we raise additional funds by issuing equity securities, our stockholders will experience dilution. Debt financing, if available, will result in increased fixed payment obligations and may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Any debt or equity financing that we complete may contain terms, such as liquidation and other preferences, which are not favorable to us or our stockholders. If we raise additional funds through collaboration or partnership arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies, future revenue streams or product candidates or to grant licenses on terms that may not be favorable to us. Additionally, there can be no assurance that we will be able to complete any such financings or capital-raising transactions on acceptable terms or otherwise.


20

If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we will need to curtail and reduce our operations and costs and modify our business strategy which may require us to, among other things:
•
significantly delay, scale back or discontinue the development or commercialization of one or more of our product candidates or one or more of our other research and development initiatives;
•
seek collaborators for one or more of our current or future product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available;
•
sell or license on unfavorable terms our rights to technologies or product candidates that we otherwise would seek to develop or commercialize ourselves; or
•
seek bankruptcy protection which may result in the termination of agreements pursuant to which we license certain intellectual property rights including our exclusive channel collaboration agreements with Intrexon.

These factors raise substantial doubt about our ability to continue as a going concern. As a result, our independent registered public accounting firm included an explanatory paragraph in its audit report on our Consolidated Financial Statements for the year ended December 31, 2015 in our 2015 Form 10-K related to our ability to continue as a going concern.

Cash Flows
Our cash flow activity is summarized below for the following periods:
 
Six months ended June 30,
($ in thousands)
2016
 
2015
Net cash flows (used in) provided by:
 
 
 
Operating activities
$
(20,853
)
 
$
(10,787
)
Investing activities
$
(143
)
 
$
(111
)
Financing activities
$
(111
)
 
$
253


Operating Activities. Cash used in operating activities during the six months ended June 30, 2016 was approximately $20.9 million, an increase of $10.1 million as compared to the same period last year, primarily due to the $10 million up-front technology access fee payment to Intrexon in January 2016 in connection with the 2015 ECC.

Investing Activities. Cash used in investing activities during both the six months ended June 30, 2016 and 2015 was related primarily to equipment purchases.

Financing Activities. Cash used in financing activities during the six months ended June 30, 2016 was related to payments of deferred offering costs in connection with our “at-the-market” equity offering program. Cash provided by financing activities during the same period in 2015 related to cash received for employee stock option exercises. See Note 11 in the accompanying Notes to the Condensed Consolidated Financial Statements for additional information regarding our “at-the-market” offering program. To date, no shares of common stock have been sold and thus no proceeds have been received from this program.

21

Results of Operations

Comparison of Three and Six Months Ended June 30, 2016 and 2015

Revenue and Cost of Revenue

Revenue and cost of revenue were comprised of the following:
 
For the Three Months
Ended June 30,
 
For the Six Months
Ended June 30,
 
 
($ in thousands)
2016
 
2015
 
% Change
 
2016
 
2015
 
% Change
 
 
Revenue from product sales
$
73

 
$
55

 
32.7
 %
 
$
85

 
$
168

 
(49.4
)%
 
(1)
Collaboration revenue
14

 
82

 
(82.9
)%
 
18

 
163

 
(89.0
)%
 
(2)
Total revenue
87

 
137

 
(36.5
)%
 
103

 
331

 
(68.9
)%
 
 
Cost of product sales
392

 
77

 
409.1
 %
 
409

 
221

 
85.1
 %
 
(3)
Cost of collaboration revenue
—

 
85

 
(100.0
)%
 
1

 
88

 
(98.9
)%
 
(4)
Total cost of revenue
392

 
162

 
142.0
 %
 
410

 
309

 
32.7
 %
 
 
Gross (loss) profit
$
(305
)
 
$
(25
)
 
1,120.0
 %
 
$
(307
)
 
$
22

 
(1,495.5
)%
 
 

(1)
Revenue from product sales solely relates to, and is recognized based on, the shipment of LAVIV injections to patients. Although the number of injections can fluctuate from period to period, product revenues continue to be, and are expected to remain, insignificant to our operations. In connection with the wind-down of azficel-T operations, the Company is no longer accepting new prescriptions.

(2)
Collaboration revenue is related to a research and development agreement that we have with a third party to investigate potential new non-pharmaceutical applications for our conditioned fibroblast media technology. Revenue recognized to date relates to an upfront license fee of approximately $0.1 million that is being amortized over the estimated total contract period and $0.2 million for a proof-of-concept study that was completed during the fourth quarter of 2015. Collaboration revenue for the three and six months ended June 30, 2016 solely relates to amortization of the upfront license fee while collaboration revenue for the three and six months ended June 30, 2015 includes amortization of both the upfront license fee and proof-of-concept study.

(3)
Cost of product sales includes direct and indirect costs related to the processing of cells for LAVIV. Cost of product sales increased approximately $0.3 million, or 409.1%, for the three months ended June 30, 2016 and $0.2 million, or 85.1%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The increases for both the three and six month periods are primarily due to the write-down of raw materials inventory and reserve for work in process inventory, both recorded during the second quarter of 2016 in connection with the wind-down of our azficel-T operations.

(4)
Cost of collaboration revenue during the three and six months ended June 30, 2015 relates to a proof-of-concept study which was completed during 2015. As such, no such expenses were incurred during the three and six months ended June 30, 2016.

Research and Development Expense

For each of our research and development programs, we incur both direct and indirect expenses. We track direct research and development expenses by program, which include third party costs such as contract research, consulting and pre-clinical and clinical development costs. We do not allocate indirect research and development expenses, which may include regulatory, laboratory (equipment and supplies), personnel, facility, process development and other overhead costs (including depreciation and amortization), to specific programs, as these resources are to be deployed across all of our product candidates. We expect research and development costs to continue to be significant for the foreseeable future as a result of our pre-clinical studies and clinical trials, as well as our ongoing collaborations with Intrexon.






22

Research and development expense was comprised of the following:
 
For the Three Months
Ended June 30,
 
For the Six Months
Ended June 30,
 
 
($ in thousands)
2016
 
2015
 
% Change
 
2016
 
2015
 
% Change
 
 
Direct costs:
 
 
 
 


 
 
 
 
 


 
 
FCX-007
$
895

 
$
905

 
(1.1
)%
 
$
1,918

 
$
2,227

 
(13.9
)%
 
(1)
FCX-013
109

 
254

 
(57.1
)%
 
419

 
704

 
(40.5
)%
 
(2)
azficel-T for vocal cord scarring
135

 
436

 
(69.0
)%
 
170

 
724

 
(76.5
)%
 
(3)
Other
22

 
43

 
(48.8
)%
 
56

 
102

 
(45.1
)%
 
 
Total direct costs
1,161

 
1,638

 
(29.1
)%
 
2,563

 
3,757

 
(31.8
)%
 
 
Indirect costs:
 
 
 
 
 
 
 
 
 
 
 
 
 
Regulatory costs
275

 
239

 
15.1
 %
 
450

 
480

 
(6.3
)%
 
 
Intangible amortization
93

 
138

 
(32.6
)%
 
231

 
276

 
(16.3
)%
 
 
Compensation and related expense
959

 
888

 
8.0
 %
 
2,055

 
1,816

 
13.2
 %
 
(4)
Process development
401

 
176

 
127.8
 %
 
999

 
192

 
420.3
 %
 
(5)
Other indirect R&D costs
388

 
615

 
(36.9
)%
 
905

 
1,160

 
(22.0
)%
 
(6)
Total indirect costs
2,116

 
2,056

 
2.9
 %
 
4,640

 
3,924

 
18.2
 %
 
 
Total research and development expense
$
3,277

 
$
3,694

 
(11.3
)%
 
$
7,203

 
$
7,681

 
(6.2
)%
 
 

(1)
Costs for our FCX-007 program for the three months ended June 30, 2016 were consistent with those incurred during the same period in 2015. Costs decreased approximately $0.3 million, or 13.9%, for the six months ended June 30, 2016 as compared to the same period in 2015 primarily due to the completion of pre-clinical development activities in the first quarter of 2016 that were ongoing during the first and second quarters of 2015, offset by the initiation of the Phase I portion of our Phase I/II clinical trial for FCX-007 in adults in the second quarter of 2016.

Through June 30, 2016, we have incurred approximately $19.1 million in direct research and development costs related to this program, life-to-date, which include non-cash expenses of $6.9 million in stock issuance costs associated with the 2012 ECC with Intrexon. Other costs include product and assay development, key opinion leader development, pre-clinical studies and manufacturing, the design of the Phase I/II clinical trial protocol and recruiting subjects. Going forward, research and development investments for this program are expected to support clinical product manufacturing, statistical analyses, report generation and future clinical trial costs.

(2)
Costs for our FCX-013 program decreased approximately $0.1 million, or 57.1%, for the three months ended June 30, 2016 and $0.3 million, or 40.5%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The decreases for both the three and six month periods are primarily due to the completion of our proof-of-concept study in the first quarter of 2016, as compared to early product development expenses incurred in the first half of 2015 which included gene screening and selection, construct build and optimization, vector optimization, assay development, RTS® switch and ligand optimization and some early animal model work.

Through June 30, 2016, we have incurred approximately $9.6 million in direct research and development costs related to this program, life-to-date, which include non-cash expenses of $6.4 million in stock issuance costs with the 2012 ECC with Intrexon. Other costs include product and assay development and pre-clinical work, including execution of our proof-of concept study. Going forward, research and development investments for this program are expected to support ongoing product and assay development, pre-clinical study execution, key opinion leader development, National Institutes of Health Recombinant DNA Advisory Committee (NIH RAC) meeting preparation expenses and the design and execution of clinical trials.

(3)
Costs for our azficel-T for vocal cord scarring program decreased approximately $0.3 million, or 69.0%, for the three months ended June 30, 2016 and $0.6 million, or 76.5%, for the six months ended June 30, 2016 as compared to the same periods in 2015 as dosing in the Phase II trial was complete as of December 31, 2015. Therefore, no subject enrollment or clinical manufacturing costs were incurred in the 2016 periods.

Through June 30, 2016, we have incurred approximately $2.6 million in direct research and development costs related to this program, life-to-date. These costs include the author and review of clinical trial protocols, recruiting investigator sites, the cost to manufacture clinical trial material, recruiting subjects, executing our Phase I and II clinical trials and statistical analyses. Going forward, no significant research and development investments for this

23

program are anticipated as the Phase II trial did not meet primary efficacy endpoints and the trial will be terminated upon assessment of the final 12-month endpoint.

(4)
Compensation and related expense increased approximately $0.1 million, or 8.0%, for the three months ended June 30, 2016 and $0.2 million, or 13.2%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The increases for both the three- and six-month periods are primarily due to increases in salaries and other employee benefits.

(5)
Process development costs increased approximately $0.2 million, or 127.8%, for the three months ended June 30, 2016 and $0.8 million, or 420.3%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The increases for both the three and six month periods are primarily due to an increase in internal process development work as additional resources were directed towards optimizing our current manufacturing processes, benefiting several of our ongoing development programs.

(6)
Other indirect R&D costs decreased approximately $0.2 million, or 36.9%, for the three months ended June 30, 2016 and $0.3 million, or 22.0%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The decreases for both the three and six month periods are primarily due to a research agreement with an unrelated third party that was ongoing during the 2015 periods but terminated in the second half of 2015.

Selling, General and Administrative Expense
Selling, general and administrative expense was comprised of the following:
 
For the Three Months
Ended June 30,
 
For the Six Months
Ended June 30,
 
 
($ in thousands)
2016
 
2015
 
% Change
 
2016
 
2015
 
% Change
 
 
Compensation and related expense
$
1,352

 
$
1,638

 
(17.5
)%
 
$
2,750

 
$
2,525

 
8.9
 %
 
(1)
Professional fees
434

 
1,277

 
(66.0
)%
 
1,018

 
2,569

 
(60.4
)%
 
(2)
Facilities and related expense and other
754

 
725

 
4.0
 %
 
1,512

 
1,470

 
2.9
 %
 
 
Total selling, general and administrative
     expense
$
2,540

 
$
3,640

 
(30.2
)%
 
$
5,280

 
$
6,564

 
(19.6
)%
 
 

(1)
Compensation and related expense decreased approximately $0.3 million, or 17.5%, for the three months ended June 30, 2016 as compared to the same period in 2015, primarily due to decreases in bonus and non-cash stock-based compensation expenses, offset by an increase in other employee benefits.
    
Compensation and related expense increased approximately $0.2 million, or 8.9%, for the six months ended June 30, 2016 as compared to the same period in 2015, primarily due to increases in salaries and other employee benefits, offset by a decrease in bonus expense.

(2)
Professional fees decreased approximately $0.8 million, or 66.0%, for the three months ended June 30, 2016 and $1.6 million, or 60.4%, for the six months ended June 30, 2016 as compared to the same periods in 2015. The decreases for both the three- and six-month periods are primarily due to legal fees related to litigation and contract matters that were incurred in the prior year period and did not recur in 2016. Additionally, in the second quarter of 2015, we hired in-house general counsel which further reduced legal costs incurred with outside vendors.

Intangible Asset Impairment Expense

During the three months ended June 30, 2016 we recorded a non-cash impairment charge of approximately $3.9 million to write off the Company’s intangible assets. No such charges were incurred in the prior periods. See Note 3 in the accompanying Notes to the Condensed Consolidated Financial Statements contained in this Form 10-Q.

Restructuring Costs
    
During the three months ended June 30, 2016 we recorded restructuring costs totaling approximately $0.3 million which were comprised of employee severance and benefit related charges associated with our reduction in workforce and non-cash impairment charges against the carrying values of equipment. No such costs were incurred in the prior periods. See

24

additional information included under the heading “Wind-down of azficel-T Operations” in Item 2 of this Form 10-Q and in Note 9 in the accompanying Notes to the Condensed Consolidated Financial Statements contained in this Form 10-Q.

Warrant Revaluation Income (Expense)

During the three months ended June 30, 2016 and 2015, we recorded non-cash income of approximately $2.3 million and $0.6 million for warrant revaluation charges in our Condensed Consolidated Statements of Operations, respectively. During the six months ended June 30, 2016 and 2015, we recorded non-cash income of approximately $7.5 million and non-cash expense of $1.1 million for warrant revaluation charges in our Condensed Consolidated Statements of Operations, respectively. Due to the nature and inputs of the model used to assess the fair value of our outstanding warrants, it is not abnormal to experience significant fluctuations from period to period. These fluctuations are due to a variety of factors including changes in our stock price, changes in the remaining contractual life of the warrants, and changes in management's estimated probability of certain events occurring that would impact the warrants. The primary reason for the significant changes between the warrant revaluation charges for both the three and six month ended comparable periods noted above was the decrease in our stock price during both the three and six months ended June 30, 2016 compared to an increase in our stock price experienced during both the three and six months ended June 30, 2015.
Contractual Obligations

During the six months ended June 30, 2016, there have been no material changes to our contractual obligations outside the ordinary course of business from those specified in our 2015 Form 10-K.
Critical Accounting Policies

Management’s Discussion and Analysis of Financial Condition and Results of Operations is based upon our Condensed Consolidated Financial Statements, which have been prepared in conformity with U.S. generally accepted accounting principles (GAAP). Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses. Estimates are based on our historical operations, our future business plans and projected financial results, the terms of existing contracts, our observance of trends in the industry, information provided by our customers and information available from other outside sources, as appropriate. These estimates and assumptions are affected by the application of our accounting policies. Critical accounting policies and practices are both important to the portrayal of a company’s financial condition and results of operations, and require management’s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effects of matters that are inherently uncertain. Actual results could differ from such estimates due to changes in economic factors or other conditions that are outside the control of management.

A summary of our significant accounting policies is described in Note 3 to our Consolidated Financial Statements contained in our 2015 Form 10-K. However, please refer to Note 3 in the accompanying Notes to the Condensed Consolidated Financial Statements contained in this Form 10-Q for updated policies and estimates, if applicable, that could impact our results of operations, financial position, and cash flows.
Recently Issued Accounting Pronouncements
    
See Note 3 in the accompanying Notes to the Condensed Consolidated Financial Statements of this Form 10-Q for discussion on recently issued accounting pronouncements.
Item 3. Quantitative and Qualitative Disclosures About Market Risk.
    
There have been no material changes to our market risk since December 31, 2015.
Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures 
    
Our management, including our principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act), as of the end of the period covered by this Form 10-Q. Based upon that evaluation, our Chief

25

Executive Officer and Chief Financial Officer, concluded that, as of June 30, 2016, our disclosure controls and procedures were effective to provide reasonable assurance that (a) the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and (b) such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarterly period ended June 30, 2016 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. 
PART II. OTHER INFORMATION
Item 1A. Risk Factors
 
You should carefully consider each of the risk factors set forth under the heading "Risk Factors" in our Form 10-K for 2015. The risk factor set forth below supplements those risk factors. The occurrence of any one or more of these risks could materially harm our business, operating results, financial condition and prospects. These risks and uncertainties could also cause actual results to differ materially and adversely from those expressed or implied by forward-looking statements that we make from time to time. Please see "Note Regarding Forward-Looking Statements" appearing at the beginning of this Form 10-Q.

We recently announced the wind-down of our azficel-T (including LAVIV) operations at our Exton, PA facility and related workforce reduction that are expected to result in significant cost savings as we focus our efforts and resources on our gene-therapy portfolio of product candidates. If we are unable to realize the anticipated cost-saving benefits of these measures or we incur additional costs as we progress through the wind-down process, our operating results and financial condition could be adversely affected.

In June 2016, we announced that we are focusing our efforts and resources on our gene-therapy portfolio of product candidates and, as a result, determined to wind-down azficel-T (including LAVIV) operations at our Exton, PA facility and reduce the workforce that supports such operations. In connection with this reduction in workforce, 25 positions were eliminated, primarily in the areas of manufacturing and quality operations, representing approximately 50% of our employees. We have incurred one-time termination costs in connection with the reduction in workforce, which include severance, benefits and related costs, of approximately $0.3 million for the quarter ended June 30, 2016 and expect to incur an additional $0.1 million for the quarter ended September 30, 2016. We have incurred $0.3 million and $0.1 million, respectively, for non-cash impairment charges against the carrying values of inventory and equipment used in our azficel-T operations for the quarter ended June 30, 2016. Additionally, we expect to incur other cash expenditures to decommission our azficel-T manufacturing facility and to terminate and wind-down our contractual and other obligations relating to our azficel-T operations, as well as potential non-cash charges related to future impairments of the carrying values of inventory and equipment used in our azficel-T operations, but cannot estimate them at this time.

If we are unable to realize the expected cost savings from the workforce reduction and wind-down activities, our operating results and financial condition would be adversely affected. In addition, as we progress through the wind-down activities, we may incur additional costs and expenses, including costs to decommission our azficel-T manufacturing facility and to terminate and wind-down our contractual and other obligations relating to our azficel-T operations. The wind-down process may also be difficult to manage and may increase the likelihood of turnover of other key employees, all of which may have an adverse impact on our business, as well as on our operating results and financial condition.
Item 6.   Exhibits.
 
See the Exhibit Index following the signature page of this Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference.

26

SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
 
FIBROCELL SCIENCE, INC.
 
 
By:
/s/ Keith A. Goldan
 
Keith A. Goldan
 
Senior Vice President and Chief Financial Officer
 
(Principal Financial and Accounting Officer)
 
 
Date:
August 4, 2016


27

EXHIBIT INDEX

EXHIBIT NO.
 
IDENTIFICATION OF EXHIBIT
3.1*
 
Certificate of Amendment of the Restated Certificate of Incorporation of Fibrocell Science, Inc.
10.1*
 
Amendment to the Fibrocell Science, Inc. 2009 Equity Incentive Plan
31.1*
 
Certification pursuant to Rule 13a-14(a) and 15d-14(a), required under Section 302 of the Sarbanes-Oxley Act of 2002
31.2*
 
Certification pursuant to Rule 13a-14(a) and 15d-14(a), required under Section 302 of the Sarbanes-Oxley Act of 2002
32.1*
 
Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*
 
Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS
 
XBRL Instance Document. 
101.SCH
 
XBRL Taxonomy Extension Schema Document.
101.CAL
 
XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB
 
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE
 
XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF
 
XBRL Taxonomy Extension Definition Linkbase Document.
 
* Filed or furnished, as applicable, herewith.

28
 EX-3.1 2 fcscex31.htm EXHIBIT 3.1 Exhibit

Exhibit 3.1



STATE OF DELAWARE

CERTIFICATE OF AMENDMENT
OF THE RESTATED CERTIFICATE OF INCORPORATION OF
FIBROCELL SCIENCE, INC.


Fibrocell Science, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”) for the purpose of amending its Restated Certificate of Incorporation of the Corporation, as amended, in accordance with the General Corporation Law of Delaware, does hereby make and execute this Certificate of Amendment to the Restated Certificate of Incorporation, as amended, and does hereby certify that:

1.
The provisions of the present Article IV of the Restated Certificate of Incorporation of the Corporation, as amended, are amended by amending and restating the first sentence of Article IV, with no changes to be made to the subsequent sentences and provisions of Article IV:

“The Corporation shall have the authority to issue an aggregate of 155,000,000 shares, of which 5,000,000 shares shall be preferred stock, par value $0.001 per share (hereinafter the “Preferred Stock”), and 150,000,000 shares shall be common stock, par value $0.001 per share (hereinafter the “Common Stock”).”

2.
The foregoing amendment has been duly adopted in accordance with the provisions of Section 242 of the General Corporation law of the State of Delaware by the vote of a majority of each class of outstanding stock of the Corporation entitled to vote thereon.

IN WITNESS WHEREOF, I have signed this Certificate of Amendment this 12th day of July, 2016.
 

 
 
 
 /s/ David Pernock
Chairman of the Board and Chief Executive Officer



 EX-10.1 3 fcscex101.htm EXHIBIT 10.1 Exhibit

Exhibit 10.1


AMENDMENT TO THE
FIBROCELL SCIENCE, INC. 2009 EQUITY INCENTIVE PLAN

WHEREAS, Fibrocell Science, Inc. (the “Company”), maintains the Fibrocell Science, Inc. 2009 Equity Incentive Plan, as amended (the “Plan”);

WHEREAS, pursuant to Section 17(a) of the Plan, the Board of Directors of the Company (the “Board”) is authorized to amend the Plan from time to time, provided that such amendment shall be contingent on the approval of the Company’s shareholders (“Shareholder Approval”) when such approval is required pursuant to the Internal Revenue Code of 1986, as amended and/or stock exchange requirements; and

WHEREAS, the Board desires to increase the number of shares of common stock of the Company reserved for issuance under the Plan (the “Share Increase”) and to include an annual limit on the number of shares underlying awards made to any one participant under the Plan in any calendar year (the “Annual Limit”); and

WHEREAS, pursuant to Section 17(a) of the Plan, in order to effect each of these desired changes, Shareholder Approval must be obtained; and

WHEREAS, the Board desires to amend the Plan to provide for the Share Increase and the Annual Limit as set forth in this Amendment to the Plan (the “Amendment”), subject to timely Shareholder Approval.

NOW, THEREFORE, the Board hereby amends the Plan, subject to timely Shareholder Approval, as follows:

1.
Section 5(a) of the Plan, subject to timely Shareholder Approval, is hereby amended to read in its entirety as follows:

“Shares Authorized.  The aggregate number of shares of Company Stock that may be issued under the Plan is 7,600,000 shares, subject to adjustment as described in subsection (d) below.”

2.
A new Section 5(e) is, subject to timely Shareholder Approval, hereby added to the Plan to read in its entirety as follows:

“Limitations. In accordance with the requirements under Section 162(m) of the Code, subject to adjustment as described in subsection (d) above, the maximum number of shares of Company Stock underlying Grants that may be granted during a calendar year to any individual Participant shall be 1,500,000 shares of Company Stock.”

3.
Except as specifically provided in and modified by this Amendment, the Plan is in all other respects hereby ratified and confirmed and references to the Plan shall be deemed to refer to the Plan as modified by this Amendment, contingent upon obtaining timely Shareholder Approval.

IN WITNESS WHEREOF, the Company has executed this Amendment to the Fibrocell Science, Inc. 2009 Equity Incentive Plan, as amended, as of April 15, 2016.
 
FIBROCELL SCIENCE, INC.
 
 
By:
 
/s/ David Pernock
Name:  
Its:
 
David Pernock
Chairman of the Board and CEO



 EX-31.1 4 fcsc-2016630ex311.htm EXHIBIT 31.1 Exhibit


Exhibit 31.1
 
OFFICER’S CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, David Pernock, certify that:
1.  I have reviewed this Quarterly Report on Form 10-Q of Fibrocell Science, Inc.;
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
August 4, 2016
By:
/s/ David Pernock
 
David Pernock
 
Chief Executive Officer



 EX-31.2 5 fcsc-2016630ex312.htm EXHIBIT 31.2 Exhibit


Exhibit 31.2
 
OFFICER’S CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
 
I, Keith A. Goldan, certify that:
1.  I have reviewed this Quarterly Report on Form 10-Q of Fibrocell Science, Inc.;
2.  Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;
3.  Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.  The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; 
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors:
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date:
August 4, 2016
By:
/s/ Keith A. Goldan
 
Keith A. Goldan
 
SVP and Chief Financial Officer



 EX-32.1 6 fcsc-2016630ex321.htm EXHIBIT 32.1 Exhibit


Exhibit 32.1
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 of Fibrocell Science, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, David Pernock, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
•The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and
•The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 4, 2016
By:
/s/ David Pernock
 
David Pernock
 
Chief Executive Officer
 
A signed original of this written statement required by Section 906 has been provided to Fibrocell Science, Inc. and will be retained by Fibrocell Science, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-32.2 7 fcsc-2016630ex322.htm EXHIBIT 32.2 Exhibit


Exhibit 32.2
 
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q for the fiscal quarter ended June 30, 2016 of Fibrocell Science, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Keith A. Goldan, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:
 
•The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and
•The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
Date:
August 4, 2016
By:
/s/ Keith A. Goldan
 
Keith A. Goldan
 
SVP and Chief Financial Officer
 
A signed original of this written statement required by Section 906 has been provided to Fibrocell Science, Inc. and will be retained by Fibrocell Science, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.INS 8 fcsc-20160630.xml XBRL INSTANCE DOCUMENT 0000357097 2016-01-01 2016-06-30 0000357097 2016-07-29 0000357097 2015-12-31 0000357097 2016-06-30 0000357097 2015-04-01 2015-06-30 0000357097 2015-01-01 2015-06-30 0000357097 us-gaap:AffiliatedEntityMember 2016-01-01 2016-06-30 0000357097 2016-04-01 2016-06-30 0000357097 us-gaap:AffiliatedEntityMember 2015-01-01 2015-06-30 0000357097 us-gaap:AffiliatedEntityMember 2015-04-01 2015-06-30 0000357097 us-gaap:AffiliatedEntityMember 2016-04-01 2016-06-30 0000357097 fcsc:DeficitAccumulatedMember 2016-01-01 2016-06-30 0000357097 us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000357097 fcsc:DeficitAccumulatedMember 2016-06-30 0000357097 us-gaap:AdditionalPaidInCapitalMember 2016-01-01 2016-06-30 0000357097 us-gaap:CommonStockMember 2015-12-31 0000357097 us-gaap:CommonStockMember 2016-06-30 0000357097 fcsc:DeficitAccumulatedMember 2015-12-31 0000357097 us-gaap:AdditionalPaidInCapitalMember 2016-06-30 0000357097 2014-12-31 0000357097 2015-06-30 0000357097 2012-01-01 2012-01-01 0000357097 fcsc:AccountingStandardsUpdate201609Member us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember fcsc:DeficitAccumulatedMember 2015-12-31 0000357097 2009-09-03 0000357097 fcsc:AccountingStandardsUpdate201609Member us-gaap:NewAccountingPronouncementEarlyAdoptionEffectMember us-gaap:AdditionalPaidInCapitalMember 2015-12-31 0000357097 us-gaap:CostOfSalesMember 2016-04-01 2016-06-30 0000357097 fcsc:WarrantLiabilityMember 2016-01-01 2016-06-30 0000357097 fcsc:WarrantLiabilityMember 2015-01-01 2015-12-31 0000357097 fcsc:WarrantLiabilityMember 2015-12-31 0000357097 fcsc:WarrantLiabilityMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInAugust2011FinancingMember 2015-12-31 0000357097 fcsc:WarrantsIssuedWithConvertibleNotesMember 2015-12-31 0000357097 fcsc:WarrantsIssuedToPlacementAgentsInAugust2011FinancingMember 2015-12-31 0000357097 fcsc:WarrantsIssuedToPlacementAgentsInAugust2011FinancingMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInSeriesEPreferredStockOfferingExpiringDec2017Member 2016-06-30 0000357097 fcsc:WarrantsIssuedInAugust2011FinancingMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInMarch2010FinancingMember 2016-06-30 0000357097 fcsc:WarrantsIssuedWithConvertibleNotesMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInSeriesEPreferredStockOfferingExpiringDec2017Member 2015-12-31 0000357097 fcsc:WarrantsIssuedInSeriesBandDPreferredStockOfferingsMember 2015-12-31 0000357097 fcsc:WarrantsIssuedInSeriesBandDPreferredStockOfferingsMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInJune2011FinancingMember 2016-06-30 0000357097 fcsc:WarrantsIssuedInSeriesEPreferredStockOfferingExpiringDec2018Member 2016-06-30 0000357097 fcsc:WarrantsIssuedInMarch2010FinancingMember 2015-12-31 0000357097 fcsc:WarrantsIssuedInJune2011FinancingMember 2015-12-31 0000357097 fcsc:WarrantsIssuedInSeriesEPreferredStockOfferingExpiringDec2018Member 2015-12-31 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2016-04-01 2016-06-30 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2016-01-01 2016-06-30 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-01-01 2015-06-30 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:WarrantMember 2015-04-01 2015-06-30 0000357097 us-gaap:WarrantMember 2016-06-30 0000357097 us-gaap:WarrantMember 2016-01-01 2016-06-30 0000357097 us-gaap:WarrantMember 2015-12-31 0000357097 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000357097 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000357097 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2015-12-31 0000357097 us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000357097 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000357097 us-gaap:FairValueInputsLevel2Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000357097 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:FairValueMeasurementsRecurringMember 2016-06-30 0000357097 2015-01-01 2015-12-31 0000357097 fcsc:ShareBasedCompensationStockOptionsMember fcsc:EquityIncentiveConsultantsMember 2013-12-31 0000357097 fcsc:ShareBasedCompensationStockOptionsMember fcsc:EquityIncentivePlan2009Member 2009-09-03 2009-09-03 0000357097 fcsc:ShareBasedCompensationStockOptionsMember fcsc:EquityIncentivePlan2009Member 2016-06-30 0000357097 fcsc:ServiceBasedStockOptionsMember 2016-06-30 0000357097 fcsc:ShareBasedCompensationStockOptionsMember fcsc:EquityIncentivePlan2009Member us-gaap:DirectorMember 2009-09-03 2009-09-03 0000357097 fcsc:ServiceBasedStockOptionsMember 2016-01-01 2016-06-30 0000357097 fcsc:EquityIncentivePlan2009Member 2009-09-03 0000357097 fcsc:PassthroughCostsMember us-gaap:AffiliatedEntityMember 2016-01-01 2016-06-30 0000357097 fcsc:PassthroughCostsMember us-gaap:AffiliatedEntityMember 2016-04-01 2016-06-30 0000357097 fcsc:DirectExpensesforWorkPerformedMember us-gaap:AffiliatedEntityMember 2016-01-01 2016-06-30 0000357097 us-gaap:DirectorMember 2016-01-01 2016-06-30 0000357097 fcsc:A2015ECCMember us-gaap:AffiliatedEntityMember 2016-01-01 2016-06-30 0000357097 us-gaap:AffiliatedEntityMember 2015-12-31 0000357097 fcsc:DirectExpensesforWorkPerformedMember us-gaap:AffiliatedEntityMember 2016-04-01 2016-06-30 0000357097 fcsc:DirectExpensesforWorkPerformedMember us-gaap:AffiliatedEntityMember 2015-01-01 2015-06-30 0000357097 us-gaap:AffiliatedEntityMember 2016-06-30 0000357097 fcsc:DirectExpensesforWorkPerformedMember us-gaap:AffiliatedEntityMember 2015-04-01 2015-06-30 0000357097 fcsc:TechnologyAccessFeeMember 2016-01-01 2016-01-31 0000357097 fcsc:PassthroughCostsMember us-gaap:AffiliatedEntityMember 2015-04-01 2015-06-30 0000357097 fcsc:PassthroughCostsMember us-gaap:AffiliatedEntityMember 2015-01-01 2015-06-30 0000357097 fcsc:A2015ECCMember us-gaap:AffiliatedEntityMember 2015-01-01 2015-06-30 0000357097 us-gaap:EmployeeSeveranceMember 2016-01-01 2016-06-30 0000357097 fcsc:AssetImpairmentsMember 2016-06-30 0000357097 fcsc:AssetImpairmentsMember 2016-01-01 2016-06-30 0000357097 us-gaap:EmployeeSeveranceMember 2015-12-31 0000357097 fcsc:AssetImpairmentsMember 2015-12-31 0000357097 us-gaap:EmployeeSeveranceMember 2016-06-30 0000357097 fcsc:AssetImpairmentsMember 2016-04-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyWarrantsOutstandingMember 2015-01-01 2015-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyWarrantsOutstandingMember 2015-04-01 2015-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyOptionsOutstandingMember 2015-04-01 2015-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyWarrantsOutstandingMember 2015-04-01 2015-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyWarrantsOutstandingMember 2016-04-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyWarrantsOutstandingMember 2016-01-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyStockOptionsOutstandingMember 2015-01-01 2015-06-30 0000357097 us-gaap:PerformanceSharesMember 2016-04-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyStockOptionsOutstandingMember 2016-01-01 2016-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyOptionsOutstandingMember 2015-01-01 2015-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyOptionsOutstandingMember 2016-04-01 2016-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyWarrantsOutstandingMember 2015-01-01 2015-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyWarrantsOutstandingMember 2016-01-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyWarrantsOutstandingMember 2016-04-01 2016-06-30 0000357097 us-gaap:PerformanceSharesMember 2015-04-01 2015-06-30 0000357097 us-gaap:PerformanceSharesMember 2016-01-01 2016-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyStockOptionsOutstandingMember 2016-04-01 2016-06-30 0000357097 fcsc:SharesUnderlyingOutOfTheMoneyOptionsOutstandingMember 2016-01-01 2016-06-30 0000357097 us-gaap:PerformanceSharesMember 2015-01-01 2015-06-30 0000357097 fcsc:SharesUnderlyingInTheMoneyStockOptionsOutstandingMember 2015-04-01 2015-06-30 0000357097 fcsc:CantorFitzgeraldCo.Member 2016-01-01 2016-06-30 0000357097 fcsc:CantorFitzgeraldCo.Member us-gaap:CommonStockMember 2016-01-01 2016-01-31 0000357097 fcsc:CantorFitzgeraldCo.Member 2016-01-01 2016-01-31 0000357097 2016-03-31 iso4217:USD fcsc:director xbrli:shares xbrli:pure fcsc:agreement iso4217:USD xbrli:shares fcsc:employee false --12-31 Q2 2016 2016-06-30 10-Q 0000357097 43898785 Smaller Reporting Company Fibrocell Science, Inc. fcsc 0 0.00 325902 6.55 0 0.00 4.55 1.15 82000 163000 14000 18000 85000 88000 0 1000 0 11000 50000000.0 62000 0 -65000 0 151000 2 2 0.03 P10Y 0.38 0.5 8275000 0 0 8275000 8275000 764000 0 0 764000 764000 1910000 5000 6365000 759000 602000 -1061000 2254000 7511000 5800000 7.14 7.18 499000 553000 10700000 900000 1779000 1253000 1242000 1401000 161330000 162555000 1125000 1125000 800000 1000000 600000 1100000 -1000 -12000 100000 1654200 4831352 1482614 1201698 100000 1442200 4831352 1518957 1201698 0 3979650 5340877 216000 0 0 3556497 4751145 545500 0 36712000 10516000 30994000 8906000 0 46000 37495000 26850000 29268000 8161000 8200000 29268000 0 0 29268000 8161000 0 0 8161000 -10645000 -21107000 7.14 7.18 18.75 22.50 6.25 6.25 2.50 7.50 13.635 2.50 5666779 565759 6113 319789 1970594 60000 1568823 50123 1125578 5340877 565759 0 0 1970594 60000 1568823 50123 1125578 0.001 0.001 100000000 100000000 150000000 43898785 43898785 43898785 43898785 43898785 43898785 44000 44000 77000 221000 392000 409000 162000 309000 392000 410000 -100000 100000 -100000 100000 779000 785000 457000 408000 346000 391000 0 0 0 -1958000 10720000 924000 -0.17 -0.37 -0.18 -0.22 -0.17 -0.37 -0.18 -0.26 4700000 P2Y9M -600000 1100000 -2300000 -7500000 0 0 P1Y8M P1Y3M 0.852 0.972 0.0098 0.0049 -7449000 8275000 764000 P12Y 2204000 0 -25000 22000 -305000 -307000 0 0 3905000 3900000 3905000 -6756000 -15281000 -8092000 -9499000 0 0 0 0 1061000 -3000 -2000 -12000 599000 -518000 84000 -49000 -338000 -9796000 -87000 -222000 0 64000 -549000 -728000 0 0 0 36034 4136000 0 6300000 1000 3000 4000 8000 482000 260000 482000 109000 338000 71000 0 200000 151000 144000 189000 200000 22509000 4687000 36712000 10516000 15365000 3143000 253000 -111000 -111000 -143000 -10787000 -20853000 -6756000 -15281000 -8092000 -9499000 -9499000 -6756000 -15281000 -8092000 -9499000 -6756000 -15281000 -8092000 -11457000 -7359000 -14223000 -10319000 -16987000 0 64000 0 0 -31000 -31000 0 0 0 0 109000 111000 143000 0.001 0.001 5000000 5000000 0 0 0 0 1244000 636000 255000 0 1582000 1546000 10000000 800000 300000 1100000 0 1700000 1200000 2900000 300000 600000 900000 0 800000 1400000 2200000 2000 2000 2567000 1127000 4814000 2867000 2352000 925000 4954000 2249000 25 0.50 0 0 300000 292000 34000 300000 292000 34000 258000 300000 0 0 0 258000 0 258000 -34000 -34000 0 -147171000 -156770000 137000 331000 87000 103000 55000 168000 73000 85000 3640000 6564000 2540000 5280000 1044000 1125000 P4Y P1Y 0 0 1.033 0.924 0.0156 0.0140 7600000 3365103 1954190 7.50 188 29256 1091000 3.57 1.53 1630000 43000 25000 3134094 4195650 6.23 5.15 0.00 4.24 4.61 2.01 0.25 P6Y1M P6Y1M 0 P6Y11M P8Y0M P8Y0M 1600000 0 0 14203000 -147171000 161330000 44000 5829000 -156770000 162555000 44000 40889732 40875704 43898785 43934819 40889732 40875704 43898785 43898785 <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below is a summary of the Company&#8217;s warrant activity during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,666,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(325,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the calculated aggregate fair values, along with the inputs and assumptions utilized in each calculation:&#160;&#160;&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands except per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Calculated aggregate value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average exercise price per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Closing price per share of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average remaining expected life</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1 year, 3 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1 year, 8 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s outstanding common stock warrants were classified as derivative liabilities and accounted for based on the guidance in ASC 815, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> as the warrants contain &#8220;down-round protection&#8221; or other terms that could potentially require &#8220;net cash settlement&#8221; and hence were determined not to be indexed to the Company&#8217;s own stock. The warrants will continue to be classified as a liability, regardless of the likelihood that such instruments will ever be settled in cash, until they are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes outstanding liability-classified warrants to purchase common stock:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of&#160;Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability-classified&#160;warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Dates</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in March&#160;2010 financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mar 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in June&#160;2011 financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jun 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series B and D Preferred Stock offerings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,970,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,970,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jul 2016 - Dec 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in August&#160;2011 financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">565,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">565,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aug 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued to placement agents in August&#160;2011 financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13.635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aug 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series&#160;E Preferred Stock offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">60,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">60,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dec 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued with Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,125,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,125,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jun 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series&#160;E Preferred Stock offering</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,568,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,568,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dec 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,666,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The table below is a summary of the Company&#8217;s warrant activity during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,666,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.14</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(325,902</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Outstanding at June 30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting for Liability-classified Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">The foregoing warrants were recorded as derivative liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income or expense in the Company&#8217;s Condensed Consolidated Statements of Operations in each subsequent period. The change in the estimated fair value of the warrant liability for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> resulted in non-cash income of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$7.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The change in the estimated fair value of the warrant liability for the three and </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2015</font><font style="font-family:inherit;font-size:10pt;"> resulted in non-cash income of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> and non-cash expense of approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. The Company utilizes a Monte Carlo simulation valuation method to value its liability-classified warrants.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumptions Used in Determining Fair Value of Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of warrants is determined using Level 2 and Level 3 inputs.&#160; Inherent in the Monte Carlo simulation valuation method are the following assumptions:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volatility. </font><font style="font-family:inherit;font-size:10pt;">The Company estimates stock price volatility based on the Company&#8217;s historical stock price performance over a period of time that matches the expected remaining life of the warrants.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free interest rate</font><font style="font-family:inherit;font-size:10pt;">. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the valuation date commensurate with the expected remaining life assumption.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected remaining life.</font><font style="font-family:inherit;font-size:10pt;"> The expected life of the warrants is assumed to be equivalent to their remaining contractual term.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend rate.</font><font style="font-family:inherit;font-size:10pt;"> The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Scenarios. </font><font style="font-family:inherit;font-size:10pt;"> &#160;The probability of complex features of the warrants being triggered is subjective (no observable inputs or available market data) and based on internal and external information known to management at the valuation date. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the calculated aggregate fair values, along with the inputs and assumptions utilized in each calculation:&#160;&#160;&#160;&#160;&#160;&#160;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:63%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands except per share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Calculated aggregate value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average exercise price per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.18</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.14</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Closing price per share of common stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.15</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.55</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">97.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">85.2</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Weighted average remaining expected life</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1 year, 3 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1 year, 8 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.49</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">0.98</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividend yield</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.&#160; In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.&#160; These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015 (2015 Form 10-K), filed with the Securities and Exchange Commission (SEC). The Company&#8217;s significant accounting policies are described in the Notes to Consolidated Financial Statements in the 2015 Form 10-K and updated, as necessary, in Note 3 in this Form 10-Q. The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All intercompany accounts and transactions have been eliminated in consolidation. The Company's international operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.</font></div><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prior year Condensed Consolidated Financial Statements presented in this Form 10-Q contain certain reclassifications made to the Condensed Consolidated Statement of Operations and the Condensed Consolidated Statement of Cash Flows to conform to the current year&#8217;s presentation. Specifically, related party payables were reclassified from accounts payable and accrued expenses as of June 30, 2015.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form&#160;10-Q and Article&#160;10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.&#160; In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.&#160; These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company&#8217;s Annual Report on Form&#160;10-K for the year ended December&#160;31, 2015 (2015 Form 10-K), filed with the Securities and Exchange Commission (SEC). The Company&#8217;s significant accounting policies are described in the Notes to Consolidated Financial Statements in the 2015 Form 10-K and updated, as necessary, in Note 3 in this Form 10-Q. The results of the Company&#8217;s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All intercompany accounts and transactions have been eliminated in consolidation. The Company's international operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restructuring Costs</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Restructuring charges are primarily comprised of severance costs related to workforce reductions, contract termination and wind-down costs, asset impairments and costs of decommissioning the Company&#8217;s azficel-T manufacturing facility. In accordance with ASC 420, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exit or Disposal Cost Obligations</font><font style="font-family:inherit;font-size:10pt;">, the Company recognizes restructuring charges when the liability has been incurred, except for one-time employee termination benefits that are incurred over time. Generally, one-time employee termination benefits (i.e. severance costs) are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments. Other costs, including but not limited to, contract termination and wind-down costs and manufacturing facility decommissioning costs, will be recorded as incurred. Asset impairment charges have been, and will be, recognized when management has concluded that the assets have been impaired in accordance with ASC 360-10-35, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">, or other applicable authoritative guidance. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2009 Equity Incentive Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s Board of Directors (the Board) adopted the 2009 Equity Incentive Plan (as amended to date, the Plan) effective September&#160;3, 2009.&#160; The Plan is intended to further align the interests of the Company and its stockholders with its employees, including its officers, non-employee directors, consultants and advisers by providing equity-based incentives.&#160; The Plan allows for the issuance of up to </font><font style="font-family:inherit;font-size:10pt;">7,600,000</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock.&#160; In addition, there are </font><font style="font-family:inherit;font-size:10pt;">25,000</font><font style="font-family:inherit;font-size:10pt;"> options outstanding that were issued outside the Plan to consultants in 2013.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The types of awards that may be granted under the Plan include options (both non-qualified stock options and incentive stock options), stock appreciation rights, stock awards, stock units and other stock-based awards.&#160; The term of each award is determined by the Compensation Committee of the Board at the time each award is granted, provided that the terms of options do not exceed </font><font style="font-family:inherit;font-size:10pt;">ten years</font><font style="font-family:inherit;font-size:10pt;">.&#160; Vesting schedules for stock options vary, but generally vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> per year over </font><font style="font-family:inherit;font-size:10pt;">four years</font><font style="font-family:inherit;font-size:10pt;"> for employee options and on the </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-year anniversary date for non-employee director options. The Plan had </font><font style="font-family:inherit;font-size:10pt;">3,365,103</font><font style="font-family:inherit;font-size:10pt;"> shares available for future grants as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Accounting for Stock-Based Compensation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes non-cash compensation expense for stock-based awards based on their grant date fair value, determined using the Black-Scholes option-pricing model. During the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the weighted average fair market value for options granted was </font><font style="font-family:inherit;font-size:10pt;">$1.53</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$3.57</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stock-based compensation expense recognized using the straight-line attribution method and included in operating expenses in the Condensed Consolidated Statements of Operations was approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$0.8</font><font style="font-family:inherit;font-size:10pt;"> million for the </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively, and approximately </font><font style="font-family:inherit;font-size:10pt;">$1.1</font><font style="font-family:inherit;font-size:10pt;"> million and </font><font style="font-family:inherit;font-size:10pt;">$1.0</font><font style="font-family:inherit;font-size:10pt;"> million for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumptions Used in Determining Fair Value of Stock Options</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inherent in the Black-Scholes option-pricing model are the following assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volatility. </font><font style="font-family:inherit;font-size:10pt;">The Company estimates stock price volatility based on the Company&#8217;s historical stock price performance over a period of time that matches the expected term of the stock options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free interest rate</font><font style="font-family:inherit;font-size:10pt;">. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected term</font><font style="font-family:inherit;font-size:10pt;">. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, described in the SEC&#8217;s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Forfeitures. </font><font style="font-family:inherit;font-size:10pt;"> The Company accounts for forfeitures when they occur. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair market value of these stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 1 month</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 1 month</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">For the six months ended June 30, 2016, the Company estimated expected volatility based on the historical volatility of its own common stock on a stand-alone basis. Prior to January 1, 2016, including the six months ended June 30, 2015, the Company estimated expected volatility based on the historical volatility of a peer group.</font></div></td></tr></table><div style="line-height:120%;padding-left:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Option Activity</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted- average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">remaining</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">contractual</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">intrinsic</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,134,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,091,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(29,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at June 30, 2016</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,195,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercisable at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,954,190</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 11 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.</font></div></td></tr></table><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The total fair value of options vested during the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> was approximately </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">. Additionally, as of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, there was approximately </font><font style="font-family:inherit;font-size:10pt;">$4.7 million</font><font style="font-family:inherit;font-size:10pt;"> of unrecognized compensation expense related to non-vested stock options which is expected to be recognized over a weighted-average period of </font><font style="font-family:inherit;font-size:10pt;">2.8</font><font style="font-family:inherit;font-size:10pt;"> years.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Loss Per Share</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during that period.&#160; The diluted loss per share calculation gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period.&#160; Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money common stock equivalents based on the average market price during the period.&#160; Common stock equivalents have been excluded where their inclusion would be anti-dilutive. </font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Details in the computation of basic and diluted loss per share are as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three&#160;months&#160;ended &#160;June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six&#160;months&#160;ended &#160;June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per share - basic:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Numerator for basic loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for basic loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per share - diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Numerator for diluted loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,499</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjust: Warrant revaluation income (expense) for dilutive warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss attributable to common share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for basic loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Plus: Incremental shares underlying dilutive warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for diluted loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,934,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted net loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three&#160;months&#160;ended &#160;June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six&#160;months&#160;ended &#160;June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;In the money&#8221; stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">216,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,482,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,518,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;Out of the money&#8221; stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,979,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,654,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,556,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,442,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;In the money&#8221; warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,201,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,201,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;Out of the money&#8221; warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,831,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,751,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,831,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other securities excluded from the calculation of diluted loss per share:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options with performance condition</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Fair Value Measurements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the guidance in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement,</font><font style="font-family:inherit;font-size:10pt;"> to account for financial assets and liabilities measured at fair value on a recurring basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The guidance requires fair value measurements be classified and disclosed in one of the following three categories within the hierarchy:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following fair value hierarchy table presents information about each major category of the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis as of:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,161</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:25%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 2</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Assets:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">29,268</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liabilities:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Warrant liability</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis - Common Stock Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrant</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Represents the fair value as of the beginning of the year for warrants expiring during the year and has been recorded to warrant revaluation income or expense in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2016.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Effect of Fibrocell&#8217;s Stock Price and Volatility Assumptions on the Calculation of Fair Value of Warrant Liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value of the warrant liability is based on Level 3 inputs. As discussed in Note 5, the Company uses a Monte Carlo simulation valuation method to value its liability-classified warrants. The determination of fair value as of the reporting date is affected by Fibrocell&#8217;s stock price as well as assumptions regarding a number of subjective variables that do not have observable inputs or available market data to support the fair value. These variables include, but are not limited to, expected stock price volatility over the term of the warrants and the risk-free interest rate. The primary factors affecting the fair value of the warrant liability are the Company&#8217;s stock price and volatility as well as certain assumptions by the Company as to the likelihood of provisions to the underlying warrant agreements being triggered. The methods described above and in Note 5 may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Certain Financial Assets and Liabilities</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company believes that the fair values of the Company&#8217;s current assets and liabilities approximate their reported carrying amounts. There were no transfers between Level 1, 2 and 3 during the periods presented.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Warrant</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8,275</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expiration of warrants</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(62</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Change in fair value of warrant liability</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(7,449</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Balance at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">764</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Represents the fair value as of the beginning of the year for warrants expiring during the year and has been recorded to warrant revaluation income or expense in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2016.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, all of the Company&#8217;s outstanding common stock warrants were classified as derivative liabilities and accounted for based on the guidance in ASC 815, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Derivatives and Hedging</font><font style="font-family:inherit;font-size:10pt;"> as the warrants contain &#8220;down-round protection&#8221; or other terms that could potentially require &#8220;net cash settlement&#8221; and hence were determined not to be indexed to the Company&#8217;s own stock. The warrants will continue to be classified as a liability, regardless of the likelihood that such instruments will ever be settled in cash, until they are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assumptions Used in Determining Fair Value of Warrants</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The estimated fair value of warrants is determined using Level 2 and Level 3 inputs.&#160; Inherent in the Monte Carlo simulation valuation method are the following assumptions:</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Volatility. </font><font style="font-family:inherit;font-size:10pt;">The Company estimates stock price volatility based on the Company&#8217;s historical stock price performance over a period of time that matches the expected remaining life of the warrants.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Risk-free interest rate</font><font style="font-family:inherit;font-size:10pt;">. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the valuation date commensurate with the expected remaining life assumption.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Expected remaining life.</font><font style="font-family:inherit;font-size:10pt;"> The expected life of the warrants is assumed to be equivalent to their remaining contractual term.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Dividend rate.</font><font style="font-family:inherit;font-size:10pt;"> The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Scenarios. </font><font style="font-family:inherit;font-size:10pt;"> &#160;The probability of complex features of the warrants being triggered is subjective (no observable inputs or available market data) and based on internal and external information known to management at the valuation date.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Assets and Liabilities Measured at Fair Value on a Recurring Basis</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows the guidance in ASC 820, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Fair Value Measurement,</font><font style="font-family:inherit;font-size:10pt;"> to account for financial assets and liabilities measured at fair value on a recurring basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity&#8217;s own assumptions (unobservable inputs). The guidance requires fair value measurements be classified and disclosed in one of the following three categories within the hierarchy:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are research and development assets related to the Company&#8217;s primary study on azficel-T that were capitalized on the balance sheet upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identifiable intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">. Azficel-T had </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> current or target indications: the Company's FDA-approved product LAVIV</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and a clinical development program for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Effective January 1, 2012, the Company launched LAVIV and as a result, the research and development intangible assets related to the Company&#8217;s primary study were considered to be finite-lived intangible assets and began amortizing over </font><font style="font-family:inherit;font-size:10pt;">12 years</font><font style="font-family:inherit;font-size:10pt;">, the estimated useful life of the assets which is analogous with the exclusivity period granted to the Company under the BLA. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews the estimated remaining useful life of its intangible assets on an annual basis with any changes, if applicable, accounted for prospectively. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In June 2016, based on its failure to achieve primary efficacy endpoints for its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring, the Company determined to wind-down its azficel-T operations as more fully described in Note 9. As a result, management concluded that the Company&#8217;s intangible assets had become fully impaired.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 270,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Interim Reporting,</font><font style="font-family:inherit;font-size:10pt;"> and ASC 740,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</font><font style="font-family:inherit;font-size:10pt;">, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.&#160; For the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> tax expense or benefit due to the expected current year loss and its historical losses.&#160; The Company has not recorded its net deferred tax asset as of either </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> because it maintains a full valuation allowance against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Inventory </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consist of raw materials and work in process intended for use in the manufacture of LAVIV, which was approved by the FDA in 2011 for the improvement of nasolabial fold wrinkles in adults. However, raw materials may be used for clinical trials and are charged to research and development (R&amp;D) expense when consumed for such activities. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following as of:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials (LAVIV and product candidates)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work in process (LAVIV)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Reserve for work in process expiration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the wind-down of the Company&#8217;s azficel-T operations, as more fully described in Note 9, the Company recognized inventory write-downs of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> in cost of goods sold and recorded a reserve for work in process expiration of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> during the second quarter of 2016. With respect to LAVIV, the Company is no longer accepting new prescriptions.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Business and Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell Science, Inc. (as used herein, &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;Fibrocell&#8221; or the &#8220;Company&#8221;) is the parent company of Fibrocell Technologies, Inc. (Fibrocell Tech). Fibrocell Tech is the parent company of Isolagen International, S.A., a company organized under the laws of Switzerland (Isolagen Switzerland). The Company&#8217;s international activities are currently immaterial. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Effective April 1, 2016, Fibrocell Science Hong Kong Limited (&#8220;Fibrocell Hong Kong&#8221;), a company organized under the laws of Hong Kong and former subsidiary of Fibrocell, was dissolved. As this entity had no historical financial or operational activities, the impact of the dissolution did not, and is not expected to have, a material impact on the Company&#8217;s present or future consolidated financial statements.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Business Overview</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. The Company is focused on discovering and developing therapies for the localized treatment of diseases affecting the skin and connective tissue. All of the Company&#8217;s product candidates incorporate its proprietary autologous fibroblast technology. The Company&#8217;s research and development efforts focus on gaining regulatory approvals of its product candidates in the United States.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity and Financial Condition</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects to continue to incur losses and will require additional capital to advance its product candidates through development to commercialization. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had cash and cash equivalents of approximately $</font><font style="font-family:inherit;font-size:10pt;">8.2 million</font><font style="font-family:inherit;font-size:10pt;"> and working capital of approximately $</font><font style="font-family:inherit;font-size:10pt;">5.8 million</font><font style="font-family:inherit;font-size:10pt;">. The Company believes that its cash and cash equivalents at </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> will be sufficient to fund operations into the fourth quarter of 2016. The Company will require additional capital to fund operations beyond that point. To meet its capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company&#8217;s business, results of operations and financial condition. These conditions raise substantial doubt about its ability to continue as a going concern. Consequently, the audit report prepared by the Company&#8217;s independent registered public accounting firm related to its Consolidated Financial Statements for the year ended December 31, 2015 included a going concern explanatory paragraph.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had or is expected to have a material impact on the Company&#8217;s present or future consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The prior year Condensed Consolidated Financial Statements presented in this Form 10-Q contain certain reclassifications made to the Condensed Consolidated Statement of Operations and the Condensed Consolidated Statement of Cash Flows to conform to the current year&#8217;s presentation. Specifically, related party payables were reclassified from accounts payable and accrued expenses as of June 30, 2015. </font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Related Party Transactions</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company and Intrexon Corporation (Intrexon) are parties to </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> distinct exclusive channel collaboration agreements including the Exclusive Channel Collaboration Agreement entered into in October 2012 and amended in June 2013 and January 2014 (as amended, the 2012 ECC) and the Exclusive Channel Collaboration Agreement entered into in December 2015 (the 2015 ECC). Pursuant to these agreements, the Company engages Intrexon for support services for the research and development of product candidates covered under the respective agreements and reimburses Intrexon for its cost for time and materials for such work. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">three months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred total expenses of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, no expenses were incurred for work performed under the 2015 ECC. Of the </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> incurred during the 2016 period, </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to direct expenses for work performed by Intrexon and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> related to pass-through costs. Of the </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> incurred during the 2015 period, </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> related to direct expenses for work performed by Intrexon and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> related to pass-through costs. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company incurred total expenses of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> expenses were incurred for work performed under the 2015 ECC. Of the </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;"> incurred during the 2016 period, </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;"> related to direct expenses for work performed by Intrexon and </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> related to pass-through costs. Of the </font><font style="font-family:inherit;font-size:10pt;">$2.9 million</font><font style="font-family:inherit;font-size:10pt;"> incurred during the 2015 period, </font><font style="font-family:inherit;font-size:10pt;">$1.7 million</font><font style="font-family:inherit;font-size:10pt;"> related to direct expenses for work performed by Intrexon and </font><font style="font-family:inherit;font-size:10pt;">$1.2 million</font><font style="font-family:inherit;font-size:10pt;"> related to pass-through costs. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had outstanding payables to Intrexon of </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$10.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. In connection with the 2015 ECC, in consideration for the license and the other rights that the Company receives under the agreement, the Company paid Intrexon an up-front technology access fee of </font><font style="font-family:inherit;font-size:10pt;">$10 million</font><font style="font-family:inherit;font-size:10pt;"> in cash in January 2016.</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Randal J. Kirk is the chairman of the board and chief executive officer of Intrexon and, together with his affiliates, owns more than </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of Intrexon&#8217;s common stock. Affiliates of Randal J. Kirk (including Intrexon) own approximately </font><font style="font-family:inherit;font-size:10pt;">38%</font><font style="font-family:inherit;font-size:10pt;"> of our common stock. Additionally, </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> of our directors, Julian Kirk (who is the son of Randal J. Kirk) and Marcus Smith, are employees of Third Security, LLC, which is an affiliate of Randal J. Kirk.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Restructuring Costs</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"></font><font style="font-family:inherit;font-size:10pt;">In June 2016, the Company determined to wind-down its azficel-T operations at the Company&#8217;s Exton, PA facility and to reduce the workforce that supports such operations. This decision enables the Company to focus its resources towards pre-clinical and clinical research and development of its gene-therapy product candidates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring-related charges for both the three and six months ended June 30, 2016 totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;"> million and were comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;"> million of employee severance and benefit related charges and less than </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million of asset impairments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring and asset impairment activity for the six months ended June 30, 2016 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Severance and Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued restructuring balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Additional accruals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-cash settlements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued restructuring balance as of June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring-related charges incurred during the three and six months ended June 30, 2016 related to employee severance and benefits resulting from the reduction-in-workforce and the impairment of property and equipment. In connection with the reduction-in-workforce, </font><font style="font-family:inherit;font-size:10pt;">25</font><font style="font-family:inherit;font-size:10pt;"> positions were eliminated, primarily in the areas of manufacturing and quality operations, representing approximately </font><font style="font-family:inherit;font-size:10pt;">50%</font><font style="font-family:inherit;font-size:10pt;"> of the Company's employees. The accrued restructuring balance as of June 30, 2016 relates to employee severance and benefits which are expected to be paid in the third quarter of 2016 and is recorded as a current liability within accrued expenses in the Condensed Consolidated Balance Sheet. Additionally, the Company recognized inventory write-downs in cost of goods sold related to the wind-down of its azficel-T operations as described in Note 4.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company expects to incur additional charges in the future for employee severance and benefits, contract termination and wind-down costs, assets impairments and costs to decommission the Company&#8217;s azficel-T manufacturing facility, but cannot estimate them at this time.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;padding-top:4px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive:&#160;</font></div><div style="line-height:120%;padding-bottom:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three&#160;months&#160;ended &#160;June 30,</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six&#160;months&#160;ended &#160;June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;In the money&#8221; stock options</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">216,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,482,614</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">545,500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,518,957</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;Out of the money&#8221; stock options</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,979,650</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,654,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,556,497</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,442,200</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;In the money&#8221; warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,201,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,201,698</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8220;Out of the money&#8221; warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,831,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,751,145</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,831,352</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Other securities excluded from the calculation of diluted loss per share:</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Stock options with performance condition</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">100,000</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Details in the computation of basic and diluted loss per share are as follows:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:49%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three&#160;months&#160;ended &#160;June 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Six&#160;months&#160;ended &#160;June 30,</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands,&#160;except&#160;share&#160;and&#160;per&#160;share data)</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per share - basic:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Numerator for basic loss per share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,499</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for basic loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Basic loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.22</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Loss per share - diluted:</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Numerator for diluted loss per share</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(9,499</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Adjust: Warrant revaluation income (expense) for dilutive warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,958</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Net loss attributable to common share</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(8,092</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(6,756</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(11,457</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(15,281</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for basic loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Plus: Incremental shares underlying dilutive warrants outstanding</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">36,034</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Denominator for diluted loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,898,785</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,889,732</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43,934,819</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">40,875,704</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Diluted net loss per common share</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.18</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.17</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.26</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(0.37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Inventories consisted of the following as of:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:0%;" rowspan="1" colspan="1"></td><td style="width:67%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June 30, 2016</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December 31, 2015</font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Raw materials (LAVIV and product candidates)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">71</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">338</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Work in process (LAVIV)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">189</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">144</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Total inventory, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">260</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">482</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Less: Reserve for work in process expiration</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(151</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td rowspan="1" colspan="1"><font>&#160;</font></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total inventory, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">109</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">482</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Restructuring-related charges for both the three and six months ended June 30, 2016 totaled approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;"> million and were comprised of approximately </font><font style="font-family:inherit;font-size:10pt;">$0.3</font><font style="font-family:inherit;font-size:10pt;"> million of employee severance and benefit related charges and less than </font><font style="font-family:inherit;font-size:10pt;">$0.1</font><font style="font-family:inherit;font-size:10pt;"> million of asset impairments.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The restructuring and asset impairment activity for the six months ended June 30, 2016 was as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:55%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Employee Severance and Benefits</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Asset Impairments</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued restructuring balance as of December 31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Additional accruals</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">34</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">292</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Cash payments</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Non-cash settlements</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Accrued restructuring balance as of June 30, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">258</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes stock option activity for the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13" rowspan="1"></td></tr><tr><td style="width:39%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:12%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">($&#160;in&#160;thousands&#160;except&#160;share&#160;and&#160;per&#160;share&#160;data)</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted-</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Weighted- average</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">remaining</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">contractual</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">term</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Aggregate</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">intrinsic</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">value</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">3,134,094</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8 years</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,630</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,091,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.01</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Forfeited</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(29,256</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.61</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expired</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">(188</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4.24</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Outstanding at June 30, 2016</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">4,195,650</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5.15</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">8 years</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">43</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Exercisable at June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,954,190</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.50</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 11 months</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:13px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair market value of these stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the </font><font style="font-family:inherit;font-size:10pt;">six</font><font style="font-family:inherit;font-size:10pt;"> months ended:</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.41520467836257%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:59%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2015</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Expected term</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 1 month</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6 years, 1 month</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Interest rate</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1.56</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dividend yield</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Volatility</font><font style="font-family:inherit;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">92.4</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">103.3</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">%</font></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-bottom:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;" rowspan="1" colspan="1"></td><td rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:top" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><font style="font-family:inherit;font-size:9pt;">(1)</font></div></td><td style="vertical-align:top;" rowspan="1" colspan="1"><div style="line-height:120%;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">For the six months ended June 30, 2016, the Company estimated expected volatility based on the historical volatility of its own common stock on a stand-alone basis. Prior to January 1, 2016, including the six months ended June 30, 2015, the Company estimated expected volatility based on the historical volatility of a peer group.</font></div></td></tr></table></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:8px;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes outstanding liability-classified warrants to purchase common stock:</font></div><div style="line-height:120%;padding-bottom:8px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12" rowspan="1"></td></tr><tr><td style="width:40%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:15%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:16%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Number&#160;of&#160;Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Liability-classified&#160;warrants</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">June&#160;30, 2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, 2015</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Exercise</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Expiration</font></div><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Dates</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in March&#160;2010 financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">319,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Mar 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in June&#160;2011 financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6,113</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">22.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jun 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series B and D Preferred Stock offerings</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,970,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,970,594</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">6.25</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jul 2016 - Dec 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in August&#160;2011 financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">565,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">565,759</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">18.75</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aug 2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued to placement agents in August&#160;2011 financing</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">50,123</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">13.635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Aug 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series&#160;E Preferred Stock offering</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">60,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">60,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dec 2017</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued with Convertible Notes</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,125,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,125,578</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">2.50</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Jun 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Issued in Series&#160;E Preferred Stock offering</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,568,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">1,568,823</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">7.50</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">Dec 2018</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Total</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,340,877</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">5,666,779</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#160;</font></div></td></tr></table></div></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation </font><font style="font-family:inherit;font-size:10pt;">&#8211; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation </font><font style="font-family:inherit;font-size:10pt;">(ASC 718)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">or ASC 505-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity </font><font style="font-family:inherit;font-size:10pt;">&#8211; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Based Payments to Non-Employees, </font><font style="font-family:inherit;font-size:10pt;">where applicable. The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. In addition, the Company accounts for stock-based compensation to non-employees in accordance with the accounting guidance for equity instruments that are issued to entities or persons other than employees. The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected term of the options. The value of the award that is ultimately expected to vest based on the achievement of a performance condition (i.e., service period) is recognized as expense on a straight-line basis over the requisite service period. See Note 7 for additional details.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously, ASC 718 required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. In the first quarter of 2016, the Company adopted FASB Accounting Standards Update (ASU) 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, </font><font style="font-family:inherit;font-size:10pt;">which allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures when they occur. In connection with the adoption of this ASU, the Company made an accounting policy election to account for forfeitures as they occur and applied this change in accounting policy on a modified retrospective basis. As a result, the Company recorded a cumulative-effect adjustment to retained earnings which resulted in an increase to accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> with an offsetting increase to additional paid-in capital (zero net total equity impact) as of the date of adoption, principally related to additional stock compensation expense that would have been recognized on unvested outstanding options unadjusted for estimated forfeitures.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Summary of Significant Accounting Policies</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Intangible Assets </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Intangible assets are research and development assets related to the Company&#8217;s primary study on azficel-T that were capitalized on the balance sheet upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identifiable intangible assets was </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">. Azficel-T had </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> current or target indications: the Company's FDA-approved product LAVIV</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> and a clinical development program for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Effective January 1, 2012, the Company launched LAVIV and as a result, the research and development intangible assets related to the Company&#8217;s primary study were considered to be finite-lived intangible assets and began amortizing over </font><font style="font-family:inherit;font-size:10pt;">12 years</font><font style="font-family:inherit;font-size:10pt;">, the estimated useful life of the assets which is analogous with the exclusivity period granted to the Company under the BLA. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews the estimated remaining useful life of its intangible assets on an annual basis with any changes, if applicable, accounted for prospectively. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In June 2016, based on its failure to achieve primary efficacy endpoints for its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring, the Company determined to wind-down its azficel-T operations as more fully described in Note 9. As a result, management concluded that the Company&#8217;s intangible assets had become fully impaired. Accordingly, a non-cash impairment charge of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;"> was recorded during the three months ended June 30, 2016 and is included in the Condensed Consolidated Statement of Operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company follows ASC 718, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation </font><font style="font-family:inherit;font-size:10pt;">&#8211; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Stock Compensation </font><font style="font-family:inherit;font-size:10pt;">(ASC 718)</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, </font><font style="font-family:inherit;font-size:10pt;">or ASC 505-50, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity </font><font style="font-family:inherit;font-size:10pt;">&#8211; </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Equity Based Payments to Non-Employees, </font><font style="font-family:inherit;font-size:10pt;">where applicable. The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. In addition, the Company accounts for stock-based compensation to non-employees in accordance with the accounting guidance for equity instruments that are issued to entities or persons other than employees. The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected term of the options. The value of the award that is ultimately expected to vest based on the achievement of a performance condition (i.e., service period) is recognized as expense on a straight-line basis over the requisite service period. See Note 7 for additional details.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Previously, ASC 718 required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. In the first quarter of 2016, the Company adopted FASB Accounting Standards Update (ASU) 2016-09, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, </font><font style="font-family:inherit;font-size:10pt;">which allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures when they occur. In connection with the adoption of this ASU, the Company made an accounting policy election to account for forfeitures as they occur and applied this change in accounting policy on a modified retrospective basis. As a result, the Company recorded a cumulative-effect adjustment to retained earnings which resulted in an increase to accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> with an offsetting increase to additional paid-in capital (zero net total equity impact) as of the date of adoption, principally related to additional stock compensation expense that would have been recognized on unvested outstanding options unadjusted for estimated forfeitures.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Restructuring Costs</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;"></font><font style="font-family:inherit;font-size:10pt;">Restructuring charges are primarily comprised of severance costs related to workforce reductions, contract termination and wind-down costs, asset impairments and costs of decommissioning the Company&#8217;s azficel-T manufacturing facility. In accordance with ASC 420, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Exit or Disposal Cost Obligations</font><font style="font-family:inherit;font-size:10pt;">, the Company recognizes restructuring charges when the liability has been incurred, except for one-time employee termination benefits that are incurred over time. Generally, one-time employee termination benefits (i.e. severance costs) are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments. Other costs, including but not limited to, contract termination and wind-down costs and manufacturing facility decommissioning costs, will be recorded as incurred. Asset impairment charges have been, and will be, recognized when management has concluded that the assets have been impaired in accordance with ASC 360-10-35, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Impairment or Disposal of Long-Lived Assets</font><font style="font-family:inherit;font-size:10pt;">, or other applicable authoritative guidance. See Note 9 for additional details.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with ASC 270,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Interim Reporting,</font><font style="font-family:inherit;font-size:10pt;"> and ASC 740,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Income Taxes</font><font style="font-family:inherit;font-size:10pt;">, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.&#160; For the </font><font style="font-family:inherit;font-size:10pt;">six months ended June 30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2015</font><font style="font-family:inherit;font-size:10pt;">, the Company recorded </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> tax expense or benefit due to the expected current year loss and its historical losses.&#160; The Company has not recorded its net deferred tax asset as of either </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> or </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;"> because it maintains a full valuation allowance against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2015</font><font style="font-family:inherit;font-size:10pt;">, the Company had no uncertain tax positions.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had or is expected to have a material impact on the Company&#8217;s present or future consolidated financial statements.</font></div></div> <div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Equity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock - Shares Authorized</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In July 2016, the Company amended its Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock that the Company is authorized to issue from </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">150,000,000</font><font style="font-family:inherit;font-size:10pt;">. The amendment was approved by stockholders in June at the Company&#8217;s 2016 Annual Meeting of Stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock - &#8220;At-The-Market&#8221; Equity Program</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In January 2016, the Company entered into a Controlled Equity Offering&#8482; Sales Agreement (the ATM Agreement) with Cantor Fitzgerald &amp; Co. (Cantor Fitzgerald) to implement an "At-The-Market" (ATM) equity program under which the Company, from time to time, may offer and sell shares of its common stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0</font><font style="font-family:inherit;font-size:10pt;"> million (the Shares) through Cantor Fitzgerald. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subject to the terms and conditions of the ATM Agreement, Cantor Fitzgerald will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company&#8217;s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the ATM Agreement or terminate the ATM Agreement. Cantor Fitzgerald will be entitled to a fixed commission of up to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross proceeds from Shares sold. Through </font><font style="font-family:inherit;font-size:10pt;">June&#160;30, 2016</font><font style="font-family:inherit;font-size:10pt;">, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> Shares have been sold through the ATM equity program.</font></div></div> EX-101.SCH 9 fcsc-20160630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 2102100 - Disclosure - Basis of Presentation link:presentationLink link:calculationLink link:definitionLink 2101100 - Disclosure - Business and Organization link:presentationLink link:calculationLink link:definitionLink 2401401 - Disclosure - Business and Organization (Details) link:presentationLink link:calculationLink link:definitionLink 1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 1001501 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 1002000 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 1003000 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 0001000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 2112100 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 2412401 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 2106100 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 2406402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 2306301 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 2406403 - Disclosure - Fair Value Measurements - Warrant Liability Reconciliation (Details) link:presentationLink link:calculationLink link:definitionLink 2104100 - Disclosure - Inventory link:presentationLink link:calculationLink link:definitionLink 2404402 - Disclosure - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 2404403 - Disclosure - Inventory - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2304301 - Disclosure - Inventory (Tables) link:presentationLink link:calculationLink link:definitionLink 2111100 - Disclosure - Loss Per Share link:presentationLink link:calculationLink link:definitionLink 2411403 - Disclosure - Loss Per Share - Antidilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 2411402 - Disclosure - Loss Per Share - Earnings Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 2311301 - Disclosure - Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 2108100 - Disclosure - Related Party Transactions link:presentationLink link:calculationLink link:definitionLink 2408401 - Disclosure - Related Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 2109100 - Disclosure - Restructuring Costs link:presentationLink link:calculationLink link:definitionLink 2409403 - Disclosure - Restructuring Costs - Changes in Restructuring Balance (Details) link:presentationLink link:calculationLink link:definitionLink 2409402 - Disclosure - Restructuring Costs (Details) link:presentationLink link:calculationLink link:definitionLink 2309301 - Disclosure - Restructuring Costs (Tables) link:presentationLink link:calculationLink link:definitionLink 2107100 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 2407402 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2407404 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 2307301 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 2407403 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2103100 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 2403402 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 2105100 - Disclosure - Warrants link:presentationLink link:calculationLink link:definitionLink 2405405 - Disclosure - Warrants - Aggregate Fair Values, Inputs and Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 2405402 - Disclosure - Warrants - Liability-Classified Warrants Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 2405404 - Disclosure - Warrants - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 2305301 - Disclosure - Warrants (Tables) link:presentationLink link:calculationLink link:definitionLink 2405403 - Disclosure - Warrants - Warrant Activity (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 10 fcsc-20160630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 11 fcsc-20160630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 12 fcsc-20160630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Statement of Cash Flows [Abstract] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss Net Income (Loss) Attributable to Parent Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Stock-based compensation expense Share-based Compensation Warrant revaluation (income) expense Warrant Revaluation Income (Expense) Periodic changes in fair value of warrants to purchase common stock. Depreciation and amortization Depreciation, Depletion and Amortization Provision for (recovery of) doubtful accounts Allowance for Doubtful Accounts Receivable, Period Increase (Decrease) Inventory reserve Increase (Decrease) in Inventory Reserve Increase (Decrease) in Inventory Reserve Intangible asset impairment Impairment of Intangible Assets, Finite-lived Loss on disposal or impairment of property and equipment Gain (Loss) on Disposal or Impairment of Property Plant Equipment Gain (Loss) on Disposal or Impairment of Property Plant Equipment Decrease (increase) in operating assets: Increase (Decrease) in Operating Assets [Abstract] Accounts receivable Increase (Decrease) in Accounts Receivable Inventory Increase (Decrease) in Inventories Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Other assets Increase (Decrease) in Other Operating Assets Increase (decrease) in operating liabilities: Increase (Decrease) in Operating Liabilities [Abstract] Accounts payable Increase (Decrease) in Accounts Payable Related party payable Increase (Decrease) in Due to Related Parties, Current Accrued expenses and deferred rent Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Deferred revenue Increase (Decrease) in Deferred Revenue Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Purchase of property and equipment Payments to Acquire Property, Plant, and Equipment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Payment of deferred offering costs Payments of Financing Costs Proceeds from the exercise of stock options Proceeds from Stock Options Exercised Principle payments on capital lease obligations Repayments of Long-term Capital Lease Obligations Net cash (used in) provided by financing activities Net Cash Provided by (Used in) Financing Activities Net decrease in cash and cash equivalents Cash and Cash Equivalents, Period Increase (Decrease) Cash and cash equivalents, beginning of period Cash and Cash Equivalents, at Carrying Value Cash and cash equivalents, end of period Supplemental Cash Flow Disclosures: Supplemental Cash Flow Information [Abstract] Property and equipment in accounts payable Capital Expenditures Incurred but Not yet Paid Deferred offering costs in accounts payable Decrease in Warrant Liability Decrease in Warrant Liability Restructuring and Related Activities [Abstract] Schedule of Restructuring and Related Costs [Table] Schedule of Restructuring and Related Costs [Table] Restructuring Type [Axis] Restructuring Type [Axis] Type of Restructuring [Domain] Type of Restructuring [Domain] Employee Severance and Benefits Employee Severance [Member] Asset Impairments Asset Impairments [Member] Asset Impairments [Member] Restructuring Cost and Reserve [Line Items] Restructuring Cost and Reserve [Line Items] Restructuring Reserve [Roll Forward] Restructuring Reserve [Roll Forward] Accrued restructuring, beginning balance Restructuring Reserve Additional accruals Restructuring Charges Cash payments Payments for Restructuring Non-cash settlements Restructuring Reserve, Settled without Cash Accrued restructuring, ending balance Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Document And Entity Information [Abstract] Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Trading Symbol Trading Symbol Document Type Document Type Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Amendment Flag Amendment Flag Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Equity [Abstract] Schedule of Stock by Class [Table] Schedule of Stock by Class [Table] Legal Entity [Axis] Legal Entity [Axis] Entity [Domain] Entity [Domain] Cantor Fitzgerald & Co. Cantor Fitzgerald & Co. [Member] Cantor Fitzgerald & Co. [Member] Counterparty Name [Axis] Counterparty Name [Axis] Counterparty Name [Domain] Counterparty Name [Domain] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock Common Stock [Member] Class of Stock [Line Items] Class of Stock [Line Items] Common stock, shares authorized (shares) Common Stock, Shares Authorized Aggregate offering price Equity Offering, Maximum Aggregate Shares Authorized, Value Equity Offering, Maximum Aggregate Shares Authorized, Value Fixed commission (percent) Sale of Stock, Commission Percent of Gross Proceeds Sale of Stock, Commission Percent of Gross Proceeds Stock issued during the period (shares) Stock Issued During Period, Shares, New Issues Earnings Per Share [Abstract] Loss per share - basic: Earnings Per Share, Basic [Abstract] Numerator for basic loss per share Net Income (Loss) Available to Common Stockholders, Basic Denominator for basic loss per share (shares) Weighted Average Number of Shares Outstanding, Basic Basic loss per common share (usd per share) Earnings Per Share, Basic Loss per share - diluted: Earnings Per Share, Diluted [Abstract] Numerator for diluted loss per share Adjust: Warrant revaluation income (expense) for dilutive warrants Dilutive Securities, Effect on Basic Earnings Per Share Net loss attributable to common share Net Income (Loss) Available to Common Stockholders, Diluted Plus: Incremental shares underlying dilutive warrants outstanding (shares) Incremental Common Shares Attributable to Dilutive Effect of Call Options and Warrants Denominator for diluted loss per share (shares) Weighted Average Number of Shares Outstanding, Diluted Diluted net loss per common share (usd per share) Earnings Per Share, Diluted Organization, Consolidation and Presentation of Financial Statements [Abstract] Business and Organization Nature of Operations [Text Block] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table] Related Party [Axis] Related Party [Axis] Related Party [Domain] Related Party [Domain] Affiliated Entity Affiliated Entity [Member] Director Director [Member] Related Party Transaction [Axis] Related Party Transaction [Axis] Related Party Transaction [Domain] Related Party Transaction [Domain] 2015 ECC 2015 ECC [Member] 2015 ECC [Member] Direct Expenses for Work Performed Direct Expenses for Work Performed [Member] Direct Expenses for Work Performed [Member] Pass-through Costs Pass-through Costs [Member] Pass-through Costs [Member] Technology Access Fee Technology Access Fee [Member] Technology Access Fee [Member] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items] Number of exclusive channel collaboration agreements (agreement) Number of Collaboration Agreements Number of Collaboration Agreements Expenses for work performed Related Party Transaction, Expenses from Transactions with Related Party Outstanding payables to Intrexon Accounts Payable, Trade, Current Fees to Intrexon Related Party Transaction, Amounts of Transaction Shareholder ownership percentage of related party in affiliate, more than Shareholder Ownership Percentage of Related Party in Affiliate Shareholder Ownership Percentage of Related Party in Affiliate Shareholder ownership percentage Shareholder Ownership Percentage Shareholder Ownership Percentage Number of directors (director) Number of Directors Represents the number of directors of reporting entity. Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Inventory Disclosure [Abstract] Inventory Inventory Disclosure [Text Block] Accounting Policies [Abstract] Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Statement of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets, Current [Abstract] Cash and cash equivalents Inventory, net Inventory, Net Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Total current assets Assets, Current Property and equipment, net of accumulated depreciation of $1,401 and $1,242, respectively Property, Plant and Equipment, Net Intangible assets, net of accumulated amortization of $0 and $2,204, respectively Intangible Assets, Net (Excluding Goodwill) Other assets Other Assets, Noncurrent Total assets Assets Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] Current liabilities: Liabilities, Current [Abstract] Accounts payable Accounts Payable, Current Related party payable Due to Related Parties, Current Accrued expenses Accrued Liabilities, Current Deferred revenue Deferred Revenue, Current Warrant liability, current Warrant Liability, Current Warrant Liability, Current Total current liabilities Liabilities, Current Warrant liability, long term Warrant Liability, Noncurrent Warrant Liability, Noncurrent Deferred rent Deferred Rent Credit, Noncurrent Total liabilities Liabilities Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares outstanding as of June 30, 2016 and December 31, 2015 Preferred Stock, Value, Outstanding Common stock, $0.001 par value; 150,000,000 shares authorized, 43,898,785 shares issued and outstanding as of June 30, 2016; 100,000,000 shares authorized, 43,898,785 shares issued and outstanding as of December 31, 2015 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Accumulated deficit Retained Earnings (Accumulated Deficit) Total stockholders’ equity Stockholders' Equity Attributable to Parent Total liabilities and stockholders’ equity Liabilities and Equity Working capital Working Capital Working Capital Disclosure of Compensation Related Costs, Share-based Payments [Abstract] Stock-Based Compensation Disclosure of Compensation Related Costs, Share-based Payments [Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Liability Class [Axis] Liability Class [Axis] Fair Value by Liability Class [Domain] Fair Value by Liability Class [Domain] Warrant Warrant [Member] Fair value measurements Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] December 31, 2015 Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value Expiration of warrants Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Expiration of Warrants Fair Value Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Expiration of Warrants Change in fair value of warrant liability Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings June 30, 2016 Warrants [Abstract] Warrants [Abstract] Increase (Decrease) in Warrants Outstanding [Roll Forward] Increase (Decrease) in Warrants Outstanding [Roll Forward] Increase (Decrease) in Warrants Outstanding [Roll Forward] Beginning balance, number of warrants outstanding (shares) Class of Warrant or Right, Outstanding Number of warrants granted during the period (shares) Class of Warrant or Right, Grants in Period Class of Warrant or Right, Grants in Period Number of warrants exercised during the period (shares) Class of Warrant or Right, Exercises in Period Class of Warrant or Right, Exercises in Period Number of warrants expired during the period (shares) Class of Warrant or Right, Expirations in Period Class of Warrant or Right, Expirations in Period Ending balance, number of warrants outstanding (shares) Beginning balance, weighted-average exercise price (usd per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Weighted-average exercise price, warrants granted during the period (usd per share) Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price Class of Warrant or Right, Grants in Period, Weighted Average Exercise Price Weighted-average exercise price, warrants exercised during the period (usd per share) Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price Weighted-average exercise price, warrants expired during the period (usd per share) Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price Class of Warrant or Right, Expirations in Period, Weighted Average Exercise Price Ending balance, weighted-average exercise price (usd per share) Inventory, Current [Table] Inventory, Current [Table] Income Statement Location [Axis] Income Statement Location [Axis] Income Statement Location [Domain] Income Statement Location [Domain] Cost of Sales Cost of Sales [Member] Inventory [Line Items] Inventory [Line Items] Inventory write-down Inventory Write-down Reserve for work in process expiration Inventory Valuation Reserves Loss Per Share Earnings Per Share [Text Block] General Basis of Accounting, Policy [Policy Text Block] Reclassifications Reclassification, Policy [Policy Text Block] Intangible Assets Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] Stock-Based Compensation Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] Restructuring Costs Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block] Income Taxes Income Tax, Policy [Policy Text Block] Recently Issued Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Assumptions Used in Determining Fair Value of Warrants Fair Value Measurement, Policy [Policy Text Block] Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair Value of Financial Instruments, Policy [Policy Text Block] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Issued in March 2010 financing Warrants Issued In March 2010 Financing [Member] Warrants Issued In March 2010 Financing [Member] Issued in June 2011 financing Warrants Issued In June2011 Financing [Member] Represents information pertaining to warrants issued in June 2011 financing. Issued in Series B and D Preferred Stock offerings Warrants Issued In Series B and D Preferred Stock Offerings [Member] Warrants Issued In Series B and D Preferred Stock Offerings Issued in August 2011 financing Warrants Issued In August2011 Financing [Member] Represents information pertaining to warrants issued in August 2011 financing. Issued to placement agents in August 2011 financing Warrants Issued To Placement Agents In August2011 Financing [Member] Represents information pertaining to warrants issued to placement agents in August 2011 financing. Issued in Series E Preferred Stock offering Warrants Issued In Series E Preferred Stock Offering, Expiring Dec 2017 [Member] Warrants Issued In Series E Preferred Stock Offering, Expiring Dec 2017 [Member] Issued with Convertible Notes Warrants Issued With Convertible Notes [Member] Represents information pertaining to warrants issued with convertible notes. Issued in Series E Preferred Stock offering Warrants Issued In Series E Preferred Stock Offering, Expiring Dec 2018 [Member] Represents information pertaining to warrants issued in Series E preferred stock offering. Warrants Class of Warrant or Right [Line Items] Warrants issued to purchase common stock (shares) Warrant exercise price (in dollars per share) Restructuring costs Number of employees impacted by reduction-in-force (employee) Restructuring and Related Cost, Number of Positions Eliminated Percent of employee base impacted Restructuring and Related Cost, Number of Positions Eliminated, Period Percent Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions [Table Text Block] Summary of Stock Option Activity Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] Company's Financial Assets and Liability Measured at Fair Value on a Recurring Basis Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Reconciliation of Warrant Liability Measured at Fair Value on Recurring Basis Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Restructuring and Related Costs Schedule of Restructuring Reserve by Type of Cost [Table Text Block] Number of shares Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Outstanding at beginning of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Exercised (shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period Outstanding at end of period (in shares) Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Weighted-average exercise price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Outstanding at beginning of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Exercised (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Forfeited (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Expired (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding at end of period (in dollars per share) Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price Additional disclosures Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract] Weighted-average remaining contractual term (in years), outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Weighted-average remaining contractual term (in years), exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Aggregate intrinsic value, outstanding Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value Aggregate intrinsic value, exercisable Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value Basis of Presentation [Abstract] Basis of Presentation [Abstract] Basis of Presentation Basis of Accounting [Text Block] Income Statement [Abstract] Statement [Table] Statement [Table] Statement [Line Items] Statement [Line Items] Revenue from product sales Sales Revenue, Goods, Net Collaboration revenue Collaboration Revenue Collaboration Revenue Total revenue Revenues Cost of product sales Cost of Goods Sold Cost of collaboration revenue Cost of Collaboration Revenue Cost of Collaboration Revenue Total cost of revenue Cost of Revenue Gross (loss) profit Gross Profit Research and development expense Research and Development Expense Selling, general and administrative expense Selling, General and Administrative Expense Intangible asset impairment expense Operating loss Operating Income (Loss) Other income (expense): Nonoperating Income (Expense) [Abstract] Warrant revaluation income (expense) Other expense Other Nonoperating Income (Expense) Interest income Interest Income (Expense), Net Loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income tax benefit Income Tax Expense (Benefit) Net loss Per Share Information: Earnings Per Share, Basic and Diluted [Abstract] Basic net loss (usd per share) Diluted net loss (usd per share) Weighted average number of common shares outstanding: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basic weighted average number of common shares outstanding, shares Diluted weighted average number of common shares outstanding, shares Expected life Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table] Warrant Liability Warrant Liability [Member] Warrant liability. Fair value assumptions Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items] Calculated aggregate value Warrant Liabilities Fair Value Disclosure It represents aggregate fair value of warrants. Weighted average exercise price per share (usd per share) Investment Warrants, Exercise Price Closing price per share of common stock (usd per share) Closing Price Per Share Of Common Stock Closing price per share of common stock. Volatility (as a percent) Fair Value Assumptions, Expected Volatility Rate Weighted average remaining expected life Fair Value Assumptions, Expected Term Risk-free interest rate (as a percent) Fair Value Assumptions, Risk Free Interest Rate Dividend yield Fair Value Assumptions, Expected Dividend Rate Inventories Schedule of Inventory, Current [Table Text Block] Fair Value Measurements, Recurring and Nonrecurring [Table] Fair Value Measurements, Recurring and Nonrecurring [Table] Measurement Frequency [Axis] Measurement Frequency [Axis] Fair Value, Measurement Frequency [Domain] Fair Value, Measurement Frequency [Domain] Recurring Fair Value, Measurements, Recurring [Member] Measurement Basis [Axis] Measurement Basis [Axis] Fair Value Measurement [Domain] Fair Value Measurement [Domain] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Measured at fair value Estimate of Fair Value Measurement [Member] Fair Value, Hierarchy [Axis] Fair Value, Hierarchy [Axis] Fair Value Hierarchy [Domain] Fair Value Hierarchy [Domain] Level 1 Fair Value, Inputs, Level 1 [Member] Level 2 Fair Value, Inputs, Level 2 [Member] Level 3 Fair Value, Inputs, Level 3 [Member] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Cash and cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Liabilities Liabilities, Fair Value Disclosure [Abstract] Warrant liability Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Title of Individual [Axis] Title of Individual [Axis] Relationship to Entity [Domain] Relationship to Entity [Domain] Plan Name [Axis] Plan Name [Axis] Plan Name [Domain] Plan Name [Domain] The Plan Equity Incentive Plan2009 [Member] Information related to the entity's 2009 Equity Incentive Plan. Equity incentive outside of the Plan Equity Incentive Consultants [Member] Information related to equity incentive issued to consultants outside of the 2009 Equity Incentive Plan. Award Type [Axis] Award Type [Axis] Equity Award [Domain] Equity Award [Domain] Options Share Based Compensation Stock Options [Member] An arrangement whereby the awardee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the awardee-holder pays the strike value in cash to the issuing entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits. Service Based Stock Options Service Based Stock Options [Member] Contract which gives the holder the right, but not the obligation, to purchase a certain number of shares of stock. These options vest based on the service period of the holder. Equity-based compensation Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Number of shares allowed for issuance (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized Options issued (in shares) Terms of options, not to exceed (in years) Share Based Compensation Arrangements by Share Based Payment Award, Award Options, Expiration Term The period of time, from the grant date until the time at which the share-based award options expires. Vesting percentage per year Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage Vesting period (in years) Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period Options available for grant (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant Weighted average fair market value of options granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Stock-based compensation expense Allocated Share-based Compensation Expense Fair value of options vested Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value Unrecognized compensation cost Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized Recognition period (years) Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition Restructuring Costs Restructuring and Related Activities Disclosure [Text Block] Non-cash expense (income) Fair Value Adjustment of Warrants New Accounting Pronouncement, Early Adoption [Table] New Accounting Pronouncement, Early Adoption [Table] Adjustments for New Accounting Pronouncements [Axis] Adjustments for New Accounting Pronouncements [Axis] Type of Adoption [Domain] Type of Adoption [Domain] Accounting Standards Update 2016-09 Accounting Standards Update 2016-09 [Member] Accounting Standards Update 2016-09 [Member] Equity Components [Axis] Equity Components [Axis] Equity Component [Domain] Equity Component [Domain] Accumulated deficit Deficit Accumulated [Member] Deficit Accumulated [Member] Additional paid-in capital Additional Paid-in Capital [Member] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Pronouncement, Early Adoption [Axis] New Accounting Principles, Early Adoption [Domain] New Accounting Principles, Early Adoption [Domain] New Accounting Pronouncement, Early Adoption, Effect New Accounting Pronouncement, Early Adoption, Effect [Member] New Accounting Pronouncement, Early Adoption [Line Items] New Accounting Pronouncement, Early Adoption [Line Items] Intangible assets Useful life Finite-Lived Intangible Asset, Useful Life Cumulative effect from adoption of new accounting standard Cumulative Effect of New Accounting Principle in Period of Adoption Income tax expense (benefit) Property and equipment, accumulated depreciation (in dollars) Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Intangible assets, accumulated amortization (in dollars) Finite-Lived Intangible Assets, Accumulated Amortization Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, shares authorized (shares) Preferred Stock, Shares Authorized Preferred stock, shares outstanding (shares) Preferred Stock, Shares Outstanding Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Common stock, shares issued (shares) Common Stock, Shares, Issued Common stock, shares outstanding (shares) Common Stock, Shares, Outstanding Equity Stockholders' Equity Note Disclosure [Text Block] Raw materials (LAVIV and product candidates) Inventory, Raw Materials, Gross Work in process (LAVIV) Inventory, Work in Process, Gross Total inventory, gross Inventory, Gross Reserve for work in process expiration Total inventory, net Statement of Stockholders' Equity [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Balance Balance (shares) Stock-based compensation expense Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition Balance Balance (shares) Outstanding Warrants to Purchase Common Stock Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Warrants Outstanding Roll Forward Schedule of Warrants Outstanding Roll Forward [Table Text Block] Schedule of Warrants Outstanding Roll Forward [Table Text Block] Summary of Other Assumptions Used by Entity Summary of Calculated Aggregate Fair Values and Assumptions [Table Text Block] Summary of calculated aggregate fair values and net cash settlement value as of the dates indicated along with the assumptions utilized in each calculation. Warrants Warrants Disclosure [Text Block] The entire disclosure for warrants. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] “In the money” stock options Shares Underlying Out of the Money Options Outstanding [Member] Represents information pertaining to the shares underlying out of the money options outstanding. “Out of the money” stock options Shares Underlying In The Money Stock Options Outstanding [Member] Represents information pertaining to the shares underlying in the money stock options outstanding. “In the money” warrants Shares Underlying Out of the Money Warrants Outstanding [Member] Represents information pertaining to the shares underlying out of the money warrants outstanding. “Out of the money” warrants Shares Underlying in the Money Warrants Outstanding [Member] Represents information pertaining to the shares underlying in the money warrants outstanding. Antidilutive Securities [Axis] Antidilutive Securities [Axis] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Performance based options Performance Shares [Member] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from EPS (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount EX-101.PRE 13 fcsc-20160630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 14 fcsccolorlogo.jpg begin 644 fcsccolorlogo.jpg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end GRAPHIC 15 fcscpipelinejuly16.jpg begin 644 fcscpipelinejuly16.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# (! 0(! 0(" @(" @(" P4# P,# M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_ MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P, M# P,# P,# P,# P,# P,# P,# P,# S_P 1" &J ] # 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]*/\ @JK_ M ,%5=7_X)V^+_"&F:9X0TWQ,OB:SN+J1[J]>W,!B=% 53G.[]*^4/\ B)O\ M5_\ 1*?#W_@XF_\ C='_ 1^H/_ !$W^*_^B4^'O_!Q-_\ M&Z/^(F_Q7_T2GP]_X.)O_C=?E]17N?ZH91_SY7WR_P SR/\ 67,_^?OX+_(_ M4'_B)O\ %?\ T2GP]_X.)O\ XW1_Q$W^*_\ HE/A[_P<3?\ QNOR^HH_U0RC M_GROOE_F'^LN9_\ /W\%_D?J#_Q$W^*_^B4^'O\ P<3?_&Z/^(F_Q7_T2GP] M_P"#B;_XW7Y?44?ZH91_SY7WR_S#_67,_P#G[^"_R/U!_P"(F_Q7_P!$I\/? M^#B;_P"-T?\ $3?XK_Z)3X>_\'$W_P ;K\OJ*/\ 5#*/^?*^^7^8?ZRYG_S] M_!?Y'Z@_\1-_BO\ Z)3X>_\ !Q-_\;H_XB;_ !7_ -$I\/?^#B;_ .-U^7U% M'^J&4?\ /E??+_,/]9_\ !Q-_\;K\ MOJ*/]4,H_P"?*^^7^8?ZRYG_ ,_?P7^1^H/_ !$W^*_^B4^'O_!Q-_\ &Z[; MX^?\'"_B7X-^+M)TV#X:Z'?+J7AO1==9WU65"C7^FVUZT8 0\(9RH/<*#WK\ MB*]D_;B_Y*GX7_[)YX/_ /4>T^N:7"F4JO&"HJS3ZRZ_P#!Q-_\;H_XB;_%?_1*?#W_ (.)O_C= M?E]11_JAE'_/E??+_,/]9_\'$W_P ;H_XB;_%?_1*?#W_@XF_^-U^7U%'^ MJ&4?\^5]\O\ ,/\ 67,_^?OX+_(_4'_B)O\ %?\ T2GP]_X.)O\ XW1_Q$W^ M*_\ HE/A[_P<3?\ QNOR^HH_U0RC_GROOE_F'^LN9_\ /W\%_D?J#_Q$W^*_ M^B4^'O\ P<3?_&Z/^(F_Q7_T2GP]_P"#B;_XW7Y?44?ZH91_SY7WR_S#_67, M_P#G[^"_R/U!_P"(F_Q7_P!$I\/?^#B;_P"-T?\ $3?XK_Z)3X>_\'$W_P ; MK\OJ*/\ 5#*/^?*^^7^8?ZRYG_S]_!?Y'Z@_\1-_BO\ Z)3X>_\ !Q-_\;H_ MXB;_ !7_ -$I\/?^#B;_ .-U^7U%'^J&4?\ /E??+_,/]9OR(KV3]O/\ Y.-D_P"Q M:\-_^F'3ZYI<*92L1&'L59J3WET_\'$W_ ,;H_P"(F_Q7_P!$I\/?^#B; M_P"-U^7U%'^J&4?\^5]\O\P_UES/_G[^"_R/U!_XB;_%?_1*?#W_ (.)O_C= M'_$3?XK_ .B4^'O_ <3?_&Z_+ZBC_5#*/\ GROOE_F'^LN9_P#/W\%_D?J# M_P 1-_BO_HE/A[_P<3?_ !NC_B)O\5_]$I\/?^#B;_XW7Y?44?ZH91_SY7WR M_P P_P!9_P#! MQ-_\;H_XB;_%?_1*?#W_ (.)O_C=?E]11_JAE'_/E??+_,/]9_^37_ M ($_]@G5_P#T[W-8N$VZNR[+NEV/MW_B) MO\5_]$I\/?\ @XF_^-T?\1-_BO\ Z)3X>_\ !Q-_\;K\OJ*Z?]4,H_Y\K[Y? MYF'^LN9_\_?P7^1^H/\ Q$W^*_\ HE/A[_P<3?\ QNC_ (B;_%?_ $2GP]_X M.)O_ (W7Y?44?ZH91_SY7WR_S#_67,_^?OX+_(_4'_B)O\5_]$I\/?\ @XF_ M^-T?\1-_BO\ Z)3X>_\ !Q-_\;K\OJ*/]4,H_P"?*^^7^8?ZRYG_ ,_?P7^1 M^H/_ !$W^*_^B4^'O_!Q-_\ &Z/^(F_Q7_T2GP]_X.)O_C=?E]11_JAE'_/E M??+_ ##_ %ES/_G[^"_R/U!_XB;_ !7_ -$I\/?^#B;_ .-T?\1-_BO_ *)3 MX>_\'$W_ ,;K\OJ*/]4,H_Y\K[Y?YA_K+F?_ #]_!?Y'Z@_\1-_BO_HE/A[_ M ,'$W_QNC_B)O\5_]$I\/?\ @XF_^-U^7U%'^J&4?\^5]\O\P_UES/\ Y^_@ MO\C]0?\ B)O\5_\ 1*?#W_@XF_\ C='_ !$W^*_^B4^'O_!Q-_\ &Z_+ZBC_ M %0RC_GROOE_F'^LN9_\_?P7^1^N_CW_ (.%_$O@[X/^ O$Z?#70YY?&,=^\ ML#:K*%MOLUR81@[.=PYYZ5Q/_$3?XK_Z)3X>_P#!Q-_\;KXB^.'_ ":?\#_^ MN&M_^G UXW7-A>%,IE!N5%;RZRZ2:74WQ'$>8QFE&KTCT75)]C]0?^(F_P 5 M_P#1*?#W_@XF_P#C='_$3?XK_P"B4^'O_!Q-_P#&Z_+ZBNG_ %0RC_GROOE_ MF8?ZRYG_ ,_?P7^1^H/_ !$W^*_^B4^'O_!Q-_\ &Z/^(F_Q7_T2GP]_X.)O M_C=?E]11_JAE'_/E??+_ ##_ %ES/_G[^"_R/U!_XB;_ !7_ -$I\/?^#B;_ M .-T?\1-_BO_ *)3X>_\'$W_ ,;K\OJ*/]4,H_Y\K[Y?YA_K+F?_ #]_!?Y' MZ@_\1-_BO_HE/A[_ ,'$W_QNC_B)O\5_]$I\/?\ @XF_^-U^7U%'^J&4?\^5 M]\O\P_UES/\ Y^_@O\C]0?\ B)O\5_\ 1*?#W_@XF_\ C='_ !$W^*_^B4^' MO_!Q-_\ &Z_+ZBC_ %0RC_GROOE_F'^LN9_\_?P7^1^H/_$3?XK_ .B4^'O_ M <3?_&Z/^(F_P 5_P#1*?#W_@XF_P#C=?E]11_JAE'_ #Y7WR_S#_67,_\ MG[^"_P C]6?AY_P*/&WQ T/1G^%V@0)J^H6]DTJZO,3&))%0L!Y?.-V:F M^*G_ */AW\3_ !'X?C^%^@W,>AZI=:>DS:M*K2B*5HPQ'E\$[L?_ $HCJW^TU_RQ5K7WEW] M3?\ UCS'V/-[76_9=O0_0G_B)O\ %?\ T2GP]_X.)O\ XW1_Q$W^*_\ HE/A M[_P<3?\ QNOR^HKI_P!4,H_Y\K[Y?YF'^LN9_P#/W\%_D?J#_P 1-_BO_HE/ MA[_P<3?_ !NC_B)O\5_]$I\/?^#B;_XW7Y?44?ZH91_SY7WR_P P_P!9_P#!Q-_\;H_XB;_% M?_1*?#W_ (.)O_C=?E]11_JAE'_/E??+_,/]9&H]!TM=02:VOGN&F)E6/:0RC ^;.: M_!NOTK_X-G/^3D/B+_V+4?\ Z51UXO$/#66X;+JM>C2M)+1W?=>9ZN29[CZ^ M.ITJM2\6]=%V?D:W_!S?_P E6^%/_8)O_P#T=%7Y?5^H/_!S?_R5;X4_]@F_ M_P#1T5?E]7M<(_\ (HH^C_\ 2F>5Q+_R,ZOR_)!1117TAX04444 %%%% !11 M10 4444 %%%% !1110 4444 %>R?MQ?\E3\+_P#9//!__J/:?7C=>R?MQ?\ M)4_"_P#V3SP?_P"H]I]8>DOSB=4/\ =Y^L?_;CQNBBBNLY0HHHH ** M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *]9_8@_P"3E-'_ M .O#5/\ TVW5>35ZS^Q!_P G*:/_ ->&J?\ IMNJY<;_ +O4_P +_(Z,)_'A MZK\SR:BBBNHYPHHHH **** "BBB@ HHHH **** "BBB@ HHHH *]D_;S_P"3 MC9/^Q:\-_P#IAT^O&Z]D_;S_ .3C9/\ L6O#?_IAT^N.?^]0_P ,OS@=,?\ M=Y>L?RD>-T445V',%%%% !1110 4444 %%%% !1110 4444 %>R?'O\ Y-?^ M!/\ V"=7_P#3O-UR8+^&_\4__ $IG3BOC M7I'_ -)04445UG,%%%% !1110 4444 %%%% !1110!UOP$_Y+IX+_P"P]8_^ ME$=6_P!IK_DY'X@_]C+J/_I5)53X"?\ )=/!?_8>L?\ THCJW^TU_P G(_$' M_L9=1_\ 2J2N/_F*_P"W?U.G_F'^?Z'#T445V',%%%% !1110 4444 %%%% M!1110 5^E?\ P;.?\G(?$7_L6H__ $JCK\U*_2O_ (-G/^3D/B+_ -BU'_Z5 M1U\[Q7_R*:_I^J/;X<_Y&5+U_1FM_P '-_\ R5;X4_\ 8)O_ /T=%7Y?5^H/ M_!S?_P E6^%/_8)O_P#T=%7Y?5/"/_(HH^C_ /2F5Q+_ ,C.K\OR05[M_P $ M[_V*&_;Y_:$_X01?$B^%0NF3ZDU\;#[=@1%!L$?F1YR7'.X8P>M>$U]V_P#! MNVX3_@H)+D@?\4M?]3_TTMZ]#.L14P^ JUJ+M*,6T<654(5L93I5%>+:3//O MC_\ \$W= \&_LH3_ !E^&'Q#-,U)-,U5ET2;1KK3Y79$7,,KNY^:2/ MA@IQ(K#(.:\(\9?LW?$3X=>$8O$'B#P%XTT+0;@J(M2U'1+FUM)-WW=LKH$. M>V#S7V+\'O\ @IMX U'Q+\,_A;H/PMT+X1?!\^-K'6_$J2ZW-J[WSI/$\,_#7P/^.XO?AQI$'@7Q%HTT-KXJU? MXK2W=GJ>Y-L!L-+>*189]S*?*C$2LZC]XW#5\_\ VSC\)5AA\1"[D]')P3Y; MI):-1 /&T.A"R@U+^TGT.Z6T^RS_ .IG\TIL\J3^!\[6[$U5^(WP%\<_!ZQL MKGQ;X,\6>%K;4LBTEU?2+BQ2ZP,GRVE10W!'3-?HI^U)^T-X_P#A_8?L.^$_ M"?B1-,T_5?"'A:[GTZ\O7M=*OYP]EY7VXIR8 T2[L@[5WD#DY^@/VG9M*TGQ MU\&/'7Q?U#6? /VKXD6L]YX,UWQ%!KVD-,MK.D.HVDBEFM[=)&0G)BB Y>)6 MVDV^)*\.1SIJT^:R3=_=NDK;ZV>MFEUMN0LBHRYU&;O'ENVM-;=?*_D^Q^/' MC/\ 9B^)7PX\)_V]XA^'OCC0=#^4?VCJ.@W5K:?,0%_>N@3DD <\DBK&@?LE M_%7Q7907.E_#/X@ZE;W5E'J<,MKX=O)DFM),^7<*5C(,3;6PX^4X.#Q7ZT>+ M;3XK?!J^_:K\5_'7Q;:ZE\$_$^AZE!X3LY]7BN8=0:;<+.*RA\S]RPA81,NU M"\C*VYMID.#H?QZ\7?#WQ+_P3\\+:-XDU'2O#_B/P[9G5;"WF\N'4?\ 1H(E M68#[ZX=L*V0&PP&X C./$V(G#]W&+>NJ;Y=(<[6VZM9_TC1Y#1C+WY22[-*^ MLN5/?9WNC\H_AO\ L_>/?C)]J_X1#P1XN\5?87$=S_8^CW%]]G8\@/Y2-M/' M0U[-^PA^P_9?M#?%SXE>%/'L?BGPQ?>!_!&H^(TM8T6TNH[RW>W6..=)HV(0 MB8DKA6/&&%?HU\!_AU_9?B[]I^X\'1>(?%_B"#XJ32-X/TWQ[)X2BMH9!#(] M_)+N>22-@RRG[1 Q M?^+Y54;CV45AB.)ZM5SHTX\ONW3OJOA>V_VM[)=KZVVH+_&GBCXDP74RZ!;^"=0MS"; /&V@:AX@E:'2[74M#NK6;4I% M*AD@21 TK N@(4$_.OJ*_0M_A#XE^/'PL_X)^^%_"7B74_!VL:AI_B,MK.G7 MCVEYI]LGV5[EXI$(8.8%E4#HQ;!X)KZ1N-5\5>%O^"JOA&;XDZ.OA_X=Z3X: MU'PS\,[K7-:M[N?4]0"VQFN7F$LDR33Q(RAYB&*A1CS&8'>7$E6E[NDG:H[- MVE[LI125DD]NUTDV_/&.14ZNNL5>"NE=>]&+=]=-^]KM)'XK_$SX%^-_@L]J MOC'P=XJ\)M?AC;#6=)GL#:B[L9&<>HKZ$_9>_X)L:IX]^''Q?UWXD^ M'?B%X,_X0KP'?^*= :XTY]/BU.X@C9U5C<0GS(N!N$94_,/F%?>/[1_Q@U/P M0GP?TGXQ?#+2_ ?A^'XK:;?6]QK/Q1E\6:EE/-8W:B5"ZV2G;N+S ('4>5AC MCIOB5X=^,OAM?VQ[GQ_XKM=0\!>(_ NN7O@K3?[4BE+6JV3XE@MPS/%''')' M%(WRAI&W8.X-7/7XEQ-2C&*48-]>9._O)>[:Z;L]5?8WHY#0A5;;Z MW[U[.U]M#\.J***^]/C0KV3]N+_DJ?A?_LGG@_\ ]1[3Z\;KV3]N+_DJ?A?_ M +)YX/\ _4>T^N2?^\P])?G$ZH?[O/UC_P"W'C=%%%=9RA1110 4444 %%%% M !1110 4444 %%%% !1110 4444 %%%% !1110 5ZS^Q!_RI_A?Y'1A/X\/5?F>34445U'.%%%% M !1110 4444 %%%% !1110 4444 %%%% !7LG[>?_)QLG_8M>&__ $PZ?7C= M>R?MY_\ )QLG_8M>&_\ TPZ?7'/_ 'J'^&7YP.F/^[R]8_E(\;KO?V7O@<_[ M2W[0OA#P%'J2Z.WBK4H]/^W-!YXM0W5_+W+NP >-PSZBN"KW[_@EDX3_ (*' M_"$D@?\ %10#GU.0*>.J2IX:I4ANHMKY(,)",Z\(2V;2_$]H^,?_ 1RT+PO MX%^*=YX$^-FE^.O$GP;@DNO$^@S^')M)FM8HT:20I(TT@DPB.05!0E2-P-?) MU]^S=\1-,\'-XBN? 7C2W\/I8PZFVIRZ'%KWQ3IXG,=G?V MJR61E^TJ/]9&(XCPV1C=ZFOF,#F690A3=9/Q-K/@+QII/AN8(T>K7N MB7,%BX<@(1,Z!#N)&.>:4_@#Q%X4NK:W\7ZG\5I)M/O0 M]JR1_8M*:.1(K@.PPD8C$CJN9.01^?/[/O[:OP%\$?M)?"C7/#_P,_X5E+H' MB2WGU;7CXSO=9#VCPS6\@,$Z!% >:.8LOS 0;1]ZM\OS[$XK#2K1HW:O;EE% MK:Z3]Z^^EE=]TC#&Y/0P]>--U;)[W4D][::6VU[=FQ/B[_P2S\ ? QM2\->) M?VDO!&G?%72M);4;CPU)I$ZV2RB'S1;'4#($5VR H:,.0RG9S4WB;_@F5X-' MBOX%:5;>+/&>DCXI?#J#Q?J-Q#X?L:C(ROP(B)&>@^Q1?X'\J\NKG%:.&A6IU^> M7+)R2Y5RM0;MMT?22;74]&GEE*5>5*='E7-%+XM5S)7WZKJK(_(WPO\ LU>/ M_B+:QWOA3P1XT\4:3=W'/&.H>*O FJ^$-$GU:2T3P9?ZQ=EHMF8YX(0'MDPZDS2@(N5SU% M?4'A7X_^,OV=_P#@A/X8U3P/XCU+POJFI?%&2PGN["3RIW@^S3S% _WE!DAB M)VD9 *G*LP/UW\4H(8?^"H?Q-O!L$M_^S;=W5S)P/,?[9&NX_P# 47\ *[L7 MGV(@YPLDO?2:>ON.*UNFM;G)ALGH34)7;?NMI[>\GV:>EC\;?!7[/_CSXD^% MKS7/#O@GQ=K^BZ<66[U#3='N+JUM2H#,'E1"JX!!.2, U=\(?LL_$[X@^%%U M[0?ASX\UO0W5F74=/T"[N;1@I(8B5(RF 00>>"#Z5^FNG>'_ (P?%;]AW]FN M]_9I\;:3X9T+PGI$L?C&1-6AL+73KX)&99;^-\^;'Y@N"4*/DN'V$$,/9_\ M@FUX;F\,_L_?L\7N@_V_XUT*\TJ3^UM;?Q^^GZ;X7N'!_P!".EQ,(KQ_.D>) M5D1F1H\E@<5GB^*:E*E*HHQNI-E[P_#T*E2,'*5F MD[VT=^7:UVTKZ^FK73\K/#?[)7A[6?\ @F-X@^-4E]K*^)])\=)X8BM%EC^P M/;&U@E+LGE^9YFZ4\B3;@#Y>]?/5?H_^TE''9_\ !,G]HJ)%2)%_:.U-(T4! M0 %@P /H/TK\X*]W)\5.O&I.;^V[>2LG;\3Q\SH0HRIQC_*K^;N]0KV3X]_\ MFO\ P)_[!.K_ /IWN:\;KV3X]_\ )K_P)_[!.K_^G>YKMQ'\2E_B_P#;9'+0 M^"IZ?^W1/&Z***ZSF"BBB@#]!]._X(@^%9M2\"^'+[]H#3M*\?\ Q$T)-;T; M0KGPE-Y5R#$':,70N"F5Y'(#$*2$KS/QG_P3"U'0?V,4\3Z5IWBWQ)\5+7XE M7O@:_P!&T>'[?:B*UBN3+)%%'"9F826_W]VW:?N@\U]D?MT?MO>%/V*]2^ W MB,_"S3/&OC^'X?V\NA:]>:Y-!'HR/$(R/LJHR2YRQWY5L$@$5XUK/[77Q$\$ M_P#!&:U\=:!XIU#P_P"*_&GQAO)=5O\ 3F$$T_GQ7-W*JL.45IHT)VD9 VG* ML0?@,)C\VJ0IUG+24DES+;SQ58@M*=&\0ZCL^R:7?:3/;WMUO;:GEPN@=MS @8! MR1BOVI\=> +#Q'_P5&\6ZI!J>K'Q3+\';26ST'2=<&AW?BF1[F;=$+Q2LD6# M;VXW(RD%E)8*I!YS]J[Q%XM\.?M*_L7ZIH_AK1+?QK:P^*(SH>N^+GU&,2+9 M6ZR6^AC/A MN$82DYO226U].91^_6]KW\NI^/7C3X$>./AOXGT_1/$7@WQ7H.LZL5%C8:CI M%Q:W5Z6;8OE1N@9\L0!M!R>*7XE_ 7QS\%H[1O&/@OQ9X36_S]E;6=(N+ 7. M.NSS47=C(SCUK]H[^'PM\-?V^_@9K'CSQ%KFCZWKFGZ\=.\(^+];AU>;POJ$ M_D &.]1I-J2JKI&LDSKDJL04ED'AG_!6;X@>-]-_8>UCPYXW^%VF^"X+[Q3! M/I=SJGQ3E\5ZE=R LS7%G%+$SK;E ZX,D>P2']T,D5KA>)ZM:M2I*FK3W=TN MK7NW?O6MKR\WK:S>>(R"G2I5*CF[QV5F^B>MEI>^E[?FE^4=%%%?9GRP4444 M >R?'#_DT_X'_P#7#6__ $X&O&Z]D^.'_)I_P/\ ^N&M_P#IP->-UR8+^&_\ M4_\ TIG3BOC7I'_TE!11176%/":W8L&\4:Q9Z0+HQ^8+8 MW$Z1>9MR-VW?G&1G'45]K?$#_@B7H=MKGQ \*>!_CGI/C#XF?#K3O[4U'PK< M^&I=*E>'9')E)FGD1_DD3E RAI$5F3=D?*'[%IV_MB_"8G_HEM+W7VM#YK_: _X)KWWAS]GGX'>*OAMH/Q!\;:O\1/#LVLZ_ M;VE@VHQ://BW?7UMX4\$^+O$US MICB.\BTG1[B]>T8YP)%C1BA^5N#C[I]*_3Z^_:(\:_"7PA_P3Q\/>&_$NI:+ MHOBJ6PAUJTM9 D>I1&>P@,B_:I2^)IW_Z>.&M[)6Z.Z7=GH3R2A6J+V;:V35O^G?-INWYZ7['XXZ?\!/' M6K_$6?PA:^"_%ESXMM1NGT2+2+A]1A& V6MPGF#AE/*]&'K42?!+QG)\2&\& MKX1\3MXO1MC:&-*G.I*VS?@V^WS,[#N^[TYZ5^V7Q0\2>*;#_@I!XC7PEX;T MOQ9%XA^%FDP:KIMCXH&D:]+#)>7J_:-.O&9 YC'WF,D9.865P0*Q?@W:^'OA M=_P4#^-OAZ#Q9+\1/'M]X$TV/0K?6=>2QU9"OVCS=+_M*%=ZR@?9&\WF7:R, MS.4+TUQ;5<'/V:^!2M?6[LG?LE?K;3KO9/ANGS*/._B<;V]=N[=NE_0_%_XB M_"CQ3\']<73/%OAK7_"^I/&)EM-7T^:RG9"2 P255;;D'G&.#7/U^A'_ 6V M^(OB?6?AW\(_#WC/X?:?X#UG2CJ,EO:S>/F\6ZU#;G[.#]JF:/<%=L%&::4M MY3CY=G/Y[U]1E6,GBL+&O-)-WV::T;6C3:U]3Y_,<-'#XB5&#NE;=-/57V=G M^ 4445Z)PG6_ 3_DNG@O_L/6/_I1'5O]IK_DY'X@_P#8RZC_ .E4E5/@)_R7 M3P7_ -AZQ_\ 2B.K?[37_)R/Q!_[&74?_2J2N/\ YBO^W?U.G_F'^?Z'#T44 M5V',%?1G[ G[".F_MFZ=\1M4UOQXO@#0?AKHPUO4;[^Q7U4F "5I#Y:2QM\B M1.WR[F/ "DU\YU^@?_!$;6])\._!G]JF^UW2!X@T6R\ R7&H:5]K>T_M.W2" M\,MOYR9>+S%RF]1E=V1R*\C/,15H8*=6@[2]VUK7UDEUTZ]3TLHH4ZV+C3JJ M\=>_1-]-?N,_PM_P1W\.ZG\3O@O?Z=\3E^(/PC^+.IS:6-R_LJ^MIDMYY MMGE3>=M/[AP=PRI1@R@XKYE_:>_9+\5_ #Q[XK)\)^,[;P/I6OWFE:7KNI:7 M,EK>Q17$D<3?:/+6)V94!^7 /.!BOLO]D#_@H%'^TE^V?^SO\-_"7@/2_AE\ M-?!.K7-S8Z):WSZA))]K:][7U/S)X96V^V-J[:!=BQ$&W=YIG\OR]FWG=G&.G*[7>K66CW$]C:A!ES),J%%"CDY(QWK]\_@%X4;PI?:! M::,/!%[X#CBM?&FH>/GN;+5)/*&+6'1E;[.6\I-_GK&N%)&6^:OG7_@G MMI_B;XA_\$__ 9I^LW]QX#\)>&]$U&]T[Q[X7\5P)96F^27S;;5M-EPDKK\ MV=T K?X@PZ#IB1 M:X+/XC2>%8-#OE5?/>]ME!2[5I?-9A(KG^((P?-?D'^VEXKC\ZOOJE\]SRLRRNGA:%.I&=W*W1VU5]'L^VC?Z'F-%%%?0GB!7Z5_\ M!LY_R[_ $5SY5HK[B^-W_!.SX6Z+I7[ M/_C3P)JGQ*U7P7\:-:CTC^P=4%C;>)26E$8-N6$=ORQVAG_=@O&V\HX->2:S M_P $^?&_Q2_:O\=_#WX3>!_%^I+X0NC'+:ZU=6*W>GID*!=7$<@M-Y;=C9)A M@I*YVG')1SC"U(\W-RI)M\VEK/E=[^9TU1\\45]@_L MH_\ !.#7_!W_ 42^&OPU^.O@2^L=)\5&\E>SDO,0ZA'%:3O\ES:RX)61$)" M29&5SPPSQ&B_\$Y_B9^T7\:OB-IWPF\#7VLZ#X2\1WNEB4WD-O;VRI/((X?. MN9$#N$5<@,S %2?O#-?VOA.=Q5-1=[N/+9\UTD M]K=F?.M%>R6G_!/KXS7O[0UTN97:M>ZUU)IY=BINRIO M>U[.R>VNA\B45[Y\/_\ @G3\4_VC/B#XWLOA?X$U_6-(\):S<:;))J%W9V[V MQ21@L,DS2)!).J!=ZQ,P!((X926?"C_@F+\=_C==^)(/#7P[U.]D\(ZA+I.J M^==VMH+:[B_UD(,TJ"1UR,A"W##U%4\SPD;\]6*M:]Y+2^U]="5@,2[:SOK&9[>XMYD*202(Q5D93R&!!!![BJU=M M[ZHY0HHHIB"O9/VXO^2I^%_^R>>#_P#U'M/KQNO9/VXO^2I^%_\ LGG@_P#] M1[3ZY)_[S#TE^<3JA_N\_6/_ +<>-T445UG*%%%% !1110 45]*?\$J?V-_# M7[<_[43^"?%=_KNG:4NC7.H^;I,T45QYD;1*HS)'(NWYSGY<\#D5S?P%_P"" M;WQJ_:=\"VGB7P+X'N-?T.^NY;&*[CU"SA431C+AQ)*I0 ?Q. I) !).*X*F M98:G4E3JS4>6U[NR]Z]M7Z,[(8"O.$9TXN7->UM7I:^B]4>'T5[#IO[ ?QAU M?]HBX^%%OX$U5_'UI#]JGTPR0J(H,*?.:G&^L$DMXGS=7,$GV,%F= MBFV3E<#[P;&5X<_X)9_'SQ9\6->\#V/P[OI/$WAF""YU*U>_LXDMXI]WDN)G MF$3A]CX*.?N-Z&K6:X3E4I5(K12U:T3V;UVU(>7XGFY53;U:T3W738^?J*^R M/V7?^"*OQ0^-/[1>M?#_ ,:0W'PV?P_I4>J7M]-#!J059G=+<(D=PHD61H9Q MOC=@IA8'G%.OA+::=<.NCZEI$FEZ5]LC,D1 MO=TIDE5UVD?9=Y7G=BL_[:P3FZ<*B;7+HGTDTD^SU:V[KNKW_9>*45.4&D[[ M_P!U7?Y/[GV9\Q45]#_#W_@E'^T)\5/AA:^,="^&FJWF@7UM]KMIFO+2":YB MZAT@DE69@PY7"'<"",@BL/X%?\$ZOC1^TMX;FU;P3X$O]:L+76)= N9/M=M; M-:WL42S212I-(C1A4=#2DW5C[NC]Y:/SUT,OJ&*NE[.6 MNVCU].YXI178_';X >,?V9OB+<^$_'6@W?A[7[1$E>VG9'#(XRKI(A9)%/(W M(Q&0PSD$#CJZX5(SBIP=T]FMCGG"4).,U9H****L@**** "O6?V(/^3E-'_Z M\-4_]-MU7DU>L_L0?\G*:/\ ]>&J?^FVZKEQO^[U/\+_ ".C"?QX>J_,\FHH MHKJ.<**** "BOT0\%_\ !./]GG0_A9^SW/XWU3XVR^*_CW9[K,>'3836-E.H M@W^8CP&98Q]H3&WS#A7)P!7A/Q'_ ."77Q#F_;-\??"3X::5?>/I?!,L;R7B MF*TCC@FC26+SI)76)),2;<;AN*.5& <>/0SW"5)2C?ELF[RT5E+E;OMH]#U* MN48F$5*U[V5EJ[M4""N_S-N[Y<[N*-?\ ^"=WQH\,_M 6'PMN_ >I#QUJ=D-1 MMM,AN+>??;$NOGF9)&A6/=&X+,X *X)S79_:&%_Y^QVONMN_IY['+]2Q'_/N M6]MGOV]?(\6HKW#XI_\ !-WXW?!7Q_X8\,>)/ &I6.L^,[D6>C11W-M6OIKK\@>!Q,5)RIR]W?1Z> MO8\.HKZ!^)'_ 2R^/OPE\+G6==^'.H6]A]LM=/1H+ZTNY+B>Y*+!'%'#*[R M%F=5^13@G!P017H/P6_X)5_$/X9_M0?"?3_C3\/[K3O!7C3Q%#I4H.IPNMT6 M1Y#"SVLQ>)BJ,>2K85L=*RGF^"C!S56+WVDFW97:6NKL:QRS%2FH.FUMNG97 M=E?0^/:*^J?VU_\ @EY\4?@/XH^(OB^R^'>I:9\*-(\17\6EW?VR*+R2 M.V=HS*UQY>SR\2.O((8GG-?*U=&$QE'$T_:T))KR:=O)VZF&)PU6A/V=6+3\ MUOYKR"BBBNHYPKV3]O/_ ).-D_[%KPW_ .F'3Z\;KV3]O/\ Y.-D_P"Q:\-_ M^F'3ZXY_[U#_ R_.!TQ_P!WEZQ_*1XW17TI_P $J?V-_#7[<_[4A\$^*[_7 M-.TE-&N=1,NDRQ17!>-HU5=TDG>&_V#O@/^V%\&_&>I?L^^ M+/B7'XY\$:<^L3^&?&D-FT^IVR9W>2ULH4$\ '&'-B,XP]"LZ-2^ MEKNVBYM%=]-CHH996K4U4A;6]E?5VWLOF?#M%>Z_ C_@FA\4L\J-* %;W6)O#\=U-<0^:E_"9EDMY( _G1.I@ESYB+]SW&>I8[#.;IJI'F3M M:ZO?M;OIL<[PE=0]HX.UKWL[6[^AYS17T!IG_!+7X]ZS\5V\$6OP[OIO$L>E M0ZW+;+?V?EVUI,S)$\LWG>5&SE'Q&[ASL8[< UZS^P'_ ,$W[A?^"BFE_"KX M]>![VVAN-&N]2;3I;YHUN56-O+E2>UE =0P/*2$94@]"*YJ^<8.E3E4512Y8 M\UDTW;NEA*; MZTFAO;J1T1(3-'*T<;EG7B1EX)/0$CJ-1_X([_M*Z7I'VV7X4ZR8?MGV';%> M6DLOF>;Y6?+68OY>[GS=OE[?GW;/FJ'FF"24G6C9[>\M?374I9?BFW%4I76_ MNO3UT/FBBO6/CI^PU\6?V;/'N@^&/&7@G5-,USQ3@:1:PO%??VDQ<)LB:W>1 M6<,R@H#N&]<@;AG<^/O_ 34^.'[,'P[_P"$L\<> ;[1O#PD2*2]6]M;M+=G M(">:()7:,%B%!< ;B!U(%6LPPKY;5(^_\.JU]._R)>#Q"YKTY>[OH]/7M\SP MNBOIC4/^".W[2>F:)J>H2?"W4VM=(A\^=HM1LI6D3RQ)F%$F+3G:1Q$'.E3+=7]WF^A\.[;9-^EA"YOOM+7 4< _N2F_\ M'BN>>=8"*4G6C9M+1IZO;;;YFTR?'O\ Y-?^!/\ MV"=7_P#3O-T445UG,%%%% !1110 45]*?\$J?V-_#7[<_[43^"?%=_KNG:4NC7.H^; MI,T45QYD;1*HS)'(NWYSGY<\#D5\UUS0Q5.=:=!?%%)O_MZ]OR9O+#SC2C6> MTFTOE:_YA111728!1110 4444 >R?'#_ )-/^!__ %PUO_TX&O&Z]D^.'_)I M_P #_P#KAK?_ *<#7C=_^L\SHOOG MBQ>/I8;E]KUO;Y1E>&-6EL;6:]='N)(UQ@N455+<\D*!["O,:Z*-6-6G&K#9I-?,PJTY M4YNG+=.WW!1116IF%%%% '6_ 3_DNG@O_L/6/_I1'5O]IK_DY'X@_P#8RZC_ M .E4E5/@)_R73P7_ -AZQ_\ 2B.K?[37_)R/Q!_[&74?_2J2N/\ YBO^W?U. MG_F'^?Z'#T445V',%%%% !117TI^QC^QOX:_:,_9=_:"\;:U?Z[::K\)]&M- M1TF*RFB2WN9)5O&83AXV9E_T=,;&0\MR>,TE^+-\/AYU MY^SAO9O[DV_P1\UT5]Y:9_P2W\!7OC;]DK36UGQ>(/CSHTVHZ^PN;??9R):0 M3@6O[C"+ND8?O!(< %KJ#[!I>D)> M*\QN+E$2((!Y9((CY7=C",6S+SXW?#OX[K^V!\++'XI^$/ VM?$/Q/'J>A^) M=0U)(-'UBU0Q;[M?E917BQX8I1BE&;36JT5D^93T M6UKK8]26?U)2NX*SWU=VN5QU>][/<_6SP1^T;\.OA!\;OV/_ (<7OQ1\(>,+ MKX6QZQ-XA\7QZK$=)L!/93I#;)=OM1D!*QCY@<10Y&Y@!PVH^+_ W[8G[%_C M'X4:-\7_ )\-?$VD_%/4O$,LGB+5ET[3?$ME+=7#Q2+<+D2*!*C+PWS6R9 M!1Q^9E%4N&H1:G&H^96=[+?FE*]MOM/3IH2\]FTX2@N5Z6N]N6,;7W^RM3]O MOA7\7_"/QN_:&\7V&D>)=)\=>'_AQ\$X_"WB3Q)J%\+#1]=N'E+.;G4$4O#' MM21C+$''[Z8@?N_FXCQ+/J7PV_;/_97\8Z[)\)?"GP)\+6VHZ%X$_$7@WQ[\;?@[\1/ %KXUO;Z]E\6ZE-HVOQ7$:J(]6TVX:1GF:0Y((964E MBLO)%?E)17IU.'(RIRI*HU%N^RNF]VGOZ:Z>:."&>.,XU'33:5MW9KTV]3K/ MCS>:/J'QR\9S^'K^^U7P_/KM])IE[>R/):Y. MBBOHH1Y8J/8\.4N:3EW"BBBK)"O9/VXO^2I^%_\ LGG@_P#]1[3Z\;KV3]N+ M_DJ?A?\ [)YX/_\ 4>T^N2?^\P])?G$ZH?[O/UC_ .W'C=%%%=9RA1110 44 M44 ?9_\ P0@^*OACX._MQR:OXM\1:'X7TH^&[V 7NK7\5E;^8SP%4\R1E7<0 MIP,Y.#46L_'/3]"_X(D^&?"FD>,+.S\5/\3&NKW1[/55CU V0MKAEDD@5O,\ MGSEA(9AMWJAZ@5\:T5Y%;*(5,3]9;UO!V_PH++>J4 M>Y23$G2Y5&H[*VEEJTG%>>SV M.ZKQ!.HI7@KN_5[-I_FMS]+E-F[=&P#$[9I=HRK5Q'['^@?"[X13?%'PSKWQA^#_ M ,3_ !_#H&DVVAW?CK5)9/! 5#(7M%9W*W"P97:0,C< BI^]K\QJ*M<-QC2= M&%5J+4>BWBHJ]][-15U?N3_;K=1594TVN;J]I-O;:Z[T&\U+0[V&'1-.O/,C<1X\QOLL1\IA&DC9 *#)SFOC MGX#V_A;]E[]EK]L;X?W_ ,1_A_KVI7^E>'H=(NM)UF.6VU^3_2995LBQ5I_* M,RJ^Q3M(.>*^%:*,/PW"C'DC4=GR7T7V)\Z?XM!6SV=67.X*_O=_M1Y7_F?L M1K7Q/^&OQH_;(^$7[1&G?M > ?#/@SP;X;CM[_PS?ZO]FUJU=$FWV\5GCYE? MS%5\8)V?+O&TCYT^*G[5?AKQG_P3;^.O]A>*+32]6\=?'*_UZRT4:@D&IW&F M7"02*[6X82&+C!.-FY,9R*^ J*JAPW2IN+%XY'1F D"LA*DY&X9'-?&%%%>Q@,)'"X>.'B[J*L>7C,2\16E6DK-A11 M178L_L0?\G*:/\ ]>&J?^FVZKR:O6?V(/\ DY31_P#KPU3_ --M MU7+C?]WJ?X7^1T83^/#U7YGDU%%%=1SA1110!^L_AS_@J=:?LK?!S]CK2_#_ M (O\.:GX=FTM]/\ B%I-M<6]S<:?$%LXXY)MH::WDB\RX=5RN_RV!! XV?@Q M\4_A5\$_$O[2'PUT3XA_!K6[OQKJT'B;P[JOCS4X]9\-ZW;S*IDL[RY64EWA MD$J_O'+_ +Q9-LGS@_C_ $5\K+A3#N+49--[Z+5\_.F_3;T]$?11XBK)IRC> MVV^BY>5I>N_J?J[J/[7^JO\ MJ>!HX?C!^S-8:AX8\#7FGYTS3[B#P;)YL\/ M_$HDNWN'PA2)9$FC"A/+"F-MV#V7P\_:*_9V_9^_;@%MX?\ $_@32KCQ-\-Y M='FNH=4;6/!N@Z@;GSQ9P3$J$MI&,KO&IBB.U.$>0U^.%%$^%:,H\G.TN6VB M2OK>[[V;TO\ >$>(JL7S#?B1X[_9 MO7P;I/C)]4ETSX26]W#8Z2BVUPL,TUVDYCB1KB:/?&(T."S%RJM6C^WO\9/A M[!_P3E^,GA/2/%/[.JZEJOB*SOM(TGX=7<2RWMG]NMRDUR-V9[SRXBTK1KA0 MHR2,&OR1HJH\,4U4IU/:/W&G:RLVI?S<)PY%[R:O=W2:L?J)^TS M^VKX'\/_ /!9OX1^,I/&>G>(/A_X=T2UM;FZTS4$U"QL))8KJ-F_=LR@H\L; MOCY@%SC(%8K>$_#?P7_;_P##7Q"N_P!I+P!XO\/>*OBFNMC2M/\ $(N(K.U> M.Y<7U^QD$,$D(98 #GY93AE *U^:M%:QX=A"$80FU:'(]%JM7\G=]#-YW*4G M*<$_>YEJ]'I]^Q^E?P[_ &F/#6L7'_!05-=^(&C7$/BQ=07PN+W78V765634 MDMULMS_O@(_LZH(L_)Y8'&*_-2BBO2P.70PLIN#^+E_\EBH_H<.+QLL0HJ2^ M&_XMO]0HHHKT3A"O9/V\_P#DXV3_ +%KPW_Z8=/KQNO9/V\_^3C9/^Q:\-_^ MF'3ZXY_[U#_#+\X'3'_=Y>L?RD>U_P#!"#XK>&/@[^W*^J^+?$6A^%]*?PY> MVXO=6OHK*W\QGA*IYDC*NXA6P,\XKTS]E_0OAW_P2@\ ?$;Q]K'QA^&_Q'\? M>(?#=QX;T'0/!6K#5829W1_,FD 4J \,1)*J%57P79E%?G)17GXO)5B*TZCF MU&:BI*RU46VM>E[ZG;ALU=&E&"@G*+DT]=.:W3KMH?L1\!?VNO"WB_\ 9(^! M!\(>,?V9-$U_X=:9%8:M%\4(6&J://%&D;7&G;)4;/[7QQHVKW#)I.G:J8+^,SB&.ZD;RUGB MMX?W;.SA9Y22Q!-?EC17%_JM12FHS:/+AW[<\--/B3\"#IW@_P;J5G->>#MVG M>'M(>50$M%NKB=XYL"-=FSRP V-F:_(.BIEPGA[RY9-*2MLM/=Y='Z+^D-<1 MU[1YHIM._77WN;\S]#?A9-X1_:T_X);?"[X::?\ &CP-\+?%GP[\27>H:M;^ M)M6_LJ.[CDN;B:.>)L9ED19DV 'J&!*X!KZ?\(?M >$?VH_VO?VA[CPEXW^P M:/HGP<_X1V?QHFX1P31M<-)J,;(59EB\W=N4C)B)4XVM7XIUVOPE_:&\8_ O M2/%=CX5U@Z5:>-]'FT'6XQ;0S?;;*4%9(LR(Q3()^9-K#/!%&,X:]HING/5M MM)VLG*2E+I=[:7#"Y[R.*G#1))VOKRQ:773?6Q^A_B#XG> OV>O@C^RA\)KC MXK^!O'6N^&/BUIOBC5]7T;5DN],TBQ2\E+>9VHK\2]&AF\0Z3Y7A.Z'B"-6U)X[>]2-;%_,S*5W1A?*)QN7'45^ M5M%;?ZM4FGSS;;WT6[FIO\58S_MZHFN6*26VK_E";&6?Q+KP:ZC;S;UDN/+BFCCW. M9760,4(&PL,?E1127#-%5HUN=Z-NUE_.Y_+5_P!,;S^JZ4J7*M5;K_*H_DOZ M1^QLG[8'@=O^"UOA+7#\3_"Q\#V?P^-@VH_\)%!_9,$[+(SPF7S/*5RR1DKG M)94[@5X-X1\1_#_XT?\ !)_Q[\,K/XA> _!VL^'O'E[K=M9ZWJB6O]H64?[R M/[(@W/,74[$"CEE(X&"?SKHHI\-4Z:CR3:<>2VB^PY._SYF$\^G-RYH*TN;O M]JWY6"O9/CW_ ,FO_ G_ +!.K_\ IWN:\;KV3X]_\FO_ )_[!.K_P#IWN:] MO$?Q*7^+_P!MD>30^"IZ?^W1/&Z***ZSF"BBB@ HHHH ^S_^"$'Q5\,?!W]N M.35_%OB+0_"^E'PW>P"]U:_BLK?S&> JGF2,J[B%.!G)P:^,***XZ6$C#$U, M2GK-17_@-_\ ,ZJF)D?_ M $E!11176Y_P"$U\*8\%0W*^(3_:T'_$A+)8*/ MM?S?N,E'_P!9M^XWH:_,*BO-S#+8XOE"_^P]8_P#I1'5O]IK_ ).1 M^(/_ &,NH_\ I5)7'_S%?]N_J=/_ ##_ #_0X>BBBNPY@HHHH *^S_\ @F]\ M5?#'@/\ 8<_:VTC6_$6AZ/JOB7PW80:197M_%!<:I(J:@&2"-F#2L#(F0@)& M]?6OC"BN/'818JC[&3MK%_\ @,E+]#JPF)>'J^U2OHU]Z:_4_531?VB_A_#\ M2_V 9V\<^$%@\&^'+BW\02'6+<)H M RB&%J>TC)O1K[Y2E_[=8Z<9F4L1#DDK:I_=%1_0****]@\P**** "OTK_X- MG/\ DY#XB_\ 8M1_^E4=?FI7Z5_\&SG_ "*_\ D4U_ M3]4>WPY_R,J7K^C/T9OO@_X1_:2_::^(.G>/_"?ACQE9^$[;2ET=-8TFWNSI MXN(97F$;.A8!V12>?X16Y_P[P^ W_1&OAE_X3=I_\;J;X0_\G:_&+_KAH7_I M-/7KU?A,,9B(1Y83:7DV?KTL-1D^:4$WZ(\;_P"'>'P&_P"B-?#+_P )NT_^ M-T?\.\/@-_T1KX9?^$W:?_&Z]DHJ_K^*_P"?DOO9/U/#_P B^Y'C?_#O#X#? M]$:^&7_A-VG_ ,;H_P"'>'P&_P"B-?#+_P )NT_^-U[)11]?Q7_/R7WL/J>' M_D7W(\;_ .'>'P&_Z(U\,O\ PF[3_P"-T?\ #O#X#?\ 1&OAE_X3=I_\;KV2 MBCZ_BO\ GY+[V'U/#_R+[D>-_P##O#X#?]$:^&7_ (3=I_\ &Z/^'>'P&_Z( MU\,O_";M/_C=>R44?7\5_P _)?>P^IX?^1?'_D M7W(\;_X=X? ;_HC7PR_\)NT_^-T?\.\/@-_T1KX9?^$W:?\ QNO9**/K^*_Y M^2^]A]3P_P#(ON1XW_P[P^ W_1&OAE_X3=I_\;H_X=X? ;_HC7PR_P#";M/_ M (W7LE%'U_%?\_)?>P^IX?\ D7W(\;_X=X? ;_HC7PR_\)NT_P#C=<5\!?V5 M?A7\<_"6JZKXI^%_PZU>_P!+\2:UX=M9I_#EH6AL-.U*YL+* ?)]V*VMX8U] MD%?3->0_L5_\DQ\2_P#8_>+?_3_?TOKV)O?VDOO8_JE"UN1?'_D7W(\;_P"'>'P&_P"B-?#+_P )NT_^-T?\.\/@-_T1KX9? M^$W:?_&Z]DHH^OXK_GY+[V'U/#_R+[D>-_\ #O#X#?\ 1&OAE_X3=I_\;H_X M=X? ;_HC7PR_\)NT_P#C=>R44?7\5_S\E][#ZGA_Y%]R/&_^'>'P&_Z(U\,O M_";M/_C='_#O#X#?]$:^&7_A-VG_ ,;KV2BCZ_BO^?DOO8?4\/\ R+[D>-_\ M.\/@-_T1KX9?^$W:?_&Z/^'>'P&_Z(U\,O\ PF[3_P"-U[)11]?Q7_/R7WL/ MJ>'_ )%]R/&_^'>'P&_Z(U\,O_";M/\ XW1_P[P^ W_1&OAE_P"$W:?_ !NO M9**/K^*_Y^2^]A]3P_\ (ON1XW_P[P^ W_1&OAE_X3=I_P#&Z/\ AWA\!O\ MHC7PR_\ ";M/_C=>R44?7\5_S\E][#ZGA_Y%]R/&_P#AWA\!O^B-?#+_ ,)N MT_\ C='_ [P^ W_ $1KX9?^$W:?_&Z]DHH^OXK_ )^2^]A]3P_\B^Y'C?\ MP[P^ W_1&OAE_P"$W:?_ !NC_AWA\!O^B-?#+_PF[3_XW7LE%'U_%?\ /R7W ML/J>'_D7W(\;_P"'>'P&_P"B-?#+_P )NT_^-T?\.\/@-_T1KX9?^$W:?_&Z M]DHH^OXK_GY+[V'U/#_R+[D>-_\ #O#X#?\ 1&OAE_X3=I_\;KD/CQ^R5\)O M@=\,+SQ+X6^%OPYTC6[.XM+>&ZA\.6@=$GNHK>4#Y/XHI9%/LQKZ3KRS]M#_ M )-VU;_K^TS_ -.-M2>.Q+5G4E][&L)06J@ON1G?\.\/@-_T1KX9?^$W:?\ MQNC_ (=X? ;_ *(U\,O_ F[3_XW7LE%/Z_BO^?DOO8OJ>'_ )%]R/&_^'>' MP&_Z(U\,O_";M/\ XW1_P[P^ W_1&OAE_P"$W:?_ !NO9**/K^*_Y^2^]A]3 MP_\ (ON1XW_P[P^ W_1&OAE_X3=I_P#&Z/\ AWA\!O\ HC7PR_\ ";M/_C=> MR44?7\5_S\E][#ZGA_Y%]R/&_P#AWA\!O^B-?#+_ ,)NT_\ C='_ [P^ W_ M $1KX9?^$W:?_&Z]DHH^OXK_ )^2^]A]3P_\B^Y'C?\ P[P^ W_1&OAE_P"$ MW:?_ !NC_AWA\!O^B-?#+_PF[3_XW7LE%'U_%?\ /R7WL/J>'_D7W(\;_P"' M>'P&_P"B-?#+_P )NT_^-T?\.\/@-_T1KX9?^$W:?_&Z]DHH^OXK_GY+[V'U M/#_R+[D>-_\ #O#X#?\ 1&OAE_X3=I_\;H_X=X? ;_HC7PR_\)NT_P#C=>R4 M4?7\5_S\E][#ZGA_Y%]R/&_^'>'P&_Z(U\,O_";M/_C='_#O#X#?]$:^&7_A M-VG_ ,;KV2BCZ_BO^?DOO8?4\/\ R+[D>-_\.\/@-_T1KX9?^$W:?_&ZXG]G MO]E7X5_'SX9)XD\6_"_X=:SK3:IJ>F&ZG\.6AR44?7\5_S M\E][#ZGA_P"1?-_\.\/@-_T1KX9?^$W:?\ QNC_ (=X M? ;_ *(U\,O_ F[3_XW7LE%'U_%?\_)?>P^IX?^1?_ MLJ_"KQ]\5?'_ (7U;X7_ ZO="\!WEG::%:2>'+0IIT5Q9Q74RH-G ::5W/N MQKZ9KR+X&?\ )RGQN_["NE?^FJVI?7L2]ZDOO8_JE#^1?'P&_Z(U\,O_";M/\ XW7LE%'U_%?\_)?> MP^IX?^1?R44?7\5_S\E][#ZGA_P"1?-_\.\/@-_T M1KX9?^$W:?\ QNC_ (=X? ;_ *(U\,O_ F[3_XW7LE%'U_%?\_)?>P^IX?^ M1? _V5?A7XY^+_ (\\)ZI\+_AU=^'_ -)8QZ' M9OX'P&_Z(U\,O_";M/_C=3?!;_DZ7XT?] M=]&_](!7KU)8[$K:I+[V/ZI0>\%]R/&_^'>'P&_Z(U\,O_";M/\ XW1_P[P^ M W_1&OAE_P"$W:?_ !NO9**?U_%?\_)?>Q?4\/\ R+[D>-_\.\/@-_T1KX9? M^$W:?_&Z/^'>'P&_Z(U\,O\ PF[3_P"-U[)11]?Q7_/R7WL/J>'_ )%]R/&_ M^'>'P&_Z(U\,O_";M/\ XW1_P[P^ W_1&OAE_P"$W:?_ !NO9**/K^*_Y^2^ M]A]3P_\ (ON1XW_P[P^ W_1&OAE_X3=I_P#&Z/\ AWA\!O\ HC7PR_\ ";M/ M_C=>R44?7\5_S\E][#ZGA_Y%]R/&_P#AWA\!O^B-?#+_ ,)NT_\ C='_ [P M^ W_ $1KX9?^$W:?_&Z]DHH^OXK_ )^2^]A]3P_\B^Y'C?\ P[P^ W_1&OAE M_P"$W:?_ !NC_AWA\!O^B-?#+_PF[3_XW7LE%'U_%?\ /R7WL/J>'_D7W(\# M^(7[#OP6\ > =_LKB/PY:!H)XHV>-Q\G4,H/X5#\+/V M*/@U\3OACX<\2ZY\)OAOJ&M^(=+MM3U"ZD\.6A>YN)HEDED;Y.K.S$_6O6/C MG_R1/QC_ -@.]_\ 1#U5_9O_ .3=_ 7_ &+FG_\ I-'2^O8F]_:2^]C^J4+6 MY%]R./\ ^'>'P&_Z(U\,O_";M/\ XW1_P[P^ W_1&OAE_P"$W:?_ !NO9**? MU_%?\_)?>Q?4\/\ R+[D>-_\.\/@-_T1KX9?^$W:?_&Z/^'>'P&_Z(U\,O\ MPF[3_P"-U[)11]?Q7_/R7WL/J>'_ )%]R/&_^'>'P&_Z(U\,O_";M/\ XW1_ MP[P^ W_1&OAE_P"$W:?_ !NO9**/K^*_Y^2^]A]3P_\ (ON1XW_P[P^ W_1& MOAE_X3=I_P#&Z/\ AWA\!O\ HC7PR_\ ";M/_C=>R44?7\5_S\E][#ZGA_Y% M]R/&_P#AWA\!O^B-?#+_ ,)NT_\ C='_ [P^ W_ $1KX9?^$W:?_&Z]DHH^ MOXK_ )^2^]A]3P_\B^Y'C?\ P[P^ W_1&OAE_P"$W:?_ !NC_AWA\!O^B-?# M+_PF[3_XW7LE%'U_%?\ /R7WL/J>'_D7W(\;_P"'>'P&_P"B-?#+_P )NT_^ M-U@R?!?P;^S3^T1\,X/A]X0\+>#4\67>H66L'1](M[1]0ABL)IXXW9$#;5E1 M6QGJM?05>1?'/_DY3X(_]A75?_35N>_X*OH9/\ @EK^THJ@ MEC\*_% Y)_LBZKF-SPW_@GE_P58^.'[:.E>&_&_BO]EF#X6? [Q#HUQKG_ M G\_P 4M-U2*UMXX7D1VL5@BN K,FTE@NP'<1@5R?PB_P""Z_Q'_:C$OC3X M/?LA?$OXA_ 6#4I-/_X3B+Q!965_?+'*8I)[32)%,]S&&!^Z^X88,%92H\8_ MX)0_\$H=2^(7_!';3O$.D_''X^WVK_%7X/ZOX?L?!^M>,3/X+TF;4;.>WC>" MP\H>4(V960^8=N6/.:H_\$;?^"R7PL_86_8?\"_LX?%?1/B/X2^/'P_ENM%? MP.GA&^NM1UB22]GECDMBD7E;660(32K#'( MQ2/#9C<#.QB-#XM_\%V-+NO!OP&A^!WPM\0?&SXC?M#:-+X@\.>$DU>VT-K& MR@0MW_9MU7QC\6/ _C:7P1XU^'&H M^-K#0YO#D\,4C3SB_G3RIT601Q@!%9F=S@",Y=_P3N_X*]?$C]L#]O#X@_ ; MXA_L[CX0:]\-O#J:UK%W!X^M?%$=K/+);"WLY#:VZQ+)+%/)*/WI($# ISD> M$_\ !*G]HJ#]G#]E7]MC]K[Q5H.I>'?ASXY\?ZQXV\+6^H0&SN=\$?L::Q\;?'P>7XH?M/:W+\0-=N)%PXM9 MF=K"(<9$?E2-,B\[1=$# & ?H71110 4444 %%%% !1110 5Y#^Q7_R3'Q+ M_P!C]XM_]/\ ?UZ]7D/[%?\ R3'Q+_V/WBW_ -/]_0!W7Q8^,?A'X#>"+GQ- MXY\5>'/!GANS=$N-5UW4X=.L8&=@B!YIF5%+,0H!/)( Y-9OP1_:4^'7[3&B M7FI_#CQ]X*^(&FZ=.+6[N_#6N6NJP6TI4-Y;O [JK[2#M)!P0:^;?^"Z$^H6 MW[$^B2:3;6=[JL?Q-\$M9V]W=-:V]Q,/$=@8TDE6.1HT+8!=8W*@DA&Q@_.7 MQ%_:D\7_ +-'[0'[8_QW\5>&O#/A;XS?#/X8:)IFG^"=/NY-2T36=.::YEL] M?>_=;26^474MQ;R)]GMC"EF(S)^]610#]5:*_/;PY\>OVH?V;;SQ!XL\3>%O MC'XL^'?A[P%KFNZ_+\1AX'LY;/4[&T-S:+IH\.W+RF*X*S121W$-;CPE>Z#IMGHUO?/9I>P)82V MD$5U';19>-AKJ68 ^X**^"/V8/B%^UEJGQ?\ 7-UH?Q1UCP=XIT M>^?Q7>_$*/P1::/HUTUB9["YTI-"NWO_ "&NU\AH;G[2WDW"-YH:)FDP?V>/ MVDOVA-2^&?Q,\#ZEXB\6_P##6=IX"EUJR\!>/?#6DVFC+J,<<)^V:%J6FI': MW6EF>\2WVW-Q<31R)")F@(E$H!]Q?'O]H+PA^S%\.V\6>.-7_L30$OK+36NO MLLUSBXO+F*UMTV0H[_/--&N=N%W98A02.SK\T_&O[>WC?X>?L._%*?2_B1\3 MF^+'@+Q=X1T_5]*^(O@[2-/\1^%8]1\16FFS1EK*V33+VQNH$N6M[BW248DD M87#G8(>X^-7[9'Q7^$:_M*?#!==2Z^*?]O:+#\)-0DTV &&P\3N++3W,0B\J M9=/OH=2+O(&S%9J92>2P!]Z5F^,?&6D?#OPGJ6O>(-5TW0M#T:VDO=0U'4+E M+6TL8(U+22RRN0D:*H)+,0 237YO^,?VH_VH/CA\0OC=!\*['XP7UW\'_$3 M^#/#D.@V7@;_ (1W7+^SL;6X>37&U6ZAU$FYFN1O&GBV2*W>+RR\H9S]%_\ M!4O4M6UG_@C+\=[O7].31]=NOA-K$VHV"3+,MC/]7LK8WMQ8^&_%-CJMS! &5#*\<$KLJ!G M1=Q&,NHSDBO3J^ _^"I&CVNE_P#!/SX(^--(2&#XK>$?%O@=?A_?1@B\6_O- M2T^TN+6,K\[1W%G)&?!.N/IEGYJ^%]8)U*#4A!Y/D3-9:=;:K"S&(J9-/!?%=&O?!^LZ8;2\:P.GZB+: M:>UUN&.V2ZDCU61H972:.*UE22,Q?._[-WBSXI?LV^.OC6QBM_!5W\1-=\:C0O#[>(-7(O(["'3+:-M/-A;VL M;R-,[-:RSG]PGFJ"Y?R?6OVX/C@_@;1?!NG^.].@\6Z'^TN/@O>>+;CPY;7! MU_2FTF2\6YFM5\N%;D>="&:#RD\ZV)"+&S0D ^_OCQ\=_"O[,OPCUOQWXWU7 M^Q/"OAR%9]1OOLTUS]G1G6,'RX4>1OF=1\JD\UO^*?$UEX+\,:CK&IS?9M-T MFUEO;N;8S^5%&A=VVJ"QPH)P 2<<"ORL_P""G'Q0\?>#/V<_VQ?@;XI\=:I\ M3-/\/^ /#GC+0_$.MZ=I]MJEB+[49;6:PN!I]O:VTJ+)8":-A"D@$\BLS@(5 M^B-;^+OQ7_9C_;4/@#7OB=J/Q#TGQS\*M?\ %]JU_H>FV/\ PC6KZ7<6JD60 MMH(V-G(E]@17;W4J?9X\SOERP!];?!WXN^'OC]\)_#?CCPEJ']K>%_%VFV^L M:3>^1+!]KM9XUDBD\N55D30#725^=/[)_[4OQ>_;=?]GWP--\3M M:\!7>M? G2OBGXI\3Z#H^DR:MXBO[N1+46\:7EI<6=O"K"263R[;<6DA56C4 M,'^_?AYI&L^'_ FD6/B'68?$6NV=I'#?ZI%8BQ749E4!YO(#,L>\C<5#$ DX MP,"@#9HHHH *\L_;0_Y-VU;_ *_M,_\ 3C;5ZG7C_P"WM_R:=XK_ .W/_P!+ M(*WPU'VU:%&]N9I?>['+CL3]6PU3$6OR1&?5!1110 4444 %%%% M!1110 4444 >0_!;_DZ7XT?]=]&_](!7KU>0_!;_ ).E^-'_ %WT;_T@%>O4 M %%%% !1110 4444 %%%% !1110 4444 JO[-_ M_)N_@+_L7-/_ /2:.K7QS_Y(GXQ_[ =[_P"B'JK^S?\ \F[^ O\ L7-/_P#2 M:.@#M**** "BBB@ HHHH **** "BBB@ HHHH *\B^.?_ "0_"'_ M ).U^,7_ %PT+_TFGKK?VA/CKX?_ &8?@7XN^(GBN>:V\-^"=)N=9U)X8_,E M\F"-I&"+D;G(7"KD98@=Z .QHKXSU7XX_M:6G[*DGQL@T?X,R[-%'BH?"?\ MLW4#JS66T3&P_P"$B%YY'V[[-D[AI9B\_P#= LG^D'T&[_X*M?!#2O!OPOU> M^\3ZC!-\9?#:>*?"&DVV@W^IZKK5H5MF9(;:SAFDDN$%U%N@0-( LK;2D4C* M ?1=%?/WC?\ X*B?!3X?>.+WPK?^(]?F\8Z;96>IW?AK3O!VM:EKUM:75NUQ M'V!WCCE,6\YF>Z6!4B@ FDE*PA69O+(!]LT5Y-\ M-?VX_A=\5OAGXJ\6Z;XG-EH_@6XDM/$BZWIMWH=]H$R(LACN[.]BAN8&*.C* M)(QO5U*[@15?X/\ [>'PS^-_B[7_ [I&I>(M,\2>&=)CUZ_T7Q+X3U?PUJ: MZ=(\L:WD=KJ-M;S30>9#(ADB1U5U"DAB 0#V&BOG+X._\%:/@!\?=8\'VOA/ MQU<:G;^/YEL_#VJOX=U2VT;5;MH&G%C'J,ULEI]M$:/FT,HG5D9#&'!4=%_P M4>_:0US]D#]A'XK?$_PU:Z5?:_X&\.76KV%OJ<4DMG-+$N5658W1RGJ%=3[B M@#VNBOC[P;^UK\7O@_\ M;?!7X>?%+4/AEXRTGX]Z;J4NBW_ (5\/WOAZ\T* M\L++[=*EQ!<7]\+B!X3M$J/$4DV@JWF#'I'P3_X*:_!+]HG2-5U7PAXQGU/P M[H-C=ZAJWB*70M2L] T>.T/^DI=:E/;I9V\T2_O&@EE641D2;-A#$ ]YHKQ' MX&_\%$_A-^T1XZTGPWX=UKQ!;ZUXATV36-$M_$'A+6/#H\06<80R3V#ZA:P) M>HJRQLQMS)A9%8X4@U\X?\%:O^"P7A7X"?L:_&]OAAX]N=-^)O@17T>RUE/# M5SI&[AK7S7E5DD4H'C8* ??M%-M#T6U\0WVF_9IAY%C:4\IMTEM,NU7+#9DJ 03PDG_!0_ MX/1_ "#XGCQ?YO@Z]UZ3PO8SQ:5>R7FJ:JE[)8&QM;)83=7-P;F*1%CAB=GV M%E#+\U 'M5%?'G[3G_!9OP!\!O!G@C6-'\.>/O%G_"4_$#3? FH61\':_I]] MX=DN9+;S&N;9].:=+E8+NWG@LI(XYKQ)4, <-NKZK\ ^-[/XD>#=/UW3X=7M M[+4X1/#%JNDW6E7B*>TMK=1QSPM_LR1JWM0!L5Y#^Q7_ ,DQ\2_]C]XM_P#3 M_?UZ]7D/[%?_ "3'Q+_V/WBW_P!/]_0!U_QL^ _A3]HKPC:Z%XQTK^V-*LM5 ML=;A@^TS6^R\LKF.ZM9=T3JQV311MM)VMMPP()!R?'W[)GPY^*GQ2?QEXD\) MZ;KFO3^&;KP;EYK:_T>YE26>QN;8MY%Q$SQJ<2QMC+8P&;/-?M\_M8ZA^ MQG\ X?%VD^&+/Q?JM_XBT;PW9Z;=ZNVE6[S:EJ$%C&\EPMO<,B(TX8[87)"D M 5K_ [^+'CKP[X?UK5OC5H?PM^&VEV3VT=E>:1X\N-9MYFED,96>2[TW3U@ M/F- D84R>8TI'R$+O ,SX%?L!_##]G22(^'M,\2WJ6NEG1+*+Q)XOUCQ-#I= MBRHKVUI'J5U<):Q.L<:NL(0.L48;(10*WPA_X)S?![X&W$_]@^&+Y[&73+K1 M(-)U?Q#J>M:/IEA$2POOW;6"Q2XY4X MK1_M?^"?@U^S[X!\4?&'XH_!_P *W/BG2;.5M7'B2"Q\/ZO>/;)+*VFSW4BF M:W8EGC.2QC*D^M %'X/_ /!.CX1_ QXET/0-:N=/M-/ETFQTG7?%.K:]I&D6 MDB>4\%G8WUS-;6D9BS%MMXXQY1,?W"5JAX/_ ."8OP9\%V'B**/0/$6KS>*- M"B\-75]X@\9:UKNHVFFQR-+';6=W>WF1VMCK$UA:/+-Q^(G@6]\%Z]="QTS7[?7[632]1N# M,T AAN1(8I)#,CQ[58G>C+C((H X+3O^":/P9LOA[XK\,W'AK5M9LO'.JZ9K M.OWFM^*-6U?5M6N=-F@FL/-U&ZN9+QH[>2VB:.'SO*7]X F)9 W9>._V3/A] M\3/C]X.^*&M^'DOO'/@**>'0]1-Y<1K:K,DD;;H4D$,Q"RR[#*CF,R.4*EB3 MES?M\? JW\#6_B>3XT_"9/#5W:2ZA!JS>+]/%C-;174=G+.LWF[&C2ZFB@9P M=JRRHA(9@#HV'[9?P@U7QCX6\.VOQ6^&USX@\J^&],B\363WGB"SD\SR M[FSB$F^XA;RI=LD893Y;X/RG !S/Q)_X)U?"3XJ_%36?&>I:%KEEKGB>"WMO M$']B>*]7T.R\3QP!UC&IV=E=0VVH8C=HB;J*4M%B)LQJ$'H_Q8^#'AGXX?!W MQ!X \3:6FH>$/%&E3:)J>G)+);+/9S1F*2$/$R/&"C$91E([$5A?$[]L#X2_ M!/XBZ7X/\9_%'X=>$O%NN1Q2Z=HFM>)+.PU'4$EE:&)H;>619) \J.BE5.YD M91D@BO-_&O[<*_"W]O[7OAYXLU+P?X8^'&A?#"S\;7&NZK%X-!N?% MOC+6O%?_ CX=51VL4U.[N$M'9%"&2 (Y3*%MI(KF]0_8:E\7?\ !6"R_:&U MJU\,&P\(_#K_ (0[PWY)D?56NY[V6>ZGGR@1(XX6$4*H['_2KLMC<@'NOBOX MJ^%_ FMV&FZYXDT'1M1U6WNKNRM+[4(K>>\AM45[F6-'8,Z0HRM(R@A P+8! M%>2?$/\ ;&T3XC? '_A,?@E\5/@-KUK;>)M-T6[US5O$L=UH$7FW=LEQ:?:+ M20@7SPW"B",M\TLT 8$/R :?AC_@GW\*?"/QFM/'EIH.K2Z[IE]>:GID%[XE MU2]TC1;N[WFYN;+3)KA[&SFD\V7,EO!&W[Z7G]XV$-)\9^(/B5XWLO!-A::IK\FB6=M+N^&3*-*UO0?$&H^' M=8L4F7;-"E]I\\%R(9 %+P^9Y;E(V9244CQ#]JO_ ()4^%OBO\%_@W\-O!V@ M>&M-\"> _B/9>+]=T[4;FY:35+5+>]2Y?S\233WTDMTLAFFD$C.&D:;> 3U_ MP)_;Z&M^)/C!X>^+VC^&/A+KWP3;3KGQ!>#Q4NH>'3I]_;F:UO$U">"T91F. M9'6:",HT8P65E->Q?$3XMZ+X&D?2Y-:T2#Q3=Z5>ZII>DW-VBW>H16JJ9I(X M=PDDCC,D0=E&%\Q,D;A0!YE9_P#!-'X,6_PJ\?>#;CPOJ6L:5\4G@?Q9=:SX MEU75=8U_[.L:6ZSZEO_A]H/Q1^'6M^/=*>>*^\-6'B2SN=7LW@;;,LEHD MAF0QGAPRC:>N* ./UK_@FU\'M7\%?#_0H?#VM:%!\+=)70?"U]X?\5:OH>K: M5IXC2/[(-0L[J*[D@*QQ[HY)F5FC5F!90:]<^'GP_P!&^%'@32/#/AZPATO0 MM!M(["PM(B2MO#&H5%R26/ Y))).2222:P-#_::^&_B?XRZE\.M-^(/@C4/B M#HT)N-0\,6VNVLNLV,8"$O+:*YF1<2QG+(!B1/[PJKX,_:U^%7Q'^+6J> ?# MWQ,^'VO>.M#,PU+PYIWB*SNM6T\PN(YA-:I(98_+P5X_^WM_R:=XK_[<_P#TL@KNRS_?*7^*/YH\ MK/?^1;B/\$__ $EGYOT445^Q'\V!1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^P%?C_ M %^P%?#\9?\ +G_M[_VT_5/#/_F)_P"W/_;@HHHKX<_5 HHHH **** "BBB@ M HHHH **** /(?@M_P G2_&C_KOHW_I *]>KR'X+?\G2_&C_ *[Z-_Z0"O7J M "BBB@ HHHH **** "BBB@ HHHH **** .5^.?\ R1/QC_V [W_T0]5?V;_^ M3=_ 7_8N:?\ ^DT=6OCG_P D3\8_]@.]_P#1#U5_9O\ ^3=_ 7_8N:?_ .DT M= ':4444 %%%% !1110 4444 %%%% !1110 5Y%\<_\ DY3X(_\ 85U7_P!- M5S7KM>1?'/\ Y.4^"/\ V%=5_P#35H ^)=2_;B\4>)OV-)? ]G\$OC-!\>+WPX_AP^%KCP M;J$.D6FJ^2ULSMK[1'1S8JX,PG6[;?#C:K2L(:Y+X,?L1Z[^S9^VI^Q=X=;2 M;[Q%H_P=^#&N>&M0\30:9*VG6VHA-)A#><5*P/-LN3&C,&*;P,@-7Z#T4 ?G M'X._:2L?V;?^"U?[6E_JW@GXA>)--O\ PGX'3^T?"?A:[\1S6,Z6NIO':R6U ME'+=+]H'F%9?+\A3;;99(V>$/Q_[.G['7Q&^$>F?L"V.N^"]2$\W*J3D5^C/A#]GWPCX#^-'C/ MXA:5I'V7QA\0;;3K37]0^U3/]OBT]9DM%\MG,/?A5X$U76/%=]IWA*\\(K<:5)+;ZW)!IIAO)+128UO) MH(@Q$2/EY(XXCRP4\?\ L_\ A+QEX]_X*?7_ (P^W?M$_$#PK%\"]?\ #L?B MGXB?#Z#PLAU%]4TF86-M#'I>G39*!W'GPG?MD\IW$.- M+_X(Y_L/^&CX)\5V_B?PCX]^'E[K6E'1[A+_ $6H7O)KF'9YD"1QF1I6< M *I8L0,U]2_\%D/ FN?$_P#X)9?'CP]X:T;5?$.OZQX.OK6PTS3+22[O+Z5D MPL<448+NY[*H)-?2U% 'A'[+7[!OPZ^ ^IZ7XTLM(\1W_CE]!M]*.K^*O$^K M>)-1TVWQO>VMI-2N9WM(V=B7C@\M7*KN!V+CXO\ A3^Q)\0O'_\ P;6:C\*= M.\%7FF?$2_.J:A_PC.L6S:3<:L\7B>>^^RS+*$*?:[>(1AI,*5G0D[#FOU'H MH ^&/B'XUOO^"A/[6/[-.I^"? ?Q.\-Z;\*_$-UXS\4:SXR\%ZGX6_LJ&32; MJS33(OMT,)NIYI;I=XMO-B18&+28*!_DK]H#PG\0/!/_ 0K^+?[+0^"?Q:\ M8?%^RU+68G72O!UW/I.K6TVNR:I%K$&H>7]DN-T,T3"W@EEO!-\AA'ER-'^S ME% 'Q?\ $[6=5_9?_P""LVO?$75/!/Q"\2>#_B%\*]-\/Z9?^%O#5WKHCU;3 MM4O96L;A;5'-J98M0A>.>Y\JW/ES!I4V<_,7[+?P3^)'PD_94_99^(OBSX8? M$"V3X4?&/QCK?C#PC;Z3/>ZWIEGJUSKEI!?I9PAI;Q+>2]@E/V9)6>%VDC#I MDU^MM% 'PQ_P4.\7:C^U;^S5X"\:^$O 7Q2ETGX7?&KPCXFN[2\\'WUGK.K: M98:A:S7EW::7+&NH.D8EE78]NDKFUE9(WB,EW.EWB*W02VUS''/"_JDB*P[@5K44 %>0_L5_\ ),?$O_8_>+?_ M $_W]>O5Y#^Q7_R3'Q+_ -C]XM_]/]_0!Y!_P6\^'VH_$O\ 8>@T_3M$\8:^ ML'CKPI?W]MX7L[^ZU:.Q@URSFNIH$L ;L-'"DC[H!YB[=RD$ UX)_P %$-8^ M'=[_ ,$?OCYI'@>P^.]_:Q_V/<7T'Q+LO&/FW7F:I:((K:;Q. 74B,AHX7V* M6!<+O!/Z<5R/QV^!/A7]I?X5:IX)\;:7_;7AC6O)^VV7VF:V\[RIDFC_ 'D+ MI(,21HWRL,[<'()% 'P5\:M"U#]J3]H:UUWX9?"KXA>"_#_PV^!7B_PIKHU; MP;=^'A=S:A'9KIF@6<4L:?;C ]C<29LQ-:IF/;*3+&&I_L]:/KG[)WQ8_9\\ M=_$3X??$C4_"T/[-6B>"+8:-X+U+Q!>>%M;A:.;4+6ZLK."6YMVN(OLJ;WB" M;K)D9E/!_2^B@#\9OA/^RO\ $?X9_#7X-^(W\&_&'X/>#?A_\7OB)>:EHW@_ MPC8:MKOA*'4;R6+2KNWTMK2_AN+>*-I(?-L8)]L-R7A8Q$O7IWQ8_8KL/'/[ M.UL_A_1_CC\2M,^)G[1W@WQ)XK7Q_P"$(--FU:VBNM.@U"_.DV]A9M:V7DPF M.=[JTA:0VTLI#PO'-)^I=% 'R9\5?@O>^*_^"T_P>\9W'A.ZU+0_"OPN\310 M:[)I;36FCZC/?:9&BK<%2D-Q);-=J &#M&9@,J7KY1TG]CS7_!W_ 2H\0:7 MHOPLU?2O&-Q^T:GB5;.R\-20:G+;1>/(WBU (D8E,::<@99L86W4$,(Q7ZPT M4 ?FYJUC7,5]I[PPR31Z;;O$GVU+2V@D'VAEC4QRM7Z5_ 3]G[PC^S%\-X M?"7@C2?[&T&"[N[\0-=37%8 MO8@^*-+\1K$E MM:RP6ECO6"2[N3)-(L2V]O.,#T'_ (+4_#^;Q[\/_@4\FB?$36="T'XOZ1JN MOMX)L]8N-7T[3X[+45DN4.D@WT85GC'F0X8%U /-?9]% 'Y&_$7]DKQ=\:?A M'^VEX:^"/A/XI?\ "L/B/X MI+(_$:RU2V\0^(_&44969;:;7 NK36IL8;&( M&Z8PK/O$) \RO:?%?Q+UG]KW_@HG\)_&'AWX8?/"WA_X7^,M.O]5\1^"M M0T.&'4;Q=)=+'9=Q1S^8!&<.8A#*2PADF:*<1?H310!^5G[,'[-/Q0M?"W[% MEC;>&O%OA?6O#_[.GBCP]>W]UIES:?\ ",:O/;:,EM%=.4!MI_,C$[_ ,1S:EX+O-+T?PHV MC3)_;-W%JTD2V-[]J"W2(UG/.UV+W5E_4JB@#\Y_@OI7BOX.?MQ:?X;^ M%OA;X@:[X%UKQ;XB\3>)?#_Q!^'4UE:_#S4Y8]3:75=&\1^7';SK>7%VD0@2 M6]0_ #2?BOX[_: _8XOM9T?XWV^L>#/%>I2^,/#!^%=MX:\" M?"Y9M%U.W%EIUPFG133VF7%O%,E[>0LD:F619)K??^NU% !1110 5X_^WM_R M:=XK_P"W/_TL@KV"O)/VZ+1M0_9=\1VZ8#W,MC"I;H"U];J,^V377E\XPQ5. M _Y^H_"/\ 5;-O^?$CYOHKZ0_X=>^/ M_P#H+^#_ /P*N?\ XQ1_PZ]\?_\ 07\'_P#@5<__ !BC^V\!_P _4'^JV;?\ M^)'S?17TA_PZ]\?_ /07\'_^!5S_ /&*/^'7OC__ *"_@_\ \"KG_P",4?VW M@/\ GZ@_U6S;_GQ(^;Z*^D/^'7OC_P#Z"_@__P "KG_XQ1_PZ]\?_P#07\'_ M /@5<_\ QBC^V\!_S]0?ZK9M_P ^)'S?17TA_P .O?'_ /T%_!__ (%7/_QB MC_AU[X__ .@OX/\ _ JY_P#C%']MX#_GZ@_U6S;_ )\2/F^BOI#_ (=>^/\ M_H+^#_\ P*N?_C%'_#KWQ_\ ]!?P?_X%7/\ \8H_MO ?\_4'^JV;?\^)'S?1 M7TA_PZ]\?_\ 07\'_P#@5<__ !BC_AU[X_\ ^@OX/_\ JY_^,4?VW@/^?J# M_5;-O^?$CYOHKZ0_X=>^/_\ H+^#_P#P*N?_ (Q1_P .O?'_ /T%_!__ (%7 M/_QBC^V\!_S]0?ZK9M_SXD?-]%?2'_#KWQ__ -!?P?\ ^!5S_P#&*YSX4_L& M>+_C!X-77--U'PW!:->WMB$NKB99-]K=2VLAPL3#:7A8KSDJ1D Y /[;P'_/ MU!_JMFW_ #XD>)45](?\.O?'_P#T%_!__@5<_P#QBC_AU[X__P"@OX/_ / J MY_\ C%']MX#_ )^H/]5LV_Y\2/F^BOI#_AU[X_\ ^@OX/_\ JY_^,4?\.O? M'_\ T%_!_P#X%7/_ ,8H_MO ?\_4'^JV;?\ /B1\WT5](?\ #KWQ_P#]!?P? M_P"!5S_\8H_X=>^/_P#H+^#_ /P*N?\ XQ1_;> _Y^H/]5LV_P"?$CYOHKZ0 M_P"'7OC_ /Z"_@__ ,"KG_XQ1_PZ]\?_ /07\'_^!5S_ /&*/[;P'_/U!_JM MFW_/B1\WT5](?\.O?'__ $%_!_\ X%7/_P 8H_X=>^/_ /H+^#__ *N?_C% M']MX#_GZ@_U6S;_GQ(^;Z*^D/^'7OC__ *"_@_\ \"KG_P",4?\ #KWQ_P#] M!?P?_P"!5S_\8H_MO ?\_4'^JV;?\^)'S?17TA_PZ]\?_P#07\'_ /@5<_\ MQBC_ (=>^/\ _H+^#_\ P*N?_C%']MX#_GZ@_P!5LV_Y\2/F^BOI#_AU[X__ M .@OX/\ _ JY_P#C%6XF$4C36Z7 M"F,B(D@)( <@<@]1S1_;> _Y^H/]5LV_Y\2/$J_8"O@__AU[X_\ ^@OX/_\ M JY_^,5]X5\CQ3CJ&(]E["2E;FO^!^B< Y7B\%[?ZU3<>;EM?K;FO^84445\ MD?H@4444 %%%% !1110 4444 %%%% 'D/P6_Y.E^-'_7?1O_ $@%>O5Y#\%O M^3I?C1_UWT;_ -(!7KU !1110 4444 %%%% !1110 4444 %%%% '*_'/_DB M?C'_ + =[_Z(>JO[-_\ R;OX"_[%S3__ $FCJU\<_P#DB?C'_L!WO_HAZJ_L MW_\ )N_@+_L7-/\ _2:.@#M**** "BBB@ HHHH **** "BBB@ HHHH *\B^. M?_)RGP1_["NJ_P#IJN:]=KR+XY_\G*?!'_L*ZK_Z:KF@!/A#_P G:_&+_KAH M7_I-/6W^UI^T1IW[)'[,'Q ^)^K6TM]I_@'P_>Z[+:1/LDO?L\+2+ K$$*TC M*$!(P"P)XK$^$/\ R=K\8O\ KAH7_I-/6K^V'^S?8_MA?LK?$+X6ZE?S:59^ M/M N]$>^AC\Q[$S1,BS!,@.48JVTD!MN"1F@#R7]GGX._M >-?A]X)\?>+OC MQJ&F^+]82TUC6O!UIX6TF7P;:13%9)=/A4VZZKE(&\M9VU$GSU$I0QDVU;7Q MC_X*,Z5\!/%L8\4_#3XK:3X#?Q%;>%F\>W&GV,.AQ7MQ.MK$6A>[74O(:Y98 M1<"R,+EE=':%EE.-^SK\_$VQUNS\3#XK)I_@-?#EKK=GF94GN/M M,DPB$H!]E_$C_@IMI'A#]I#QS\)_#GPL^,'Q)\;_ ]TVPUG5K3PQIE@8%LK MN*61)4N+N\MX2P,6SR"XGD9_W,4RQS-'>U[_ (*:_#W_ (4U\*/%WA.R\3_$ M2X^.&P^!_#WA^UA&KZZ/)-Q,P6[FMX8$MX59YGGFC1-N,EF56H?LY?L^^+_ M?_!3?]IGXA:KI'V7P?\ $'1?!EIH&H?:H7^WRZ?!J:7:^6KF2/RVN(1F15#; M_E+8./FG]GO]B'XR_LS_ 2_8R\7_P#""7GB+Q3\!++Q'HOBKP38:QIR:A<6 MNL843VLTUQ'922P/! Q5[A 8Y)0&W@+0!AI^VA_PL:\_X*)ZUXUU_P"/_@7P M7X L/#JOI>DWXT_Q3X*9-()ODTP/*UK#,TR,PF@D:"?(E265'61OL3QY^WQH MGPT^(&C?#[PYX,^)GQ6\7CPK%XJU*P\.06,MSHNE,RQ17-Y+=W5M$99G$FR" M%I;B3R966(JN:^1/B5^QC\?_ (\_"S_@H'J.J_#.W\/:Y^T)H.C6_@?0T\16 M-U-<"WTEK7R+F82B&&Y4A/-&XPJ[,LA?$WX=Z%X>NK32];TVQNO#6KZ2]R(QU;7/B'XGL='LK6)[G5KF :U??9 MXW>_EABLX8;:/ ^US01QB-(@1(T<33_M ?AKXH7 MXD?!B\.DZ_X7\3Q6&[PM<&W6YBNKX0:@(Y[-XI(F4V-Q-(WGIA/EDV>6_"K] MD3]I;X3_ + G@?PK=>'](?B-X9\!>,+?3-:US1+K4[Z[A33-5: MXMO)0S26LK#[3:3O KQLR%GB:GI/_!-3XI?$/]E3]NCPN?!NN^#;CXZ):2^" M++Q5X[/BC4[@0:-;VZ)>ZA+:2.+=LBEDAC20@'U_XB_X* KX! M^'O@NX\0_"SXEV7C_P"(-^^F^'? ,']CW6NZRT<:RSW$;PZA)8Q6T<1:1Y+B M[B"*H#8=XT?M_P!F']JS0_VH]&\1?8=+U_POXC\%ZQ)H/B7PUK\,,6JZ!>JB M2K',()9H'22"6&:.6"66*2.52KDA@ORA^U;^S/X]_:@\4? +XOW/PM^*^GW7 MPOM]8T+7O .E_$"V\-^)IK?4([-/MEEJ&FZI';/YKR']BO_DF/B7_L?O%O_I_OZ /,O^"RGC.^TK]B[_A#],NY+"_^ M,?BSP_\ #5;F.0QR0P:QJEO9W90@@AC:27 !!&TD'M@_.?[=/Q6\#?"'_@I3 MXDT/XC>(_CYH'PJ\%_ 73-=L].^'&I^+K6RT>6/5-82:\G30G6.$"VMXU\Z[ MVQ!85!;"\?4O_!6#X-Z_\7?V-=1NO"&G76L>,OAYKFC^/M"T^UC\R?4;K1]1 MM]0^S1+P6DFC@EB0 @[Y%Z]#TV@_LN6OB']LS5OCE-J4DMEXM^&^G>"'\-WV MD&)HHX;Z]O3-*SOG+B^\MH&B!7RSECNV@ ^+K.?XK>/?@Q^P%X2^+'C;QG%K M'Q \1ZI!XIN/#7C2XTNZUZP31-5N]/\ /O\ 1[B+SF\J*RD=HI2CR*QRP.3Z M#X^\2>*_V)/VM/$WPIT7QGXV\1?#OXC_ EU_P 7:'!X@UR[UK5?!6KZ4(8I MFM]2N9'O'MKE+N)_+GFE:&>$F)HTD\L=!HW_ 2<\7?#?X6_ [0?!OQVO M?V?/%FKZUX4N?$'@^;5;9=,N[>]M;;2YXH]1MY'^RV]YY:3+,NX01_NU&17H MGAG]@#5?$'CSQS\0/B7X]@\:?$SQ=X1F\#Z=>Z=H']D:'X2TN4%I(K&P-Q/- MOFFV33R7%W,[M%&J&&-1'0!XU_P1BU;P1\3_ ((_![Q&=5_:=UCXF77P^TS5 MM=O_ !CJ/Q ?PYJ-W-8VXNY8WU1_['N"\LK/'Y&\$'?#\J[A\I?L6?M,3V_P M6_9'\4:?X_\ VB4^)GBOQY::;XTUKQMJ_BMO ^J:;*]\MS ]QJ['1GEDC2.. MV%FWG-<^2L?)85^CO[$O[,/QE_93^'?P\\ ZU\4?AEXL^'_P]\/6GAN&WL?A MS?:5K%Y!:6:VUN[7;ZU<0J_[N-GQ:X;#!0F05\7\ _\ !(#Q_;?LG^"OV?\ MQA\:/"FM_!;PKJ-G?7ECH_P^GTK7];CL[\:C;V\FH2ZK4C@!6-K(1N!!KZ;H **** "BBB@ HHHH **** M"BBB@ HHHH **** "O+/VT/^3=M6_P"O[3/_ $XVU>IUY9^VA_R;MJW_ %_: M9_Z<;:@#U.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_8:_Y M-ZC_ .QB\1?^GR_KUZO(?V&O^3>H_P#L8O$7_I\OZ /7J*** "BBB@ HHHH M**** "BBB@ HHHH **** "O(O@9_RKR'X+?\G2_&C_ *[Z-_Z0"O7J "BBB@ HHHH **** "BB MB@ HHHH **** .5^.?\ R1/QC_V [W_T0]5?V;_^3=_ 7_8N:?\ ^DT=6OCG M_P D3\8_]@.]_P#1#U5_9O\ ^3=_ 7_8N:?_ .DT= ':4444 %%%% !1110 M4444 %%%% !1110 5Y%\<_\ DY3X(_\ 85U7_P!-5S7KM>1?'/\ Y.4^"/\ MV%=5_P#35KPGP)\0] \'_M=_%^/5M?@G_ *'#PM_X-H/_ (N@#JJ*Y7_A>?@G_H?@G_ *'#PM_X-H/_ (N@#JJ* MY7_A>?@G_H?@G_ *'#PM_X-H/_ (N@#JJ\A_8K_P"28^)?^Q^\6_\ I_OZ[3_A>?@G M_HX((H ^@:*Y7_A>?@G_H?@G_H?@G_H?@G_H?@G_H?@G_H?@G_H M?@G_H%O_ ;0?_%UYC^V'\9?"&I?L_:I#;^*O#<\K7NFD)'J<+,0-0MB> V> M "?PH ]XHKE?^%Y^"?\ H?@G_ M *'#PM_X-H/_ (NC_A>?@G_H?@G_ *'#PM_X-H/_ (NC_A>?@G_H('V2ZG"C;6UJ^93@MG!4@CU!!H ^@:*Y7_A>?@G_ *'#PM_X-H/_ M (NC_A>?@G_H?@G_ *'#PM_X-H/_ (NC_A>?@G_H?@G_ *'#PM_X M-H/_ (NC_A>?@G_H?@G_H'(X;G4]+:&1M3A"R@:7 M;J2IW8.""#CN* /H&BN5_P"%Y^"?^AP\+?\ @V@_^+H_X7GX)_Z'#PM_X-H/ M_BZ .JHKE?\ A>?@G_H?@G_H?@G_H?@G_H3Q5X_\ HAZJ_LW_ /)N_@+_ +%S3_\ TFCK"^-GQL\&77P9\71Q^+?#$DDF MBWBHBZI 68F!P !NY-5OV>/C5X-LO@!X&AF\6^&8I8O#]@CH^J0*R,+:,$$% ML@@T >M45RO_ O/P3_T.'A;_P &T'_Q='_"\_!/_0X>%O\ P;0?_%T =517 M*_\ "\_!/_0X>%O_ ;0?_%T?\+S\$_]#AX6_P#!M!_\70!U5%H XO_ (9O^'?_ $(7@O\ \$EM_P#$ M4?\ #-_P[_Z$+P7_ ."2V_\ B*[2B@#B_P#AF_X=_P#0A>"__!);?_$4?\,W M_#O_ *$+P7_X)+;_ .(KM** .+_X9O\ AW_T(7@O_P $EM_\11_PS?\ #O\ MZ$+P7_X)+;_XBNTHH XO_AF_X=_]"%X+_P#!);?_ !%'_#-_P[_Z$+P7_P"" M2V_^(KM** .+_P"&;_AW_P!"%X+_ /!);?\ Q%'_ S?\._^A"\%_P#@DMO_ M (BNTHH XO\ X9O^'?\ T(7@O_P26W_Q%'_#-_P[_P"A"\%_^"2V_P#B*[2B M@#B_^&;_ (=_]"%X+_\ !);?_$4?\,W_ [_ .A"\%_^"2V_^(KM** .+_X9 MO^'?_0A>"_\ P26W_P 11_PS?\._^A"\%_\ @DMO_B*[2B@#B_\ AF_X=_\ M0A>"_P#P26W_ ,17E/['GP#\"ZO\-_$4EWX+\)W,D?CGQ3 C3:1;N5C37;Y$ M0$IPJJJJ!T X%?15>0_L5_\DQ\2_\ 8_>+?_3_ '] '5?\,W_#O_H0O!?_ M ()+;_XBC_AF_P"'?_0A>"__ 26W_Q%=I10!Q?_ S?\._^A"\%_P#@DMO_ M (BC_AF_X=_]"%X+_P#!);?_ !%=I10!Q?\ PS?\._\ H0O!?_@DMO\ XBC_ M (9O^'?_ $(7@O\ \$EM_P#$5VE% '%_\,W_ [_ .A"\%_^"2V_^(H_X9O^ M'?\ T(7@O_P26W_Q%=I10!Q?_#-_P[_Z$+P7_P""2V_^(H_X9O\ AW_T(7@O M_P $EM_\17:44 <7_P ,W_#O_H0O!?\ X)+;_P"(H_X9O^'?_0A>"_\ P26W M_P 17:44 <7_ ,,W_#O_ *$+P7_X)+;_ .(H_P"&;_AW_P!"%X+_ /!);?\ MQ%=I10!Q?_#-_P ._P#H0O!?_@DMO_B*/^&;_AW_ -"%X+_\$EM_\17:44 < M7_PS?\._^A"\%_\ @DMO_B*/^&;_ (=_]"%X+_\ !);?_$5VE% '%_\ #-_P M[_Z$+P7_ ."2V_\ B*/^&;_AW_T(7@O_ ,$EM_\ $5VE% '%_P##-_P[_P"A M"\%_^"2V_P#B*/\ AF_X=_\ 0A>"_P#P26W_ ,17:44 <7_PS?\ #O\ Z$+P M7_X)+;_XBO,OVP/@#X$TCX :I/:^"O"5M.M[IJK)%H]NC@'4+92,A,\@D'V) MKZ!KRS]M#_DW;5O^O[3/_3C;4 ;_ /PS?\._^A"\%_\ @DMO_B*/^&;_ (=_ M]"%X+_\ !);?_$5VE% '%_\ #-_P[_Z$+P7_ ."2V_\ B*/^&;_AW_T(7@O_ M ,$EM_\ $5VE% '%_P##-_P[_P"A"\%_^"2V_P#B*/\ AF_X=_\ 0A>"_P#P M26W_ ,17:44 <7_PS?\ #O\ Z$+P7_X)+;_XBC_AF_X=_P#0A>"__!);?_$5 MVE% '%_\,W_#O_H0O!?_ ()+;_XBC_AF_P"'?_0A>"__ 26W_Q%=I10!Q?_ M S?\._^A"\%_P#@DMO_ (BC_AF_X=_]"%X+_P#!);?_ !%=I10!Q?\ PS?\ M._\ H0O!?_@DMO\ XBC_ (9O^'?_ $(7@O\ \$EM_P#$5VE% '%_\,W_ [_ M .A"\%_^"2V_^(H_X9O^'?\ T(7@O_P26W_Q%=I10!Q?_#-_P[_Z$+P7_P"" M2V_^(KRG]BSX!^!=9^ D<]WX+\)W4_\ PD&OQ^9-I%N[;4UJ]11DIG 50 .P M ':OHJO(?V&O^3>H_P#L8O$7_I\OZ .J_P"&;_AW_P!"%X+_ /!);?\ Q%'_ M S?\._^A"\%_P#@DMO_ (BNTHH XO\ X9O^'?\ T(7@O_P26W_Q%'_#-_P[ M_P"A"\%_^"2V_P#B*[2B@#B_^&;_ (=_]"%X+_\ !);?_$4?\,W_ [_ .A" M\%_^"2V_^(KM** .+_X9O^'?_0A>"_\ P26W_P 11_PS?\._^A"\%_\ @DMO M_B*[2B@#B_\ AF_X=_\ 0A>"_P#P26W_ ,11_P ,W_#O_H0O!?\ X)+;_P"( MKM** .+_ .&;_AW_ -"%X+_\$EM_\11_PS?\._\ H0O!?_@DMO\ XBNTHH X MO_AF_P"'?_0A>"__ 26W_Q%'_#-_P ._P#H0O!?_@DMO_B*[2B@#B_^&;_A MW_T(7@O_ ,$EM_\ $5Y3\%?@'X%O/VB?C-;S>"_"EK!$^D6[) &TNW M9@H*84%B2<=22:^BJ\B^!G_)RGQN_P"PKI7_ *:K:@#J?^&;_AW_ -"%X+_\ M$EM_\11_PS?\._\ H0O!?_@DMO\ XBNTHH XO_AF_P"'?_0A>"__ 26W_Q% M'_#-_P ._P#H0O!?_@DMO_B*[2B@#B_^&;_AW_T(7@O_ ,$EM_\ $4?\,W_# MO_H0O!?_ ()+;_XBNTHH XO_ (9O^'?_ $(7@O\ \$EM_P#$4?\ #-_P[_Z$ M+P7_ ."2V_\ B*[2B@#B_P#AF_X=_P#0A>"__!);?_$4?\,W_#O_ *$+P7_X M)+;_ .(KM** .+_X9O\ AW_T(7@O_P $EM_\11_PS?\ #O\ Z$+P7_X)+;_X MBNTHH XO_AF_X=_]"%X+_P#!);?_ !%'_#-_P[_Z$+P7_P""2V_^(KM** /G M7X/_ #\"W?[3'Q@MI?!?A.6WM)M($$3Z1;E(=UB"VT;,+D\G'4UZM_PS?\ M#O\ Z$+P7_X)+;_XBN5^"W_)TOQH_P"N^C?^D KUZ@#B_P#AF_X=_P#0A>"_ M_!);?_$4?\,W_#O_ *$+P7_X)+;_ .(KM** .+_X9O\ AW_T(7@O_P $EM_\ M11_PS?\ #O\ Z$+P7_X)+;_XBNTHH XO_AF_X=_]"%X+_P#!);?_ !%'_#-_ MP[_Z$+P7_P""2V_^(KM** .+_P"&;_AW_P!"%X+_ /!);?\ Q%'_ S?\._^ MA"\%_P#@DMO_ (BNTHH XO\ X9O^'?\ T(7@O_P26W_Q%'_#-_P[_P"A"\%_ M^"2V_P#B*[2B@#B_^&;_ (=_]"%X+_\ !);?_$4?\,W_ [_ .A"\%_^"2V_ M^(KM** /)?C5^SQX LO@WXMFA\#>#XI8M&O'1TT6V5D80.000F00:J_L]?L] M> =0^ 7@>>?P/X/FGF\/V$DDDFC6S/(QMHR6)*9))[UW7QS_ .2)^,?^P'>_ M^B'JK^S?_P F[^ O^Q"__ 26W_Q%'_#-_P . M_P#H0O!?_@DMO_B*[2B@#B_^&;_AW_T(7@O_ ,$EM_\ $4?\,W_#O_H0O!?_ M ()+;_XBNTHH XO_ (9O^'?_ $(7@O\ \$EM_P#$4?\ #-_P[_Z$+P7_ ."2 MV_\ B*[2B@#B_P#AF_X=_P#0A>"__!);?_$4?\,W_#O_ *$+P7_X)+;_ .(K MM** .+_X9O\ AW_T(7@O_P $EM_\11_PS?\ #O\ Z$+P7_X)+;_XBNTHH XO M_AF_X=_]"%X+_P#!);?_ !%'_#-_P[_Z$+P7_P""2V_^(KM** .+_P"&;_AW M_P!"%X+_ /!);?\ Q%>;_$CX4>%_ ?[4'P4N-#\-:!HUQ+J>JH\MCI\-N[K_ M &5<\$HH)%>^5Y%\<_\ DY3X(_\ 85U7_P!-5S0 GPA_Y.U^,7_7#0O_ $FG MKUZO(?A#_P G:_&+_KAH7_I-/7KU !1110 4444 %%%% !1110 4444 %%%% M !1110 4444 %>0_L5_\DQ\2_P#8_>+?_3_?UZ]7D/[%?_),?$O_ &/WBW_T M_P!_0!Z]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %>6?MH?\F[:M_U_:9_Z<;:O4Z\L_;0_P"3=M6_Z_M,_P#3C;4 >IT4 M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D/[#7_ ";U'_V,7B+_ M -/E_7KU>0_L-?\ )O4?_8Q>(O\ T^7] 'KU%%% !1110 4444 %%%% !111 M0 4444 %%%% !7D7P,_Y.4^-W_85TK_TU6U>NUY%\#/^3E/C=_V%=*_]-5M0 M!Z[1110 4444 %%%% !1110 4444 %%%% !1110!Y#\%O^3I?C1_UWT;_P!( M!7KU>0_!;_DZ7XT?]=]&_P#2 5Z]0 4444 %%%% !1110 4444 %%%% !111 M0!ROQS_Y(GXQ_P"P'>_^B'JK^S?_ ,F[^ O^QJO[-__ ";OX"_[%S3_ /TFCH [2BBB@ HHHH **** "BBB@ HHHH * M*** "O(OCG_R)?!O@'7=7.G3PPQ[Y&5$W2.HW,P49R2!S0!^&?%%[/<>'_AC- MX)AU*PNM/ANI(/\ 2]3)^UQR-Y;?-&#G"MM3=L'KO_!.O_@CGX$^''_!,3P] MX$\=_"/P)X-^*WB+X?7GA#Q?K>G:/IS:X!>P2P7*MJ$ 9I6*2. M_P#!/[P?^WM_P3@^!FB?LYV/P%^&WQ&\/>%+J>UT'XF-X[M]/TVWLI;B28-< MZ<5^V2LAD;A AQM7+$%R 9_[=G_!8CXL?\$@?VTOC)X=^*MU=>/O OQ \*MX MB^!WE:/!&]MJJNL+:+*UO$C2(LLP9GE,CK%%"'= _P"$2^!-N=7M[D0S)*)VUR5;:5_+ M\^:%!LDVR>3.RLH:-&KV'X5_\$K-"_X*7?LD?"B[_;E^#+W7QF^'VE2^'[@G MQ=.!<(C@"[#Z7>")C<*D)=V\B0+%IMO+NMU M265+EF>X,AC01@)(6++R7Q7_ &)OVK/V)_VEOVIX?V??A1X:^)O@']J6R@:R MU2Y\66FCR^ ;[[+-;S330W'SW2[KAW"H3D)&<@[U;H_VK?V)OC]^SK_P1%\$ M_LE_"+X10?&K4=>\'7>@>*-?M_&%AH4/AFZ,D,_F1PWNTW<?"WQ?XG\%>&]<\6?$#QG90?V?IB M76GPR75TL&8K7SGN)4"HYCA'F$#&%4^/_P#!"K]N+XV?M*?M'?M ^!/'/Q)T M/X__ Z^&EW9VWAWXI:3X?MM(M-;N)59I;>,6O\ H\@5<$["Y4C)=ED2M'X& M:%^T]IW_ 2)\&?#GQ)^R;\/-8\0_#FVT?P=J7@#QCXRT[5+3Q[H=CID41O( M9HUDM+6X:[CA98;D2*JQ2?,248 _'NA0Z/IOPF\.:[#J=K!=));,;Z0V@6T5E$$H78H/^F2 *@!W@'ZAT M444 %%%% !1110 4444 %>0_L5_\DQ\2_P#8_>+?_3_?UZ]7D/[%?_),?$O_ M &/WBW_T_P!_0!Z]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 4444 %>6?MH?\F[:M_U_:9_Z<;:O4Z\L_;0_P"3=M6_Z_M,_P#3 MC;4 >IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7D/[#7_ ";U M'_V,7B+_ -/E_7KU>0_L-?\ )O4?_8Q>(O\ T^7] 'KU%%% !1110 4444 % M%%% !1110 4444 %%%% !7D7P,_Y.4^-W_85TK_TU6U>NUY%\#/^3E/C=_V% M=*_]-5M0!Z[1110 4444 %%%% !1110 4444 %%%% !1110!Y#\%O^3I?C1_ MUWT;_P!(!7KU>0_!;_DZ7XT?]=]&_P#2 5Z]0 4444 %%%% !1110 4444 % M%%% !1110!ROQS_Y(GXQ_P"P'>_^B'JK^S?_ ,F[^ O^QJO[-__ ";OX"_[%S3_ /TFCH [2BBB@ HHHH **** "BBB M@ HHHH **** "O(OCG_R_[2EQ^QS^ MQ9\4?BE9Z=#J][X$\-WNL6ME,Q6*YGBB8QHY&"$+[=V.=N<N45\0:_\ ML,>+5_8DN/&:?'+XS0?'^/PS_P )#_PF'_"87XTE=76+[21_PCXE.C?8=P\C M[/\ 8S^XZLTW[\T_!'_!77QC\2-+_9ATCPK\([3Q1XT_:-^'DOC)?.\1-I&D M>'Y[>.R>X2XE%M"]3U/6-9\:>)+:/PM=7T-I-9:E M%HFI65S;7-PV5CCM[B.7S955V\J)WCBE=%$4:-QAL# M.;\//VY?&=A^TUKGPE^)_P ./#_A7Q5;^!)?B!HUUX:\63>(-*U6RM[L6EU! M)-/864L%Q')+:D+Y,B,EQD."A6@#Z9HKX6^ W_!7OQE\3OA1\#OB=XE^"$/@ M[X6_'#6=+\.66H#QFE_K&F7VH*8[662R6T2)K*2Z"PK*+H3XD1VMDR5'J?\ MP60\>:Y\,/\ @EE\>/$/AK6=5\/:_H_@Z^NK#4],NY+2\L953*R12QD.CCLR MD$4 ?2U%?FS^RY\8- O?V^?@OH_[._Q;\6_%WPCJ_AO4)_B] _Q"O_'FB^'D M6T+:;';;4%,R^(VU+Q!K-];7ILXX;&Q6S2*6*XFQ#'++=0OYV5,0CQ,P!]R M45\O>%_VYOB'X$^./PR\'?&KX4:!\/8_B^;BR\/7^@^-&\1K::I#;&[.G:@K MV%HL$KPI/L>![B-G@==XRC-\>?\ !8']NSQE^U%_P1__ &AO$?AKX4)-\%)W MN_#.F>*?^$D UN^^R:A':2ZD=):V5$T\W<,T:N+QK@HJ2M;JK,(P#]9**\A\ M-_M5_P#"0_MT^+/@M_8/D_\ "+^#-*\7_P!L_;=WVG[;>7UM]G\CRQMV?8]V M_P P[O,QM7;D^'^#_P#@KA+\1?V=/A_XBT+X=K>?$'XK>/M6\ ^%_"LOB$0V MTTNG7M[# _ /@O7-=^,/A[P?JF/&QU*QUNTO+FV"0VTKZ0TBVUQYTUO//)!; MW-L]N[0PW"-'(WV]X!O=>U'P;I\_BC3=(T?Q!)"&O[+2M2DU*SMI.ZQ7$D%N M\J]/F:&,_P"S0!L5Y#^Q7_R3'Q+_ -C]XM_]/]_7KU>0_L5_\DQ\2_\ 8_>+ M?_3_ '] 'KU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %% M%% !1110 5Y%^W;)IHSMD@DLI$;&=K+>VY!_,"O7:\?\ V]O^33O% M?_;G_P"ED%=F714L72C)73E'\T>;G,Y0R^O.#LU"336Z?*SX_P#^&]OBS_T- M?_E,L_\ XU1_PWM\6?\ H:__ "F6?_QJO'Z*_5O[,P?_ #ZC_P" K_(_G[^W MWQ9_Z&O\ \IEG_P#&J\?HH_LS!_\ /J/_ ("O M\@_MW,O^@B?_ ('+_,]@_P"&]OBS_P!#7_Y3+/\ ^-4?\-[?%G_H:_\ RF6? M_P :KQ^BC^S,'_SZC_X"O\@_MW,O^@B?_@P?\-[?%G_ *&O M_P IEG_\:H_X;V^+/_0U_P#E,L__ (U7C]%']F8/_GU'_P !7^0?V[F7_01/ M_P #E_F>P?\ #>WQ9_Z&O_RF6?\ \:H_X;V^+/\ T-?_ )3+/_XU7C]%']F8 M/_GU'_P%?Y!_;N9?]!$__ Y?YGZ/M6^)_[/7A_7-O8*_*D%%%% !1110 4444 %>1? S_DY3XW?] MA72O_35;5Z[7D7P,_P"3E/C=_P!A72O_ $U6U 'KM%%% !1110 4444 %%%% M !1110 4444 %%%% 'D/P6_Y.E^-'_7?1O\ T@%>O5Y#\%O^3I?C1_UWT;_T M@%>O4 %%%% !1110 4444 %%%% !1110 4444 _\ HAZJ M_LW_ /)N_@+_ +%S3_\ TFCJU\<_^2)^,?\ L!WO_HAZJ_LW_P#)N_@+_L7- M/_\ 2:.@#M**** "BBB@ HHHH **** "BBB@ HHHH *\B^.?_)RGP1_["NJ_ M^FJYKUVO(OCG_P G*?!'_L*ZK_Z:KF@!/A#_ ,G:_&+_ *X:%_Z33UU/[2'P M&T/]J3X >,_AQXF69M \<:-=:)?F%@LL<4\31ET)! ==VY3CAE!KEOA#_P G M:_&+_KAH7_I-/7KU 'QO<_!/]K#Q!^S(?@MJ.I?!F&WGTAO"]U\4K?5=1DU> M>PV& WJZ ]EY"7SV^ 5.IO$DS&3#H! >@\-?\$\Y?A5^UM^SYXA\'RZ79_#? MX(?#?5? 4=C=7,KZDZS?V:EHR_NRD@$=D_F.SJVY@0&RUU4VUU'=VUM=-^Z*2J]N8! MYHN PFB,.V7M/A5_P2G\2?!J#]DJULO$FA:POP.\3^(?%/BZ^N$DM)=8NM8M M-1,[6D*(ZX%W?G"R.NV)1\S,,'[DHH ^*?VBO^"!%\-_#III9)[NXO=.N(;RYNO[/LEG!6 MVF0@P*T6U,--YC>5]E^(OVA_ 'A"+Q:^K>.?!^EIX!CAF\3M=ZS;0CPXDR>9 M"UZ6_9PUS]K_ /81^*WPP\-76E6.O^.?#EUI%A<:G+)% M9PRRKA6E:-'<)ZE48^QKU+P)\1O#WQ1T-]3\,Z[HWB+38[F>R>[TN]CNX%G@ MD:*:(O&Q4/'(C(ZYRK*00""*V: ,SP7HTOASP=I.GSLC36%G#;R,A)4LB!21 MD XR/2OC;X9?\$JM=E_X(RR_LR^*_$^FZ3XFF34)8=>T3S+RVT^[;6YM5L9U M658FD$?A!XH^--I\,?"&C?!J^E M\16^G>"_$%_K;^)-:DLIK)99'NK&T^R6T*7$[K$OVAW:1 9%"'S/G_XT_P#! M*C]H?4_^"(WRW,Y,48/V4/)F+]-** /E_XP?LU_%;PG^WCZO'XL\"6_@ MG7M,\4ZE>:<=,DM+Z:ZL]1MWM[>X^T@+>7226K?9]VR$K.F6KQ;X'_\ !*WX ML? ']E_X)"R\2> M?^,OP-^(>O\ C"W>Y>ZLM!\3V>KW.I1W=K)(L,DMG(]G MJ)976&X$4T07;*AWU^A-% 'R7^U-^S-\:/VNOV>=%.MVWPMT'XB>"?B1H'CW MPUHUGK%_=:-Y>E75K.+.[U)K2.9WF:.Z;SH[%!&)HH_*D,;32?3W@:\US4/! M^G3>)=.TK2=?E@5K^STS49-1L[:7^)(KB2"!Y4'9FAC)_NBM:B@ KR']BO\ MY)CXE_['[Q;_ .G^_KUZO(?V*_\ DF/B7_L?O%O_ *?[^@#SG_@KQ\0=>^&G M[+WAO4/#FMZOH%_/\2O!EA+26LTEO/X@L89X2\9!,E^'[C^UYK#_A&]0DTG59%U#;& M"+G;%#+%Y,F$/G[LY09Z;]OG]D[4/VS/@'#X1TGQ/9^$-5L/$6C>)+/4KO2& MU6W2;3=0@OHTDMUN+=G1V@"G;,A 8D&N2\=?L;_$OX]ZI\+K[XD_$KP-J-W\ M+/B'9^.K(^&O MUH\=ZD&GW]FUG(L^JW9#,;X.)58!1$5\MM^Y0#R[6?^"O? MC#1? /Q$^(L_V9)J-E8K9LDT2J4FD MCGN+=UQ(J>:%61S]K#_@MSX7_9]^,OQ&\'Z3)\()[SX301MKUMXT^*=KX0U3 M5KA[1;P6NCVDEM.;R00O&N^9[6(S2K&)#ME:/KO%G_!*[_A*/V(OCC\&_P#A M._(_X7-XSUWQ=_;']B[O['_M/5?[1^S^1YX\[RO]7O\ ,3=][:OW:Z/4_P!B MKX@_#G]H;XB>./A%\4?#W@^R^+-Q::CXDT?Q'X,?Q!'#J%O:QV?VRPEBO[-H M'DMX8 Z3"X3?"K!5RZL <%^TU_P6 L?A!\'?"'CWP[8_"A/#/C7P5!XWT9_B M/\4;7P1=^(8)[?[1'::;;?9KR6XN40Q^:)5@C5KFW5))2TOD[6I_\%-M>^(O MQ?\ A-X0^$7PQM?&DWQ@^&I^)VF:CKWB<:#9:78>9: +>&*UNY%W+=Q@&%)C MYKHI41EYHYOC)_P3E\9^*?C5XU\7>"_BY8^&Y/BAX/T[P9XMGUGP9#K.JRV] MI]I7[1I]PEQ;0VD\B74NY9+:X@\P(XA 78=?]F'_ ()Q_P##.'Q-^#/B/_A, MO[9_X5'\%H_A!]G_ +)^S_VMLETR3^T=WG/Y6?[.QY&'_P!=_K/D^8 F_P"" MJ*?%$_LLV=S\-M/\6ZJUAXBTR]\8Z7X.U 6?B34O#D;(4TN\GU8/?V<0=9)I7N6G$:+,80ZB.(_57QW\&>.?&/AVP_X5]XXL M/ ^O:?>KZMQ-;S%/G#JT%S XDBC)9X]\4GS7KW_!)F M]\?:5XS\3^(_B4DWQM\6>*M$\9V_BW2_#:V>E:-?:(I32XHM,DN)F>U2-I%E MCENGDF\^;$L>4\L YG]O/Q?\0?%.D_L\I\1O!&A^#-7L?VA?"L=N-$\2G7M- MU&!H[AA+'/);6DRL&+HR26Z8*95G!R.?^,O_ <-?#_X4:SXTU-)?A3<^"_A M[XBF\.ZO:WGQ.M;'QW>&VNEM;RZL/#YMV-Q#&YD9!)=PRS)!(R1',7F^^>/_ M -BGX@_'K2? S_$;XJ:'J^K^"/B1I/CRW.B>#3I6FB"PC=18QP27MQ,K2L[N MT\EQ+@G"QJ!BJOPL_8;^(W[.WB;Q/I?PZ^+VCZ%\,?%?BF]\53:/J/@H:CKF MC2WUP;F^@L-0^V1VZ1/.\KQ_:;&Y,?G,"74*% &K_P % O$VK?M<_%KX?Z=\ M.M(A\'? YM.NO%OC+5O%+VL<=E=Z='?L]K:164TDUQ&C2YB9HT*QJ?.#/L7F M/!O_ 5 \93>#/A5\1O%WP>L_"WP=^,^LZ9I/A[58O%XOO$.G+JT@32;C4]- M^R)!;QSEX X@OKEH#<(&4A9"GK/@C]BFP\/_ !L_: \4ZKJ_]LZ9\>QIL5YI M/V,P?V;#:Z4NG/'YPD8R^:H+YVIMW8^;&ZO*? W_ 3#\8P>$/A9\//&?Q>L M/%GP>^#&JZ;J?AS1[?PA_9^O:@-*D5M(AU34OMDD-RMOY<)D,%G:F=X$+%5+ MHX!X1_P58_;8\;?M'?\ !-+]JB7PA\+M/U#X2^'8==\%3^)I/%:PZQ=7%D/L M]U>V^FM;>3)8QW8DAWF^69E@D=('^17]/_:._P""S_AW]G;XF^(_A[HTOP:? M7/AKHEC=Z[#X_P#BK:^"9[V>XLENX;33(GMKEKN7R&C+-)]GA5IX5$CDR>5) M\9?^"0GC/QY\!_C+\'?#/QNM?"7PB^+NJ:MK8T]O!:WVMZ'<:DWVBYMH[YKQ M(I+%KQI93$UJ)]D[Q+]M?(U"QD@D-O&D;J[S(WEH0J$-N .3TG_@JCK/Q MS^*/PP\,?!CX80>,#\5?AFGQ/L-1\2^)3X=M-*L3<0PF&\\NTNY%DS/&H\E) MLR'&!&&F7G/BO_P6 \7_ W\&?&WQS;_ 3@U/X:_L]^,)O#7BS5&\:1P:G> MV\+6IFN=,LOLC+/+%#<^8T-S/:J<(J32%F\OZ T/]D*?2OVSM!^+]UXPOM9N M=&^'$G@":VO=/A6YU)WOK>[;4)9H?+B5V,!#11VZ)F0E=@ 2O+_B1_P2N_X6 M#^R7^TS\+O\ A._LG_#1?B?4O$?]I_V+YG_"/?;(;.+R?*\\?:-GV3.[?%N\ MS&T;-;8JJF) M@3(&R-NUO/OV?/\ @FIX\^'7Q?\ @7XF\9_%OPSXDT_X ^&;SPIH.C>'_ (\ M/6MQ;7%E;VIFE)OKDB8+;19\O9#A0J0Q\L0#[$HHHH **** "O'_ -O;_DT[ MQ7_VY_\ I9!7L%>/_M[?\FG>*_\ MS_]+(*[LL_WRE_BC^:/*SW_ )%N(_P3 M_P#26?F_1117[$?S8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M4444 %%%% 'Z0?L$_P#)IWA3_M\_]+)Z]@KQ_P#8)_Y-.\*?]OG_ *63U[!7 MX[F?^^5?\4OS9_2>1?\ (MP_^"'_ *2@HHHKA/5"BBB@ HHHH **** "O(O@ M9_RNUY%\<_^3E/@C_V%=5_]-5S0 GPA_P"3M?C%_P!<-"_])IZS M_P#@I/\ M!ZO^RE^P!\8_B-X>\K_ (2#P?X1U'4M*>5!)'%=I WD2,IX95D* M,5/W@I'>M#X0_P#)VOQB_P"N&A?^DT]>@?%'X9:%\:OAKK_@_P 4Z;#K'AKQ M3IT^DZK8S%@EY:SQM'+&2I# ,C,,J01G((/- 'SE^S)_P2Q^#7A#X5^ =9U7 MPAI_B+XGZ?;V6L7OQ&NR_P#PF6JZE\LTMU-JZE;UA(Y=6B,OE&!C;E/(_=5Y ME^VO_P %1/$/['/Q:D6\^)W[-.I?8O%NDZ+=?">WNW?QU_9U_=6]M'=K<-?I M^_\ *N8KPP?V856(LHF=5%PWKWP*_9)^./P/\(^&/ T?[0.F:Q\//";P6MI< MWO@)'\:7.FV\H:"TN-4-Z;&1_*1+>2?^S!))%O8%)V^T+Y+XK_X(W^+M5^$_ MBOX8Z5\:=-TCX6^)?B"/B*]F? XN->GO#K$.K/;7>HM>B.>W\^([2EM#.-D M,SI&\[MP5=[:)X6\, M?$/]I*QO]3EG\0QS:II7A6VTN%'U)_L\,UO+>-YKQPQ*LT0S*'9L(5;Z"^$/ M[)'_ JK]L_XS?%[_A(/M_\ PMS3O#NG_P!D_8?*_LG^R8KV/?YWF-YOF_:\ MXV)L\OJ^[CQ3P+_P27U#X/\ P,_9^TWPA\2;6P^)/[.O]HPZ'XFO_#1N]-U. MVU$,M[:W>G+=QR-%(AB(V7:,LD$;[C@J0#Y8U7XJ^,?@Q=_\%0?%/Q"\*_#' MQCXF\)Z3X9N)],N].EOO#'B-(-"/D2S64KF1(YHQ&[VS32&)F:,33!!*_P!> M7W[5/Q5^,/[45S\)?A"OPU\,_P#"!^ ]+\5>(]3\2Z3=ZG#2Y=Y=FZ%5@?EJY?4/^"/6N^+OAE^U1IGBCXRW/B'Q)^U-IEA: M:EJ[^&(X(?#TUO9-:G[-;)<#=; ,HBB>3S$2-1)/.Y:9O1?&7[!7BW0/VAS\ M3/A5\3--\">(->\'V?@SQ5%JOA7^W+758;*1GL[ZW1;NW-O>PB:Y0/(;B%ED M0-"=F6 /G;_@E_\ %[Q)\*_^"2FH^)Y?$/PJ^%5XGQ,\5?V[KOCG4'GT'PNL MOB.^5SQ):B[8SM';HK7%H&,P??E1!)P7[4__ 4E^)G[0/\ P2Z_:WF\%_$[ MX;GQ'\#KQ+4_$#X>I'4G>PO$:=8GD^TW2HUO*NS+_NO? M?!W_ 1IO_AG^SM\,_"VA_%A[[Q?\)/B/J?Q&T/Q!XB\-+J-I?7-[/>NT=_8 MQ7,'G.L=](!+#- 1*HD54'[NM^+_ ()/WOCCX4_M/:#\1/B:_BO4_P!I](3J MNHV'AV/2H]"DBTR*PC%M!YTNZ*,0QF-9',@1%6265]TS &)^T[^W]XO_ &,- M)^#O@'QI\3O@5H_C[XK2WUT/&_B;39]!\+Z!IEC%;R3-+9S:HTEU=.9XH8T% M]"':5GX$3(_HW_!-7]O/_ALZT^)FC76N^ /&.K?"SQ&NBS>*? MQYWASQ/;S MVL5Y;75J//N#"XCF\F:'SYMDT$F)#G:K/&7[#?Q!\<1_##QA=?$[PG:_&WX3 M->VVD^)K/P/*FB:AI]XD45S9WFEOJ+RR!UAB;?%>PE98T9<+NC?VSX(>$/&W MA/P[>'Q]XST_QGK]_=FX,FEZ"NB:7I\81(U@M;8S7$ZI\GF,9[J=S++*59(_ M+AC .THHHH **** "BBB@ KR']BO_DF/B7_L?O%O_I_OZ]>KR']BO_DF/B7_ M +'[Q;_Z?[^@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH *\@_;QC:?\ 93\4(BEW=K-551DL3>P #U)KU^O+/VT/^3= MM6_Z_M,_].-M6V'K.C5C57V6G]SN3LIIK[U8^ O\ AGKQ_P#] M"/XP_P#!-<__ !%'_#/7C_\ Z$?QA_X)KG_XBOU0HKZO_7&M_P ^U][/S_\ MXAMAO^?TON1^5_\ PSUX_P#^A'\8?^":Y_\ B*/^&>O'_P#T(_C#_P $US_\ M17ZH44?ZXUO^?:^]A_Q#;#?\_I?/\ _H1_&'_@FN?_ (BOU0HH_P!<:W_/M?>P_P"(;8;_ )_2^Y'Y7_\ #/7C M_P#Z$?QA_P"":Y_^(H_X9Z\?_P#0C^,/_!-<_P#Q%?JA11_KC6_Y]K[V'_$- ML-_S^E]R/RO_ .&>O'__ $(_C#_P37/_ ,11_P ,]>/_ /H1_&'_ ()KG_XB MOU0HH_UQK?\ /M?>P_XAMAO^?TON1^5__#/7C_\ Z$?QA_X)KG_XBC_AGKQ_ M_P!"/XP_\$US_P#$5^J%%'^N-;_GVOO8?\0VPW_/Z7W(_*__ (9Z\?\ _0C^ M,/\ P37/_P 11_PSUX__ .A'\8?^":Y_^(K]4**/]<:W_/M?>P_XAMAO^?TO MN1^5_P#PSUX__P"A'\8?^":Y_P#B*/\ AGKQ_P#]"/XP_P#!-<__ !%?JA11 M_KC6_P"?:^]A_P 0VPW_ #^E]R/RO_X9Z\?_ /0C^,/_ 37/_Q%4]"^#7B_ MQ1IWVO3?"GB34;0R20B>UTR:6/?&[1R+N52-RNC*PZAE(/(-?JY7D/[#7_)O M4?\ V,7B+_T^7]'^N-;_ )]K[V'_ !#;#?\ /Z7W(^#?^&>O'_\ T(_C#_P3 M7/\ \11_PSUX_P#^A'\8?^":Y_\ B*_5"BC_ %QK?\^U][#_ (AMAO\ G]+[ MD?E?_P ,]>/_ /H1_&'_ ()KG_XBC_AGKQ__ -"/XP_\$US_ /$5^J%%'^N- M;_GVOO8?\0VPW_/Z7W(\K_8H\/:AX4_9D\,V&J6-YIM]!]J\VVNH6AECS=S, M-RL 1D$$9'0BO5***^4Q%9UJLJK^TV_O=S] P>&6'P]/#Q=U!)?NUY%\#/^3E/C=_V%=*_] M-5M0!Z[1110 4444 %%%% !1110 4444 %%%% !1110!Y#\%O^3I?C1_UWT; M_P!(!7KU>0_!;_DZ7XT?]=]&_P#2 5Z]0 4444 %%%% !1110 4444 %%%% M!1110!ROQS_Y(GXQ_P"P'>_^B'JK^S?_ ,F[^ O^QJO[-__ ";OX"_[%S3_ /TFCH [2BBB@ HHHH **** "BBB@ HH MHH **** "O(OCG_R6?MH?\ MF[:M_P!?VF?^G&VH ]3HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M "O(?V&O^3>H_P#L8O$7_I\OZ]>KR']AK_DWJ/\ [&+Q%_Z?+^@#UZBBB@ H MHHH **** "BBB@ HHHH **** "BBB@ KR+X&?\G*?&[_ +"NE?\ IJMJ]=KR M+X&?\G*?&[_L*Z5_Z:K:@#UVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ M#R'X+?\ )TOQH_Z[Z-_Z0"O7J\A^"W_)TOQH_P"N^C?^D KUZ@ HHHH **** M "BBB@ HHHH **** "BBB@#E?CG_ ,D3\8_]@.]_]$/57]F__DW?P%_V+FG_ M /I-'5KXY_\ )$_&/_8#O?\ T0]5?V;_ /DW?P%_V+FG_P#I-'0!VE%%% !1 M110 4444 %%%% !1110 4444 %>1?'/_ ).4^"/_ &%=5_\ 35O7J\A^$/\ R=K\8O\ MKAH7_I-/7KU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>0_L M5_\ ),?$O_8_>+?_ $_W]>O5Y#^Q7_R3'Q+_ -C]XM_]/]_0!Z]1110 4444 M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>6?MH?\F[: MM_U_:9_Z<;:O4Z\L_;0_Y-VU;_K^TS_TXVU 'J=%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 5Y#^PU_R;U'_P!C%XB_]/E_7KU>0_L-?\F]1_\ M8Q>(O_3Y?T >O4444 %%%% !1110 4444 %%%% !1110 4444 %>1? S_DY3 MXW?]A72O_35;5Z[7D7P,_P"3E/C=_P!A72O_ $U6U 'KM%%% !1110 4444 M%%%% !1110 4444 %%%% 'D/P6_Y.E^-'_7?1O\ T@%>O5Y#\%O^3I?C1_UW MT;_T@%>O4 %%%% !1110 4444 %%%% !1110 4444 _\ MHAZJ_LW_ /)N_@+_ +%S3_\ TFCJU\<_^2)^,?\ L!WO_HAZJ_LW_P#)N_@+ M_L7-/_\ 2:.@#M**** "BBB@ HHHH **** "BBB@ HHHH *\B^.?_)RGP1_[ M"NJ_^FJYKUVO(OCG_P G*?!'_L*ZK_Z:KF@!/A#_ ,G:_&+_ *X:%_Z33UZ] M7S7I^G_$>\_;$^+9\&ZOX)TZV%OHGG+K6D75Y(Q^S2XVF*YB _BSD'J/3GMO M[#^/7_0T?"+_ ,)?4?\ Y84 >O45Y#_8?QZ_Z&CX1?\ A+ZC_P#+"C^P_CU_ MT-'PB_\ "7U'_P"6% 'KU%>0_P!A_'K_ *&CX1?^$OJ/_P L*/[#^/7_ $-' MPB_\)?4?_EA0!Z]17D/]A_'K_H:/A%_X2^H__+"C^P_CU_T-'PB_\)?4?_EA M0!Z]17D/]A_'K_H:/A%_X2^H_P#RPH_L/X]?]#1\(O\ PE]1_P#EA0!Z]17D M/]A_'K_H:/A%_P"$OJ/_ ,L*/[#^/7_0T?"+_P )?4?_ )84 >O45Y#_ &'\ M>O\ H:/A%_X2^H__ "PH_L/X]?\ 0T?"+_PE]1_^6% 'KU%>0_V'\>O^AH^$ M7_A+ZC_\L*/[#^/7_0T?"+_PE]1_^6% 'KU%>0_V'\>O^AH^$7_A+ZC_ /+" MC^P_CU_T-'PB_P#"7U'_ .6% 'KU>0_L5_\ ),?$O_8_>+?_ $_W]']A_'K_ M *&CX1?^$OJ/_P L*\O_ &2='^-,OP\\0'3/$7POA@'C;Q.)5NO#E]*[3C6[ MT3,"M\H"&3>54@E5*@LQ!8@'U=17D/\ 8?QZ_P"AH^$7_A+ZC_\ +"C^P_CU M_P!#1\(O_"7U'_Y84 >O45Y#_8?QZ_Z&CX1?^$OJ/_RPH_L/X]?]#1\(O_"7 MU'_Y84 >O45Y#_8?QZ_Z&CX1?^$OJ/\ \L*/[#^/7_0T?"+_ ,)?4?\ Y84 M>O45Y#_8?QZ_Z&CX1?\ A+ZC_P#+"C^P_CU_T-'PB_\ "7U'_P"6% 'KU%>0 M_P!A_'K_ *&CX1?^$OJ/_P L*/[#^/7_ $-'PB_\)?4?_EA0!Z]17D/]A_'K M_H:/A%_X2^H__+"C^P_CU_T-'PB_\)?4?_EA0!Z]17D/]A_'K_H:/A%_X2^H M_P#RPH_L/X]?]#1\(O\ PE]1_P#EA0!Z]17D/]A_'K_H:/A%_P"$OJ/_ ,L* M/[#^/7_0T?"+_P )?4?_ )84 >O45Y#_ &'\>O\ H:/A%_X2^H__ "PH_L/X M]?\ 0T?"+_PE]1_^6% 'KU%>0_V'\>O^AH^$7_A+ZC_\L*/[#^/7_0T?"+_P ME]1_^6% 'KU%>0_V'\>O^AH^$7_A+ZC_ /+"C^P_CU_T-'PB_P#"7U'_ .6% M 'KU>6?MH?\ )NVK?]?VF?\ IQMJJ?V'\>O^AH^$7_A+ZC_\L*\X_:ST;XUQ M? G4SJ?B/X6S6?VS3]Z6OAR_BE+?;[?9AFOF& VTGCD C@G( /J6BO(?[#^/ M7_0T?"+_ ,)?4?\ Y84?V'\>O^AH^$7_ (2^H_\ RPH ]>HKR'^P_CU_T-'P MB_\ "7U'_P"6%']A_'K_ *&CX1?^$OJ/_P L* /7J*\A_L/X]?\ 0T?"+_PE M]1_^6%']A_'K_H:/A%_X2^H__+"@#UZBO(?[#^/7_0T?"+_PE]1_^6%']A_' MK_H:/A%_X2^H_P#RPH ]>HKR'^P_CU_T-'PB_P#"7U'_ .6%']A_'K_H:/A% M_P"$OJ/_ ,L* /7J*\A_L/X]?]#1\(O_ E]1_\ EA1_8?QZ_P"AH^$7_A+Z MC_\ +"@#UZBO(?[#^/7_ $-'PB_\)?4?_EA1_8?QZ_Z&CX1?^$OJ/_RPH ]> MHKR'^P_CU_T-'PB_\)?4?_EA1_8?QZ_Z&CX1?^$OJ/\ \L* /7J\A_8:_P"3 M>H_^QB\1?^GR_H_L/X]?]#1\(O\ PE]1_P#EA7E_['6C_&F7X&1G2O$7PO@L M_P"WM= 2[\.7TLOF#6+T2'5&,A2H))!) /JZBO(?[#^/7_0T?"+_ M ,)?4?\ Y84?V'\>O^AH^$7_ (2^H_\ RPH ]>HKR'^P_CU_T-'PB_\ "7U' M_P"6%']A_'K_ *&CX1?^$OJ/_P L* /7J*\A_L/X]?\ 0T?"+_PE]1_^6%'] MA_'K_H:/A%_X2^H__+"@#UZBO(?[#^/7_0T?"+_PE]1_^6%']A_'K_H:/A%_ MX2^H_P#RPH ]>HKR'^P_CU_T-'PB_P#"7U'_ .6%']A_'K_H:/A%_P"$OJ/_ M ,L* /7J*\A_L/X]?]#1\(O_ E]1_\ EA1_8?QZ_P"AH^$7_A+ZC_\ +"@# MUZBO(?[#^/7_ $-'PB_\)?4?_EA1_8?QZ_Z&CX1?^$OJ/_RPH ]>KR+X&?\ M)RGQN_["NE?^FJVI/[#^/7_0T?"+_P )?4?_ )85Y?\ !S1_C2WQ_P#B^+7Q M%\+TO5U+3?MKR^'+YHI6_LV#88U%\"H";00Q;)!(('% 'U=17D/]A_'K_H:/ MA%_X2^H__+"C^P_CU_T-'PB_\)?4?_EA0!Z]17D/]A_'K_H:/A%_X2^H_P#R MPH_L/X]?]#1\(O\ PE]1_P#EA0!Z]17D/]A_'K_H:/A%_P"$OJ/_ ,L*/[#^ M/7_0T?"+_P )?4?_ )84 >O45Y#_ &'\>O\ H:/A%_X2^H__ "PH_L/X]?\ M0T?"+_PE]1_^6% 'KU%>0_V'\>O^AH^$7_A+ZC_\L*/[#^/7_0T?"+_PE]1_ M^6% 'KU%>0_V'\>O^AH^$7_A+ZC_ /+"C^P_CU_T-'PB_P#"7U'_ .6% 'KU M%>0_V'\>O^AH^$7_ (2^H_\ RPH_L/X]?]#1\(O_ E]1_\ EA0 ?!;_ ).E M^-'_ %WT;_T@%>O5\H_"71_C2W[1OQ:6V\1?"]+]9M)^VO+XH?V'\>O\ H:/A%_X2^H__ "PH ]>HKR'^P_CU_P!#1\(O M_"7U'_Y84?V'\>O^AH^$7_A+ZC_\L* /7J*\A_L/X]?]#1\(O_"7U'_Y84?V M'\>O^AH^$7_A+ZC_ /+"@#UZBO(?[#^/7_0T?"+_ ,)?4?\ Y84?V'\>O^AH M^$7_ (2^H_\ RPH ]>HKR'^P_CU_T-'PB_\ "7U'_P"6%']A_'K_ *&CX1?^ M$OJ/_P L* /7J*\A_L/X]?\ 0T?"+_PE]1_^6%']A_'K_H:/A%_X2^H__+"@ M#UZBO(?[#^/7_0T?"+_PE]1_^6%']A_'K_H:/A%_X2^H_P#RPH [3XY_\D3\ M8_\ 8#O?_1#U5_9O_P"3=_ 7_8N:?_Z31UYE\8]%^.2_"+Q4;KQ-\*'M1H]V M9EB\,Z@DC)Y+[@I-^0#C."0?H:K? /1?C@_P*\%FR\2_"F.S.@V)@2?PU?O* ML?V>/:&87X!;&,D GL* /HJBO(?[#^/7_0T?"+_ ,)?4?\ Y84?V'\>O^AH M^$7_ (2^H_\ RPH ]>HKR'^P_CU_T-'PB_\ "7U'_P"6%']A_'K_ *&CX1?^ M$OJ/_P L* /7J*\A_L/X]?\ 0T?"+_PE]1_^6%']A_'K_H:/A%_X2^H__+"@ M#UZBO(?[#^/7_0T?"+_PE]1_^6%']A_'K_H:/A%_X2^H_P#RPH ]>HKR'^P_ MCU_T-'PB_P#"7U'_ .6%']A_'K_H:/A%_P"$OJ/_ ,L* /7J*\A_L/X]?]#1 M\(O_ E]1_\ EA1_8?QZ_P"AH^$7_A+ZC_\ +"@#UZO(OCG_ ,G*?!'_ +"N MJ_\ IJN:3^P_CU_T-'PB_P#"7U'_ .6%<1XET[XDV?[5/P7/C+6/ ^H6)U'5 M1$FBZ/=60_"'_ M ).U^,7_ %PT+_TFGKUZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "O(?V*_^28^)?^Q^\6_^G^_KUZO(?V*_^28^)?\ L?O%O_I_OZ /7J** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRS] MM#_DW;5O^O[3/_3C;5ZG7EG[:'_)NVK?]?VF?^G&VH ]3HHHH **** "BBB@ M HHHH **** "BBB@ HHHH **** "O(?V&O\ DWJ/_L8O$7_I\OZ]>KR']AK_ M )-ZC_[&+Q%_Z?+^@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR+ MX&?\G*?&[_L*Z5_Z:K:O7:\B^!G_ "KR'X+?\G2_& MC_KOHW_I *]>H **** "BBB@ HHHH **** "BBB@ HHHH Y7XY_\D3\8_P#8 M#O?_ $0]5?V;_P#DW?P%_P!BYI__ *31U:^.?_)$_&/_ & [W_T0]5?V;_\ MDW?P%_V+FG_^DT= ':4444 %%%% !1110 4444 %%%% !1110 5Y%\<_^3E/ M@C_V%=5_]-5S7KM>1?'/_DY3X(_]A75?_35 MO7J\A^$/_)VOQB_ZX:%_Z33UZ]0 4444 %%%% !1110 45B?$7XE>'?@_P"" MM0\2^+=?T7POX=TF,2WVJZO?165E9H6"AI9I65$&Y@,L1R0.]:FFZE;ZSIT% MW:3PW5I=1K-!/"X>.9& *LK#@J0001P0: )Z*** "BBB@ HHHH **** "O(? MV*_^28^)?^Q^\6_^G^_KUZO(?V*_^28^)?\ L?O%O_I_OZ /7J*** "BBB@ MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRS]M#_DW;5O M^O[3/_3C;5ZG7EG[:'_)NVK?]?VF?^G&VH ]3HHHH **** "BBB@ HHHH ** M** "BBB@ HHHH **** "O(?V&O\ DWJ/_L8O$7_I\OZ]>KR']AK_ )-ZC_[& M+Q%_Z?+^@#UZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR+X&?\G*?& M[_L*Z5_Z:K:O7:\B^!G_ "KR'X+?\G2_&C_KOHW_I M *]>H **** "BBB@ HHHH **** "BBB@ HHHH Y7XY_\D3\8_P#8#O?_ $0] M5?V;_P#DW?P%_P!BYI__ *31U:^.?_)$_&/_ & [W_T0]5?V;_\ DW?P%_V+ MFG_^DT= ':4444 %%%% !1110 4444 %%%% !1110 5Y%\<_^3E/@C_V%=5_ M]-5S7KM>1?'/_DY3X(_]A75?_35LC_@IQ^T M=K?[(G_!/KXO_$KPTD#^(O!_AB\O]+,\?FQ1W03;%(Z'AE1V5BIZA2*U_A#_ M ,G:_&+_ *X:%_Z33UW_ ,5/AAH7QL^&FO\ @_Q1IT&K^&_%&GSZ5JEC-G9= M6TT;1R(</VEOAW^UI\?/B%\6O! MUIXYUKXI^%KN\N8?!SWD<,B0//\ ;;>WM=GVA(XQ*C@[3T!"CWS]O_\ X.'I MOV)=?^%?PG^%NJ^!].$WPZTKQ/<>,/C%!K6I"Z@N+=/LML\6CPR3/>R1 2R2 MMB+#-/U>^@MA.) MQ;QZHSI+&@D52%6,*,8VD'%>K?&C_@B?KMO\8_!/Q*^ ?Q]\2? SXB^%/ EE M\.KW57\-V7B2VU[2K0((O/M)S''YWR)EQQ\B852,D \)M?\ @X.^*_Q;_8W_ M &8/'WPV^&7@G4?&?QP\=7O@+4="U2^N(;+[5"'CCFMKK*F*-G\N0^9'(0F^ M/E@'KO\ X#_\%J?B5\)KO]K3PK^TMX0\!1>.OV6M$L_$<[?#ZYN_[-\06MW: M_:(8HA=EI$?Y[<&1L#]_RB[#N]?\9_\ !)76?B+9_LX2>)?C9XJ\7:[\!O'3 M^.;[6M?TV.ZO/%,SNSFV'ER1I:1*6VQA5D"(JJ <9J+Q+_P1>\.?$?\ :Q_: ME^(7BKQ;=ZKH'[4'A73_ M?Z!;Z<+:;0DM;&&U\^.[,KB5R85D7,*A&P#O MY /BW_@FQ_P<[>-/VK?VX/AG\.?%EM\%]9T3XLR36T%IX+M]?M]9\%3B%I8X M]0DU"%+6Z+%?+)M&*C#/NP K?<7_ 6F_P"">?P?_;6_9+\4>)OB;X0_X277 M/A3X1\0ZIX5N?[5O;/\ LNY>S$K/LMYHTER]I;G$H)OVNO'?Q ^%_P ,X/LOAOP7'X8L=&0P+;O;PPW]Y$SS7T42,I5' MV@-$A_A KZR^/OPL'QS^!/C7P2U\=,'C#0;[0S>"'SC:"YMY(?-V;EW;=^=N MX9QC(ZT ?@;\./\ @GG\'_A)_P &KOB[X]^'O"']G_%CQYX .EZ[KO\ :M[+ M]NMCXDMF*?9WF:W3FTM^8XU/[OK\S9^V_P!C'_@I3^T-\)OVN?V;_@I\;_ ' MPKT+P7\=?!TL_@ZX\.:M=76K:,UAIXG\O49),0RR.B(N($"AIUP[;6%>TM_P M1R!_X(G_ /#'8^(I'_$G&D_\)<=!SS_:/VTR?8OM'_ -OG^^>U=%\4O^"5R? M$G]K?]EKXI?\)RUD/V:=,O=-&E_V-YG_ D?VBRCM0_G>>/LVW9NQLEW9QE< M9H _,77O^#Q77/\ A:#7_^$[O=/\W9]O2Z$']E MIE,2"%G+C[O)YK[F\?\ _!0O]ISQW_P5M^(?[._PB\'?!V\\-^ -.T'7[[7? M%$U]!-;6-RD;7<.()#YUQ)YG[@A$1/*;S"^Y:I_!C_@A=\0_V7]4O/"?PJ_: MU^(?P_\ @%?:U-K!\!Z?X;L'O[+SI3));VNL.3/;Q'@ )'GJ22S%J^COA'^P M&/A9_P %(_BW^T)_PE9OC\4M TG0QH']F>5_9?V%%3S?M'FMYN_;G;Y:;?5J M /S6\=?\'-GQ%^$G[;VD^#-1O_V9?&?A:_\ &T7A>Y\/^$)]?NO$EA:RW1@% MVVH/$-*D*#:6CC=B6(48&77W_P".G_!3+]K7Q3^W]^TS\%O@3X#^"&JVGP+T M[1-9M]7\77.H0,8+K2H[R6V>*"7-Q<2R.XB93!'&L)$A8LIKD=)_X-DO$7AC MP)H_PZTO]J'Q'!\%_!WC>W\<>&/!DW@JR?[#I,D]V2A=%)**A8- ML;&VL3QE_P $V?CO^T?_ ,%FOVT-;\%?$[XB_L\Z%XKT?PMIMIXEA\*+J.C^ M+[5M%A@NX8C/Y:O- \1436\HD@9W'!:@#M?@1_P7S\6_%V?]C3QI?^$_"^A_ M"7]I&\U/PAXCGD2X:^\.^);>62"VBBG\T1&WN9538&C9MN\EP5VU]*_\$L/V M]/%W_!0>Z^-OB>]TKP]I_P -O"OC^\\(^!;JQAF6[UFUL@%FO)W>5D<2.Z[# M&B 8=2&(S7S)_P %2/\ @EYHO[-O_!OQ!\$?A=X;^(GC?Q#\.+W3]2\'R>'- M+EU#77UPWYEDO]MNI:,$7%V6=<>7&^%.0H/V?_P2Q_8\C_8)_P""?7PL^%6R M)=0\,Z)&=6:/[LFHSEKB\8'N/M$LN#_="^E 'T!1110 5Y#^Q7_R3'Q+_P!C M]XM_]/\ ?UZ]7D/[%?\ R3'Q+_V/WBW_ -/]_0!Z]16=XO\ %NF^ ?">J:[K M-Y#I^D:+:2W]]=3'$=M!$A>21CZ*JDGZ5\^?\$XO^"A,W[=?@;Q5=>(/ E[\ M*_%'A*[M#>>'M1U);R=-/OM/M]0L+UG$<842P3D,F#Y#O#G[3?PGL],\>?"J\^"GCCPIXFU[5/&AUN"2Q MMI=,NM-MHA'?K.+58_,O)4DW;CO5%!4@@@'UG17!77[5'PPL?AGI'C6;XC^ MX?!OB N-*UY_$%HNF:F4AFG?R+DR>5+MAM[B0[&.$@E8\(Q'DWCK_@H)X9^' M7B'Q%X[O?B?\#[[X$:/\/8?%%O-8>(XI?$-W=M?SV_G(QF%H]A-MAMX'#!GN MR\>[[HH ^EJ*^9O _P#P4&T#]J?X??![QG\&_B#\'9_#OC+Q%96'B&T\0:[& MVJ01W&G379TJV2UF=%UI2(F:VD9@(X[@X.T&O8?#G[37PW\8?&'5/AYI/Q!\ M$:IX_P!#A:XU+PS9Z[:SZQI\:[,O-:*YFC4>;'DLH'[Q/[PR =Q1110 4444 M %%%% !1110 4444 %%%% !1110 5XW^W_\ \FD^*O\ ?L?_ $NMZ]DKQO\ M;_\ ^32?%7^_8_\ I=;UOAOXT/5?FP?L$_\G8^%/^WS M_P!(YZ\?KV#]@G_D['PI_P!OG_I'/7ZWF?\ N=7_ R_)G\[9%_R,L/_ (X? M^E(_2"BBBOQT_I,**** "BBB@ HHHH **** "BBB@ HHHH *\A_8:_Y-ZC_[ M&+Q%_P"GR_KUZO(?V&O^3>H_^QB\1?\ I\OZ /7J*** "BBB@ HHHH **** M"BBB@ HHHH **** "O(O@9_RNUY%\<_^3E/@C_V%=5_]-5S0 GP MA_Y.U^,7_7#0O_2:>O4?$?B/3_!WAZ_U?5[^STO2M+MY+R]O;R=8+>S@C4O) M+)(Q"HBJ"S,Q !)->7?"'_D[7XQ?]<-"_\ 2:>N=_X*Q?\ *++]I;_LE7BC M_P!-%U0!UGP>_;I^"7[0WBG^P_ 'QB^%?CG6_+,O]G^'_%EAJ=UL )+>5!*S M8 !)..QKU2OYOOV"OV;+[]LSPK^PY%\&?V8_&OPU\5?"S7=/\0^./C)?^&HO M#^EZ]80R;Y1!=QMNU/S0F SC>" N DCD?9_[./[<7[4'C;XC?M?_ !6U[XKZ M-)\%OV3_ !]XXMQX,C\*61U+Q38Z=;W4L%@UZ%0V\< CMRDH#RR,\HD8@+D M_7*BOQ-U#_@H%^VA^SY^Q[\%_P!K[Q?\9/ 7C'P%\4/$&F0ZI\+;?P=:64&E M:=J$CA/LNHJWVF6=45?E<_(Q.XR!&!Y'_@J__P %F_VA/ ?[9WQL^'OP[^-B M_#/Q)\/M3TS1/ ?P_P!&^&L/B>]^(DEU#;R2N]_+%,EM*@FWB/:,J0NTMR0# M]X**_)SXO_&+]LOQ%_P4G^%G[,OA'X]Z/X2U+5/@'9>+?%7B/4_ NFWDJZLF MHW,-Q>P6@78)I#%#"83)Y"(TCJF\*3\U?\%$_P#@ME^T=^S_ /%[XJ>*?A;\ M6_&/CSP;\*/%/]A:A9:?\#[63P'9R)<1P26>H>('G%S'/ND _=1[7D9%1PKJ MU '[\45^8'[1'[2/[4/[1?\ P5[N/@#\&/B]X?\ A'X;O?@S9>/Y+O4?"=IK M\VESF_$#FV$BIODD,T"'SF:-8U=E0/C/Q]X*_P""QG[9X_X)E^"?VPM>^*G@ M(^#O#OC"W\+:SX*M?!<(D\5VWG".:[NKLG=#-G($=JL28 ;.?DH _H HHHH M**** "BBB@ HHHH *\A_8K_Y)CXE_P"Q^\6_^G^_KUZO(?V*_P#DF/B7_L?O M%O\ Z?[^@#S7_@KKX,\;?';]FO3/@YX$L[X7WQIU^U\+:QK*Z3/?V'AO12'N M=1NKP1M&!$]O;O;!6EC,CW:(K*3N7RFW^ _QJ_9R_P""F7AOQQK=SX=\=^&_ MC%X+O? OB63P-X!O]$LM GTV-[W2+N[1]0O\[Q)>VJR$Q(OF1(=Q9='^'NC?#O7;#QO9^";#5;[PK;Z.UOK%Q>07D-]=Q_96 M"2-=R>5(=A'F.Y 9B ?;?'.@Q?M-?\ !4#]F#XF:?X*\4WOA'0?!WC5DU+7 MO!VH:6^A7SSZ7!"98KZWBFLYY%CN1%YB(TD>]DW(V3]IT4 ?E1SMM&;3M3F34=A3:+(W%['Q M=8ZQX-U32Y]#-GX5U*WN)I%N($W6J321Q_:D+0%W51(3Q6S^S#I'B+X1?MX: M)X0^'GAOXBZM\+]6\2>(?$/B;2?B#\.)[%/A?J$AU&6>^T;Q#Y45O>)>W-Y' M"($DOG,4CND\<7F"OT1HH **** "BBB@ HHHH **** "BBB@ HHHH **** " MO&_V_P#_ )-)\5?[]C_Z76]>R5XW^W__ ,FD^*O]^Q_]+K>M\-_&AZK\SEQW M^[5/\+_(_..O8/V"?^3L?"G_ &^?^D<]>/U[!^P3_P G8^%/^WS_ -(YZ_6\ MS_W.K_AE^3/YVR+_ )&6'_QP_P#2D?I!1117XZ?TF%%%% !1110 4444 %%% M% !1110 4444 %>0_L-?\F]1_P#8Q>(O_3Y?UZ]7D/[#7_)O4?\ V,7B+_T^ M7] 'KU%%% !1110 4444 %%%% !1110 4444 %%%% !7D7P,_P"3E/C=_P!A M72O_ $U6U>NUY%\#/^3E/C=_V%=*_P#35;4 >NT444 %%%% !1110 4444 % M%%% !1110 4444 >0_!;_DZ7XT?]=]&_](!7KU>0_!;_ ).E^-'_ %WT;_T@ M%>O4 %%%% !1110 4444 %%%% !1110 4444 J MO[-__)N_@+_L7-/_ /2:.K7QS_Y(GXQ_[ =[_P"B'JK^S?\ \F[^ O\ L7-/ M_P#2:.@#M**** "BBB@ HHHH **** "BBB@ HHHH *\B^.?_ "NS7]OH?C[0+_PYJ,MC(L=U%;7EO);RM$S*RK($D8J65@# MC((XKD/A#_R=K\8O^N&A?^DT]>O4 >=?LD_LR:!^QG^S7X-^%OA:ZU:]\/\ M@?34TNQN-4ECEO)HU)(:5HT1"QR<[44>U<1^S=_P3D^'O[,^F_&RQT]M;\1: M;\??%NK>,/%-GKLL-Q T^I#;JS,DUO9F,-N5W M9OGD;<6.[<"0?AS]K'_@EW^W#8_MS?'CQ3\,-*^)>FP?$[Q2^L^'O$'P^^-- MCX0\.6<0&RVDU;29(&N;V=453*4= Q+A20_AO\ M>?B1XNUKQ1\=O#7PIM/AMKMU;201Z+J968W5Q=B+R%E\YKAY,-O5"N/W2FO$ M_CM_P;1? OX\>(/B-)/XV^.OASPU\3]7E\1:QX1T/Q@+?PX-6D=7?4$LW@=3 M.67(\TR(N<*H"J%_0^B@#PKP=_P3Y\%^"/VYG_:!M=1\32>,W\ 1?#C[)-

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end XML 16 R1.htm IDEA: XBRL DOCUMENT v3.5.0.2
Document and Entity Information - shares
 6 Months Ended
Jun. 30, 2016
Jul. 29, 2016
Document And Entity Information [Abstract]    
Entity Registrant Name Fibrocell Science, Inc.  
Entity Central Index Key 0000357097  
Current Fiscal Year End Date --12-31  
Entity Filer Category Smaller Reporting Company  
Trading Symbol fcsc  
Document Type 10-Q  
Document Period End Date Jun. 30, 2016  
Document Fiscal Year Focus 2016  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Entity Common Stock, Shares Outstanding   43,898,785

XML 17 R2.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (unaudited) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Current assets:    
Cash and cash equivalents $ 8,161 $ 29,268
Inventory, net 109 482
Prepaid expenses and other current assets 636 1,244
Total current assets 8,906 30,994
Property and equipment, net of accumulated depreciation of $1,401 and $1,242, respectively 1,546 1,582
Intangible assets, net of accumulated amortization of $0 and $2,204, respectively 0 4,136
Other assets 64 0
Total assets 10,516 36,712
Current liabilities:    
Accounts payable 553 499
Related party payable 924 10,720
Accrued expenses 1,253 1,779
Deferred revenue 408 457
Warrant liability, current 5 1,910
Total current liabilities 3,143 15,365
Warrant liability, long term 759 6,365
Deferred rent 785 779
Total liabilities 4,687 22,509
Stockholders’ equity:    
Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares outstanding as of June 30, 2016 and December 31, 2015 0 0
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,898,785 shares issued and outstanding as of June 30, 2016; 100,000,000 shares authorized, 43,898,785 shares issued and outstanding as of December 31, 2015 44 44
Additional paid-in capital 162,555 161,330
Accumulated deficit (156,770) (147,171)
Total stockholders’ equity 5,829 14,203
Total liabilities and stockholders’ equity $ 10,516 $ 36,712
XML 18 R3.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Statement of Financial Position [Abstract]    
Property and equipment, accumulated depreciation (in dollars) $ 1,401 $ 1,242
Intangible assets, accumulated amortization (in dollars) $ 0 $ 2,204
Preferred stock, par value (in dollars per share) $ 0.001 $ 0.001
Preferred stock, shares authorized (shares) 5,000,000 5,000,000
Preferred stock, shares outstanding (shares) 0 0
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, shares authorized (shares) 150,000,000 100,000,000
Common stock, shares issued (shares) 43,898,785 43,898,785
Common stock, shares outstanding (shares) 43,898,785 43,898,785
XML 19 R4.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Operations (unaudited) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Revenue from product sales $ 73 $ 55 $ 85 $ 168
Collaboration revenue 14 82 18 163
Total revenue 87 137 103 331
Cost of product sales 392 77 409 221
Cost of collaboration revenue 0 85 1 88
Total cost of revenue 392 162 410 309
Gross (loss) profit (305) (25) (307) 22
Research and development expense 2,352 2,567 4,954 4,814
Selling, general and administrative expense 2,540 3,640 5,280 6,564
Intangible asset impairment expense 3,905 0 3,905 0
Restructuring costs 292 0 292 0
Operating loss (10,319) (7,359) (16,987) (14,223)
Other income (expense):        
Warrant revaluation income (expense) 2,254 602 7,511 (1,061)
Other expense (31) 0 (31) 0
Interest income 4 1 8 3
Loss before income taxes (8,092) (6,756) (9,499) (15,281)
Income tax benefit 0 0 0 0
Net loss $ (8,092) $ (6,756) $ (9,499) $ (15,281)
Per Share Information:        
Basic net loss (usd per share) $ (0.18) $ (0.17) $ (0.22) $ (0.37)
Diluted net loss (usd per share) $ (0.18) $ (0.17) $ (0.26) $ (0.37)
Weighted average number of common shares outstanding:        
Basic weighted average number of common shares outstanding, shares 43,898,785 40,889,732 43,898,785 40,875,704
Diluted weighted average number of common shares outstanding, shares 43,898,785 40,889,732 43,934,819 40,875,704
Affiliated Entity        
Research and development expense $ 925 $ 1,127 $ 2,249 $ 2,867
XML 20 R5.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Additional paid-in capital
Accumulated deficit
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Cumulative effect from adoption of new accounting standard     $ 100 $ (100)
Balance at Dec. 31, 2015 $ 14,203 $ 44 161,330 (147,171)
Balance (shares) at Dec. 31, 2015 43,898,785 43,898,785    
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
Stock-based compensation expense $ 1,125   1,125  
Net loss (9,499)     (9,499)
Balance at Jun. 30, 2016 $ 5,829 $ 44 $ 162,555 $ (156,770)
Balance (shares) at Jun. 30, 2016 43,898,785 43,898,785    
XML 21 R6.htm IDEA: XBRL DOCUMENT v3.5.0.2
Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Cash flows from operating activities:    
Net loss $ (9,499) $ (15,281)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 1,125 1,044
Warrant revaluation (income) expense (7,511) 1,061
Depreciation and amortization 391 346
Provision for (recovery of) doubtful accounts (12) (1)
Inventory reserve 151 0
Intangible asset impairment 3,905 0
Loss on disposal or impairment of property and equipment 65 0
Decrease (increase) in operating assets:    
Accounts receivable 12 2
Inventory 222 87
Prepaid expenses and other current assets 728 549
Other assets (64) 0
Increase (decrease) in operating liabilities:    
Accounts payable (3) 1,061
Related party payable (9,796) (338)
Accrued expenses and deferred rent (518) 599
Deferred revenue (49) 84
Net cash used in operating activities (20,853) (10,787)
Cash flows from investing activities:    
Purchase of property and equipment (143) (111)
Net cash used in investing activities (143) (111)
Cash flows from financing activities:    
Payment of deferred offering costs (109) 0
Proceeds from the exercise of stock options 0 255
Principle payments on capital lease obligations (2) (2)
Net cash (used in) provided by financing activities (111) 253
Net decrease in cash and cash equivalents (21,107) (10,645)
Cash and cash equivalents, beginning of period 29,268 37,495
Cash and cash equivalents, end of period 8,161 26,850
Supplemental Cash Flow Disclosures:    
Property and equipment in accounts payable 46 0
Deferred offering costs in accounts payable $ 11 $ 0
XML 22 R7.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business and Organization
 6 Months Ended
Jun. 30, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Business and Organization
Business and Organization

Organization

Fibrocell Science, Inc. (as used herein, “we,” “us,” “our,” “Fibrocell” or the “Company”) is the parent company of Fibrocell Technologies, Inc. (Fibrocell Tech). Fibrocell Tech is the parent company of Isolagen International, S.A., a company organized under the laws of Switzerland (Isolagen Switzerland). The Company’s international activities are currently immaterial.

Effective April 1, 2016, Fibrocell Science Hong Kong Limited (“Fibrocell Hong Kong”), a company organized under the laws of Hong Kong and former subsidiary of Fibrocell, was dissolved. As this entity had no historical financial or operational activities, the impact of the dissolution did not, and is not expected to have, a material impact on the Company’s present or future consolidated financial statements.

Business Overview

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs. The Company is focused on discovering and developing therapies for the localized treatment of diseases affecting the skin and connective tissue. All of the Company’s product candidates incorporate its proprietary autologous fibroblast technology. The Company’s research and development efforts focus on gaining regulatory approvals of its product candidates in the United States.

Liquidity and Financial Condition

The Company expects to continue to incur losses and will require additional capital to advance its product candidates through development to commercialization. As of June 30, 2016, the Company had cash and cash equivalents of approximately $8.2 million and working capital of approximately $5.8 million. The Company believes that its cash and cash equivalents at June 30, 2016 will be sufficient to fund operations into the fourth quarter of 2016. The Company will require additional capital to fund operations beyond that point. To meet its capital needs, the Company intends to raise additional capital through debt or equity financings, collaborations, partnerships or other strategic transactions. However, there can be no assurance that the Company will be able to complete any such transaction on acceptable terms or otherwise. The failure of the Company to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on the Company’s business, results of operations and financial condition. These conditions raise substantial doubt about its ability to continue as a going concern. Consequently, the audit report prepared by the Company’s independent registered public accounting firm related to its Consolidated Financial Statements for the year ended December 31, 2015 included a going concern explanatory paragraph.
XML 23 R8.htm IDEA: XBRL DOCUMENT v3.5.0.2
Basis of Presentation
 6 Months Ended
Jun. 30, 2016
Basis of Presentation [Abstract]  
Basis of Presentation
Basis of Presentation

General

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (2015 Form 10-K), filed with the Securities and Exchange Commission (SEC). The Company’s significant accounting policies are described in the Notes to Consolidated Financial Statements in the 2015 Form 10-K and updated, as necessary, in Note 3 in this Form 10-Q. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year.

All intercompany accounts and transactions have been eliminated in consolidation. The Company's international operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.
Reclassifications

The prior year Condensed Consolidated Financial Statements presented in this Form 10-Q contain certain reclassifications made to the Condensed Consolidated Statement of Operations and the Condensed Consolidated Statement of Cash Flows to conform to the current year’s presentation. Specifically, related party payables were reclassified from accounts payable and accrued expenses as of June 30, 2015.
XML 24 R9.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies

Intangible Assets

Intangible assets are research and development assets related to the Company’s primary study on azficel-T that were capitalized on the balance sheet upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identifiable intangible assets was $6.3 million. Azficel-T had two current or target indications: the Company's FDA-approved product LAVIV® and a clinical development program for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Effective January 1, 2012, the Company launched LAVIV and as a result, the research and development intangible assets related to the Company’s primary study were considered to be finite-lived intangible assets and began amortizing over 12 years, the estimated useful life of the assets which is analogous with the exclusivity period granted to the Company under the BLA.

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews the estimated remaining useful life of its intangible assets on an annual basis with any changes, if applicable, accounted for prospectively. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Impairment or Disposal of Long-Lived Assets, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In June 2016, based on its failure to achieve primary efficacy endpoints for its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring, the Company determined to wind-down its azficel-T operations as more fully described in Note 9. As a result, management concluded that the Company’s intangible assets had become fully impaired. Accordingly, a non-cash impairment charge of approximately $3.9 million was recorded during the three months ended June 30, 2016 and is included in the Condensed Consolidated Statement of Operations.

Stock-Based Compensation

The Company follows ASC 718, Compensation – Stock Compensation (ASC 718), or ASC 505-50, Equity – Equity Based Payments to Non-Employees, where applicable. The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. In addition, the Company accounts for stock-based compensation to non-employees in accordance with the accounting guidance for equity instruments that are issued to entities or persons other than employees. The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected term of the options. The value of the award that is ultimately expected to vest based on the achievement of a performance condition (i.e., service period) is recognized as expense on a straight-line basis over the requisite service period. See Note 7 for additional details.

Previously, ASC 718 required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. In the first quarter of 2016, the Company adopted FASB Accounting Standards Update (ASU) 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures when they occur. In connection with the adoption of this ASU, the Company made an accounting policy election to account for forfeitures as they occur and applied this change in accounting policy on a modified retrospective basis. As a result, the Company recorded a cumulative-effect adjustment to retained earnings which resulted in an increase to accumulated deficit of $0.1 million with an offsetting increase to additional paid-in capital (zero net total equity impact) as of the date of adoption, principally related to additional stock compensation expense that would have been recognized on unvested outstanding options unadjusted for estimated forfeitures.

Restructuring Costs

Restructuring charges are primarily comprised of severance costs related to workforce reductions, contract termination and wind-down costs, asset impairments and costs of decommissioning the Company’s azficel-T manufacturing facility. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company recognizes restructuring charges when the liability has been incurred, except for one-time employee termination benefits that are incurred over time. Generally, one-time employee termination benefits (i.e. severance costs) are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments. Other costs, including but not limited to, contract termination and wind-down costs and manufacturing facility decommissioning costs, will be recorded as incurred. Asset impairment charges have been, and will be, recognized when management has concluded that the assets have been impaired in accordance with ASC 360-10-35, Impairment or Disposal of Long-Lived Assets, or other applicable authoritative guidance. See Note 9 for additional details.

Income Taxes
    
In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.  For the six months ended June 30, 2016 and 2015, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses.  The Company has not recorded its net deferred tax asset as of either June 30, 2016 or December 31, 2015 because it maintains a full valuation allowance against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits. As of June 30, 2016 and December 31, 2015, the Company had no uncertain tax positions.

Recently Issued Accounting Pronouncements

Management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had or is expected to have a material impact on the Company’s present or future consolidated financial statements.
XML 25 R10.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventory
Inventory
    
Inventories consist of raw materials and work in process intended for use in the manufacture of LAVIV, which was approved by the FDA in 2011 for the improvement of nasolabial fold wrinkles in adults. However, raw materials may be used for clinical trials and are charged to research and development (R&D) expense when consumed for such activities.
Inventories consisted of the following as of:
 
($ in thousands)
June 30, 2016
 
December 31, 2015
 
 
Raw materials (LAVIV and product candidates)
$
71

 
$
338

 
Work in process (LAVIV)
189

 
144

 
Total inventory, gross
260

 
482

 
Less: Reserve for work in process expiration
(151
)
 
—

 
Total inventory, net
$
109

 
$
482


In connection with the wind-down of the Company’s azficel-T operations, as more fully described in Note 9, the Company recognized inventory write-downs of approximately $0.2 million in cost of goods sold and recorded a reserve for work in process expiration of approximately $0.2 million during the second quarter of 2016. With respect to LAVIV, the Company is no longer accepting new prescriptions.
XML 26 R11.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants
 6 Months Ended
Jun. 30, 2016
Warrants [Abstract]  
Warrants
Warrants

The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. As of June 30, 2016 and December 31, 2015, all of the Company’s outstanding common stock warrants were classified as derivative liabilities and accounted for based on the guidance in ASC 815, Derivatives and Hedging as the warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and hence were determined not to be indexed to the Company’s own stock. The warrants will continue to be classified as a liability, regardless of the likelihood that such instruments will ever be settled in cash, until they are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.

The following table summarizes outstanding liability-classified warrants to purchase common stock:
 
Number of Warrants
 
 
 
 
Liability-classified warrants
June 30, 2016
 
December 31, 2015
 
Exercise
Price
 
Expiration
Dates
Issued in March 2010 financing
—

 
319,789

 
$
6.25

 
Mar 2016
Issued in June 2011 financing
—

 
6,113

 
$
22.50

 
Jun 2016
Issued in Series B and D Preferred Stock offerings
1,970,594

 
1,970,594

 
$
6.25

 
Jul 2016 - Dec 2016
Issued in August 2011 financing
565,759

 
565,759

 
$
18.75

 
Aug 2016
Issued to placement agents in August 2011 financing
50,123

 
50,123

 
$
13.635

 
Aug 2016
Issued in Series E Preferred Stock offering
60,000

 
60,000

 
$
2.50

 
Dec 2017
Issued with Convertible Notes
1,125,578

 
1,125,578

 
$
2.50

 
Jun 2018
Issued in Series E Preferred Stock offering
1,568,823

 
1,568,823

 
$
7.50

 
Dec 2018
Total
5,340,877

 
5,666,779

 
 

 
 

    
The table below is a summary of the Company’s warrant activity during the six months ended June 30, 2016:
 
Number of
warrants
 
Weighted-
average
exercise
price
Outstanding at December 31, 2015
5,666,779

 
$
7.14

Granted
—

 
—

Exercised
—

 
—

Expired
(325,902
)
 
6.55

Outstanding at June 30, 2016
5,340,877

 
$
7.18



Accounting for Liability-classified Warrants

The foregoing warrants were recorded as derivative liabilities at their estimated fair value at the date of issuance, with subsequent changes in estimated fair value recorded in other income or expense in the Company’s Condensed Consolidated Statements of Operations in each subsequent period. The change in the estimated fair value of the warrant liability for the three and six months ended June 30, 2016 resulted in non-cash income of approximately $2.3 million and $7.5 million, respectively. The change in the estimated fair value of the warrant liability for the three and six months ended June 30, 2015 resulted in non-cash income of approximately $0.6 million and non-cash expense of approximately $1.1 million, respectively. The Company utilizes a Monte Carlo simulation valuation method to value its liability-classified warrants.

Assumptions Used in Determining Fair Value of Warrants

The estimated fair value of warrants is determined using Level 2 and Level 3 inputs.  Inherent in the Monte Carlo simulation valuation method are the following assumptions:

Volatility. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected remaining life of the warrants.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the valuation date commensurate with the expected remaining life assumption.

Expected remaining life. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.

Dividend rate. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.

Scenarios.  The probability of complex features of the warrants being triggered is subjective (no observable inputs or available market data) and based on internal and external information known to management at the valuation date.

The following table summarizes the calculated aggregate fair values, along with the inputs and assumptions utilized in each calculation:      
($ in thousands except per share data)
June 30, 2016
 
December 31, 2015
Calculated aggregate value
$
764

 
$
8,275

Weighted average exercise price per share
$
7.18

 
$
7.14

Closing price per share of common stock
$
1.15

 
$
4.55

Volatility
97.2
%
 
85.2
%
Weighted average remaining expected life
1 year, 3 months

 
1 year, 8 months

Risk-free interest rate
0.49
%
 
0.98
%
Dividend yield
—

 
—
XML 27 R12.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Fair Value Measurements
Fair Value Measurements

Assets and Liabilities Measured at Fair Value on a Recurring Basis
    
The Company follows the guidance in ASC 820, Fair Value Measurement, to account for financial assets and liabilities measured at fair value on a recurring basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The guidance requires fair value measurements be classified and disclosed in one of the following three categories within the hierarchy:
•
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
•
Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.
•
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period.

The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 
June 30, 2016
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
8,161

 
$
—

 
$
—

 
$
8,161

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
764

 
$
764

 

 
December 31, 2015
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
29,268

 
$
—

 
$
—

 
$
29,268

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
8,275

 
$
8,275



Changes in Level 3 Liabilities Measured at Fair Value on a Recurring Basis - Common Stock Warrants

The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:
 
Warrant
($ in thousands)
Liability
Balance at December 31, 2015
$
8,275

Expiration of warrants (1)
(62
)
Change in fair value of warrant liability
(7,449
)
Balance at June 30, 2016
$
764



(1)
Represents the fair value as of the beginning of the year for warrants expiring during the year and has been recorded to warrant revaluation income or expense in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2016.

Effect of Fibrocell’s Stock Price and Volatility Assumptions on the Calculation of Fair Value of Warrant Liabilities

The fair value of the warrant liability is based on Level 3 inputs. As discussed in Note 5, the Company uses a Monte Carlo simulation valuation method to value its liability-classified warrants. The determination of fair value as of the reporting date is affected by Fibrocell’s stock price as well as assumptions regarding a number of subjective variables that do not have observable inputs or available market data to support the fair value. These variables include, but are not limited to, expected stock price volatility over the term of the warrants and the risk-free interest rate. The primary factors affecting the fair value of the warrant liability are the Company’s stock price and volatility as well as certain assumptions by the Company as to the likelihood of provisions to the underlying warrant agreements being triggered. The methods described above and in Note 5 may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, while the Company believes its valuation method is appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value could result in a different fair value measurement at the reporting date.

Fair Value of Certain Financial Assets and Liabilities

The Company believes that the fair values of the Company’s current assets and liabilities approximate their reported carrying amounts. There were no transfers between Level 1, 2 and 3 during the periods presented.
XML 28 R13.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation

2009 Equity Incentive Plan

The Company’s Board of Directors (the Board) adopted the 2009 Equity Incentive Plan (as amended to date, the Plan) effective September 3, 2009.  The Plan is intended to further align the interests of the Company and its stockholders with its employees, including its officers, non-employee directors, consultants and advisers by providing equity-based incentives.  The Plan allows for the issuance of up to 7,600,000 shares of the Company’s common stock.  In addition, there are 25,000 options outstanding that were issued outside the Plan to consultants in 2013.

The types of awards that may be granted under the Plan include options (both non-qualified stock options and incentive stock options), stock appreciation rights, stock awards, stock units and other stock-based awards.  The term of each award is determined by the Compensation Committee of the Board at the time each award is granted, provided that the terms of options do not exceed ten years.  Vesting schedules for stock options vary, but generally vest 25% per year over four years for employee options and on the one-year anniversary date for non-employee director options. The Plan had 3,365,103 shares available for future grants as of June 30, 2016.

Accounting for Stock-Based Compensation

The Company recognizes non-cash compensation expense for stock-based awards based on their grant date fair value, determined using the Black-Scholes option-pricing model. During the six months ended June 30, 2016 and 2015, the weighted average fair market value for options granted was $1.53 and $3.57, respectively.

Total stock-based compensation expense recognized using the straight-line attribution method and included in operating expenses in the Condensed Consolidated Statements of Operations was approximately $0.6 million and $0.8 million for the three months ended June 30, 2016 and 2015, respectively, and approximately $1.1 million and $1.0 million for the six months ended June 30, 2016 and 2015, respectively.

Assumptions Used in Determining Fair Value of Stock Options

Inherent in the Black-Scholes option-pricing model are the following assumptions:

Volatility. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected term of the stock options.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected term assumption.

Expected term. The expected term of stock options granted is based on an estimate of when options will be exercised in the future. The Company applied the simplified method of estimating the expected term of the options, described in the SEC’s Staff Accounting Bulletins 107 and 110, as the historical experience is not indicative of the expected behavior in the future. The expected term, calculated under the simplified method, is applied to groups of stock options that have similar contractual terms. Using this method, the expected term is determined using the average of the vesting period and the contractual life of the stock options granted.
Forfeitures. The Company accounts for forfeitures when they occur. Ultimately, the actual expense recognized over the vesting period will be for only those shares that vest.

The fair market value of these stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the six months ended:
 
June 30, 2016
 
June 30, 2015
Expected term
6 years, 1 month

 
6 years, 1 month

Interest rate
1.40
%
 
1.56
%
Dividend yield
—

 
—

Volatility (1)
92.4
%
 
103.3
%
(1)
For the six months ended June 30, 2016, the Company estimated expected volatility based on the historical volatility of its own common stock on a stand-alone basis. Prior to January 1, 2016, including the six months ended June 30, 2015, the Company estimated expected volatility based on the historical volatility of a peer group.

Stock Option Activity
    
The following table summarizes stock option activity for the six months ended June 30, 2016:
($ in thousands except share and per share data)
Number of
shares
 
Weighted-
average
exercise
price
 
Weighted- average
remaining
contractual
term
 
Aggregate
intrinsic
value
Outstanding at December 31, 2015
3,134,094

 
$
6.23

 
8 years
 
$
1,630

Granted
1,091,000

 
2.01

 
 
 
 
Exercised
—

 
—

 
 
 
 
Forfeited
(29,256
)
 
4.61

 
 
 
 
Expired
(188
)
 
4.24

 
 
 
 
Outstanding at June 30, 2016 (1)
4,195,650

 
$
5.15

 
8 years
 
$
43

Exercisable at June 30, 2016
1,954,190

 
$
7.50

 
6 years, 11 months
 
$
—


(1)
Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.

The total fair value of options vested during the six months ended June 30, 2016 was approximately $1.6 million. Additionally, as of June 30, 2016, there was approximately $4.7 million of unrecognized compensation expense related to non-vested stock options which is expected to be recognized over a weighted-average period of 2.8 years.
XML 29 R14.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions
 6 Months Ended
Jun. 30, 2016
Related Party Transactions [Abstract]  
Related Party Transactions
Related Party Transactions

The Company and Intrexon Corporation (Intrexon) are parties to two distinct exclusive channel collaboration agreements including the Exclusive Channel Collaboration Agreement entered into in October 2012 and amended in June 2013 and January 2014 (as amended, the 2012 ECC) and the Exclusive Channel Collaboration Agreement entered into in December 2015 (the 2015 ECC). Pursuant to these agreements, the Company engages Intrexon for support services for the research and development of product candidates covered under the respective agreements and reimburses Intrexon for its cost for time and materials for such work.

For the three months ended June 30, 2016 and 2015, the Company incurred total expenses of $0.9 million and $1.1 million, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, no expenses were incurred for work performed under the 2015 ECC. Of the $0.9 million incurred during the 2016 period, $0.3 million related to direct expenses for work performed by Intrexon and $0.6 million related to pass-through costs. Of the $1.1 million incurred during the 2015 period, $0.8 million related to direct expenses for work performed by Intrexon and $0.3 million related to pass-through costs.

For the six months ended June 30, 2016 and 2015, the Company incurred total expenses of $2.2 million and $2.9 million, respectively, with Intrexon, for work performed under the 2012 ECC. During the same periods, no expenses were incurred for work performed under the 2015 ECC. Of the $2.2 million incurred during the 2016 period, $0.8 million related to direct expenses for work performed by Intrexon and $1.4 million related to pass-through costs. Of the $2.9 million incurred during the 2015 period, $1.7 million related to direct expenses for work performed by Intrexon and $1.2 million related to pass-through costs.

As of June 30, 2016 and December 31, 2015, the Company had outstanding payables to Intrexon of $0.9 million and $10.7 million, respectively. In connection with the 2015 ECC, in consideration for the license and the other rights that the Company receives under the agreement, the Company paid Intrexon an up-front technology access fee of $10 million in cash in January 2016.
Randal J. Kirk is the chairman of the board and chief executive officer of Intrexon and, together with his affiliates, owns more than 50% of Intrexon’s common stock. Affiliates of Randal J. Kirk (including Intrexon) own approximately 38% of our common stock. Additionally, two of our directors, Julian Kirk (who is the son of Randal J. Kirk) and Marcus Smith, are employees of Third Security, LLC, which is an affiliate of Randal J. Kirk.
XML 30 R15.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Costs
 6 Months Ended
Jun. 30, 2016
Restructuring and Related Activities [Abstract]  
Restructuring Costs
Restructuring Costs

In June 2016, the Company determined to wind-down its azficel-T operations at the Company’s Exton, PA facility and to reduce the workforce that supports such operations. This decision enables the Company to focus its resources towards pre-clinical and clinical research and development of its gene-therapy product candidates.

Restructuring-related charges for both the three and six months ended June 30, 2016 totaled approximately $0.3 million and were comprised of approximately $0.3 million of employee severance and benefit related charges and less than $0.1 million of asset impairments.

The restructuring and asset impairment activity for the six months ended June 30, 2016 was as follows:
($ in thousands)
 
Employee Severance and Benefits
 
Asset Impairments
 
Total
Accrued restructuring balance as of December 31, 2015
 
$
—

 
$
—

 
$
—

Additional accruals
 
258

 
34

 
292

Cash payments
 
—

 
—

 
—

Non-cash settlements
 
—

 
(34
)
 
(34
)
Accrued restructuring balance as of June 30, 2016
 
$
258

 
$
—

 
$
258



The restructuring-related charges incurred during the three and six months ended June 30, 2016 related to employee severance and benefits resulting from the reduction-in-workforce and the impairment of property and equipment. In connection with the reduction-in-workforce, 25 positions were eliminated, primarily in the areas of manufacturing and quality operations, representing approximately 50% of the Company's employees. The accrued restructuring balance as of June 30, 2016 relates to employee severance and benefits which are expected to be paid in the third quarter of 2016 and is recorded as a current liability within accrued expenses in the Condensed Consolidated Balance Sheet. Additionally, the Company recognized inventory write-downs in cost of goods sold related to the wind-down of its azficel-T operations as described in Note 4.

The Company expects to incur additional charges in the future for employee severance and benefits, contract termination and wind-down costs, assets impairments and costs to decommission the Company’s azficel-T manufacturing facility, but cannot estimate them at this time.
XML 31 R16.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loss Per Share
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Loss Per Share
Loss Per Share
    
Basic loss per share is computed by dividing net loss for the period by the weighted-average number of shares of common stock outstanding during that period.  The diluted loss per share calculation gives effect to dilutive stock options, warrants and other potentially dilutive common stock equivalents outstanding during the period.  Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock, such as shares issuable pursuant to the exercise of stock options and warrants, assuming the exercise of all in-the-money common stock equivalents based on the average market price during the period.  Common stock equivalents have been excluded where their inclusion would be anti-dilutive.
    
Details in the computation of basic and diluted loss per share are as follows:
 
Three months ended  June 30,
 
Six months ended  June 30,
($ in thousands, except share and per share data)
2016
 
2015
 
2016
 
2015
Loss per share - basic:
 

 
 

 
 

 
 

Numerator for basic loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Basic loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.22
)
 
$
(0.37
)
Loss per share - diluted:
 

 
 

 
 

 
 

Numerator for diluted loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Adjust: Warrant revaluation income (expense) for dilutive warrants
—

 
—

 
1,958

 
—

Net loss attributable to common share
$
(8,092
)
 
$
(6,756
)
 
$
(11,457
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Plus: Incremental shares underlying dilutive warrants outstanding
—

 
—

 
36,034

 
—

Denominator for diluted loss per share
43,898,785

 
40,889,732

 
43,934,819

 
40,875,704

Diluted net loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.26
)
 
$
(0.37
)

     
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive: 
 
Three months ended  June 30,
 
Six months ended  June 30,
 
2016
 
2015
 
2016
 
2015
“In the money” stock options
216,000

 
1,482,614

 
545,500

 
1,518,957

“Out of the money” stock options
3,979,650

 
1,654,200

 
3,556,497

 
1,442,200

“In the money” warrants
—

 
1,201,698

 
—

 
1,201,698

“Out of the money” warrants
5,340,877

 
4,831,352

 
4,751,145

 
4,831,352

 
 
 
 
 
 
 
 
Other securities excluded from the calculation of diluted loss per share:
 
 
 
 
 
 
 
Stock options with performance condition
—

 
100,000

 
—

 
100,000
XML 32 R17.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity
 6 Months Ended
Jun. 30, 2016
Equity [Abstract]  
Equity
Equity

Common Stock - Shares Authorized

In July 2016, the Company amended its Restated Certificate of Incorporation, as amended, to increase the number of shares of common stock that the Company is authorized to issue from 100,000,000 to 150,000,000. The amendment was approved by stockholders in June at the Company’s 2016 Annual Meeting of Stockholders.

Common Stock - “At-The-Market” Equity Program

In January 2016, the Company entered into a Controlled Equity Offering™ Sales Agreement (the ATM Agreement) with Cantor Fitzgerald & Co. (Cantor Fitzgerald) to implement an "At-The-Market" (ATM) equity program under which the Company, from time to time, may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million (the Shares) through Cantor Fitzgerald.

Subject to the terms and conditions of the ATM Agreement, Cantor Fitzgerald will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares, and may at any time suspend sales under the ATM Agreement or terminate the ATM Agreement. Cantor Fitzgerald will be entitled to a fixed commission of up to 3.0% of the gross proceeds from Shares sold. Through June 30, 2016, no Shares have been sold through the ATM equity program.
XML 33 R18.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Policies)
 6 Months Ended
Jun. 30, 2016
Accounting Policies [Abstract]  
General
General

The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by GAAP for complete consolidated financial statements.  In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included.  These financial statements and accompanying notes should be read in conjunction with the consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2015 (2015 Form 10-K), filed with the Securities and Exchange Commission (SEC). The Company’s significant accounting policies are described in the Notes to Consolidated Financial Statements in the 2015 Form 10-K and updated, as necessary, in Note 3 in this Form 10-Q. The results of the Company’s operations for any interim period are not necessarily indicative of the results of operations for any other interim period or full year.

All intercompany accounts and transactions have been eliminated in consolidation. The Company's international operations are immaterial and it has no unrealized gains or losses from the sale of investments. As a result, it does not have any items that would be classified as other comprehensive income in such a statement.
Reclassifications
Reclassifications

The prior year Condensed Consolidated Financial Statements presented in this Form 10-Q contain certain reclassifications made to the Condensed Consolidated Statement of Operations and the Condensed Consolidated Statement of Cash Flows to conform to the current year’s presentation. Specifically, related party payables were reclassified from accounts payable and accrued expenses as of June 30, 2015.
Intangible Assets
Intangible Assets

Intangible assets are research and development assets related to the Company’s primary study on azficel-T that were capitalized on the balance sheet upon emergence from bankruptcy. The portion of the reorganization value which was attributed to identifiable intangible assets was $6.3 million. Azficel-T had two current or target indications: the Company's FDA-approved product LAVIV® and a clinical development program for azficel-T for the treatment of vocal cord scarring resulting in chronic or severe dysphonia. Effective January 1, 2012, the Company launched LAVIV and as a result, the research and development intangible assets related to the Company’s primary study were considered to be finite-lived intangible assets and began amortizing over 12 years, the estimated useful life of the assets which is analogous with the exclusivity period granted to the Company under the BLA.

Finite-lived intangible assets are recorded at cost, net of accumulated amortization and, if applicable, impairment charges. Amortization of finite-lived intangible assets is provided over their estimated useful lives on a straight-line basis. The Company reviews the estimated remaining useful life of its intangible assets on an annual basis with any changes, if applicable, accounted for prospectively. In accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 360-10-35, Impairment or Disposal of Long-Lived Assets, the Company reviews its finite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. In June 2016, based on its failure to achieve primary efficacy endpoints for its Phase II clinical trial of azficel-T for the treatment of vocal cord scarring, the Company determined to wind-down its azficel-T operations as more fully described in Note 9. As a result, management concluded that the Company’s intangible assets had become fully impaired.
Stock-Based Compensation
Stock-Based Compensation

The Company follows ASC 718, Compensation – Stock Compensation (ASC 718), or ASC 505-50, Equity – Equity Based Payments to Non-Employees, where applicable. The Company accounts for stock-based awards to employees using the fair value based method to determine compensation for all arrangements where shares of stock or equity instruments are issued for compensation. In addition, the Company accounts for stock-based compensation to non-employees in accordance with the accounting guidance for equity instruments that are issued to entities or persons other than employees. The Company uses a Black-Scholes option-pricing model to determine the fair value of each option grant as of the date of grant for expense incurred. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, expected stock price volatility and expected term of the options. The value of the award that is ultimately expected to vest based on the achievement of a performance condition (i.e., service period) is recognized as expense on a straight-line basis over the requisite service period. See Note 7 for additional details.

Previously, ASC 718 required forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differed from those estimates. In the first quarter of 2016, the Company adopted FASB Accounting Standards Update (ASU) 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, which allows an entity to elect as an accounting policy either to continue to estimate the total number of awards for which the requisite service period will not be rendered or to account for forfeitures when they occur. In connection with the adoption of this ASU, the Company made an accounting policy election to account for forfeitures as they occur and applied this change in accounting policy on a modified retrospective basis. As a result, the Company recorded a cumulative-effect adjustment to retained earnings which resulted in an increase to accumulated deficit of $0.1 million with an offsetting increase to additional paid-in capital (zero net total equity impact) as of the date of adoption, principally related to additional stock compensation expense that would have been recognized on unvested outstanding options unadjusted for estimated forfeitures.
Restructuring Costs
Restructuring Costs

Restructuring charges are primarily comprised of severance costs related to workforce reductions, contract termination and wind-down costs, asset impairments and costs of decommissioning the Company’s azficel-T manufacturing facility. In accordance with ASC 420, Exit or Disposal Cost Obligations, the Company recognizes restructuring charges when the liability has been incurred, except for one-time employee termination benefits that are incurred over time. Generally, one-time employee termination benefits (i.e. severance costs) are accrued at the date management has committed to a plan of termination and employees have been notified of their termination dates and expected severance payments. Other costs, including but not limited to, contract termination and wind-down costs and manufacturing facility decommissioning costs, will be recorded as incurred. Asset impairment charges have been, and will be, recognized when management has concluded that the assets have been impaired in accordance with ASC 360-10-35, Impairment or Disposal of Long-Lived Assets, or other applicable authoritative guidance.
Income Taxes
Income Taxes
    
In accordance with ASC 270, Interim Reporting, and ASC 740, Income Taxes, the Company is required at the end of each interim period to determine the best estimate of its annual effective tax rate and then apply that rate in providing for income taxes on a current year-to-date (interim period) basis.  For the six months ended June 30, 2016 and 2015, the Company recorded no tax expense or benefit due to the expected current year loss and its historical losses.  The Company has not recorded its net deferred tax asset as of either June 30, 2016 or December 31, 2015 because it maintains a full valuation allowance against all deferred tax assets as management has determined that it is not more likely than not that the Company will realize these future tax benefits.
Recently Issued Accounting Pronouncements
Recently Issued Accounting Pronouncements

Management does not believe that any recently issued accounting pronouncements issued by the FASB or guidance issued by the SEC had or is expected to have a material impact on the Company’s present or future consolidated financial statements.
Assumptions Used in Determining Fair Value of Warrants
The Company accounts for common stock warrants as either equity instruments or derivative liabilities depending on the specific terms of the warrant agreement. As of June 30, 2016 and December 31, 2015, all of the Company’s outstanding common stock warrants were classified as derivative liabilities and accounted for based on the guidance in ASC 815, Derivatives and Hedging as the warrants contain “down-round protection” or other terms that could potentially require “net cash settlement” and hence were determined not to be indexed to the Company’s own stock. The warrants will continue to be classified as a liability, regardless of the likelihood that such instruments will ever be settled in cash, until they are exercised, expire or are amended in a way that would no longer require these warrants to be classified as a liability.
Assumptions Used in Determining Fair Value of Warrants

The estimated fair value of warrants is determined using Level 2 and Level 3 inputs.  Inherent in the Monte Carlo simulation valuation method are the following assumptions:

Volatility. The Company estimates stock price volatility based on the Company’s historical stock price performance over a period of time that matches the expected remaining life of the warrants.

Risk-free interest rate. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the valuation date commensurate with the expected remaining life assumption.

Expected remaining life. The expected life of the warrants is assumed to be equivalent to their remaining contractual term.

Dividend rate. The dividend rate is based on the historical rate, which the Company anticipates will remain at zero.

Scenarios.  The probability of complex features of the warrants being triggered is subjective (no observable inputs or available market data) and based on internal and external information known to management at the valuation date.
Assets and Liabilities Measured at Fair Value on a Recurring Basis
Assets and Liabilities Measured at Fair Value on a Recurring Basis
    
The Company follows the guidance in ASC 820, Fair Value Measurement, to account for financial assets and liabilities measured at fair value on a recurring basis. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. The Company uses a fair value hierarchy, which distinguishes between assumptions based on market data (observable inputs) and an entity’s own assumptions (unobservable inputs). The guidance requires fair value measurements be classified and disclosed in one of the following three categories within the hierarchy:
•
Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
•
Level 2: Quoted prices in markets that are not active or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability.
•
Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity).

Determining which category an asset or liability falls within the hierarchy requires significant judgment. The Company evaluates its hierarchy disclosures each reporting period.
XML 34 R19.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory (Tables)
 6 Months Ended
Jun. 30, 2016
Inventory Disclosure [Abstract]  
Inventories
Inventories consisted of the following as of:
 
($ in thousands)
June 30, 2016
 
December 31, 2015
 
 
Raw materials (LAVIV and product candidates)
$
71

 
$
338

 
Work in process (LAVIV)
189

 
144

 
Total inventory, gross
260

 
482

 
Less: Reserve for work in process expiration
(151
)
 
—

 
Total inventory, net
$
109

 
$
482
XML 35 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants (Tables)
 6 Months Ended
Jun. 30, 2016
Warrants [Abstract]  
Outstanding Warrants to Purchase Common Stock
The following table summarizes outstanding liability-classified warrants to purchase common stock:
 
Number of Warrants
 
 
 
 
Liability-classified warrants
June 30, 2016
 
December 31, 2015
 
Exercise
Price
 
Expiration
Dates
Issued in March 2010 financing
—

 
319,789

 
$
6.25

 
Mar 2016
Issued in June 2011 financing
—

 
6,113

 
$
22.50

 
Jun 2016
Issued in Series B and D Preferred Stock offerings
1,970,594

 
1,970,594

 
$
6.25

 
Jul 2016 - Dec 2016
Issued in August 2011 financing
565,759

 
565,759

 
$
18.75

 
Aug 2016
Issued to placement agents in August 2011 financing
50,123

 
50,123

 
$
13.635

 
Aug 2016
Issued in Series E Preferred Stock offering
60,000

 
60,000

 
$
2.50

 
Dec 2017
Issued with Convertible Notes
1,125,578

 
1,125,578

 
$
2.50

 
Jun 2018
Issued in Series E Preferred Stock offering
1,568,823

 
1,568,823

 
$
7.50

 
Dec 2018
Total
5,340,877

 
5,666,779

 
 

 
 
Schedule of Warrants Outstanding Roll Forward
The table below is a summary of the Company’s warrant activity during the six months ended June 30, 2016:
 
Number of
warrants
 
Weighted-
average
exercise
price
Outstanding at December 31, 2015
5,666,779

 
$
7.14

Granted
—

 
—

Exercised
—

 
—

Expired
(325,902
)
 
6.55

Outstanding at June 30, 2016
5,340,877

 
$
7.18
Summary of Other Assumptions Used by Entity
The following table summarizes the calculated aggregate fair values, along with the inputs and assumptions utilized in each calculation:      
($ in thousands except per share data)
June 30, 2016
 
December 31, 2015
Calculated aggregate value
$
764

 
$
8,275

Weighted average exercise price per share
$
7.18

 
$
7.14

Closing price per share of common stock
$
1.15

 
$
4.55

Volatility
97.2
%
 
85.2
%
Weighted average remaining expected life
1 year, 3 months

 
1 year, 8 months

Risk-free interest rate
0.49
%
 
0.98
%
Dividend yield
—

 
—
XML 36 R21.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements (Tables)
 6 Months Ended
Jun. 30, 2016
Fair Value Disclosures [Abstract]  
Company's Financial Assets and Liability Measured at Fair Value on a Recurring Basis
The following fair value hierarchy table presents information about each major category of the Company’s financial assets and liabilities measured at fair value on a recurring basis as of:
 
June 30, 2016
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
8,161

 
$
—

 
$
—

 
$
8,161

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
764

 
$
764

 

 
December 31, 2015
($ in thousands) 
Level 1
 
Level 2
 
Level 3
 
Total
Assets:
 

 
 

 
 

 
 

Cash and cash equivalents
$
29,268

 
$
—

 
$
—

 
$
29,268

Liabilities:
 

 
 

 
 

 
 

Warrant liability
$
—

 
$
—

 
$
8,275

 
$
8,275
Reconciliation of Warrant Liability Measured at Fair Value on Recurring Basis
The reconciliation of the warrant liability measured at fair value on a recurring basis using unobservable inputs (Level 3) was as follows:
 
Warrant
($ in thousands)
Liability
Balance at December 31, 2015
$
8,275

Expiration of warrants (1)
(62
)
Change in fair value of warrant liability
(7,449
)
Balance at June 30, 2016
$
764



(1)
Represents the fair value as of the beginning of the year for warrants expiring during the year and has been recorded to warrant revaluation income or expense in the Condensed Consolidated Statement of Operations for the six months ended June 30, 2016.
XML 37 R22.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation (Tables)
 6 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Schedule of Share-based Payment Award, Employee Stock Purchase Plan, Valuation Assumptions
The fair market value of these stock options at the date of grant was estimated using the Black-Scholes option-pricing model with the following weighted average assumptions for the six months ended:
 
June 30, 2016
 
June 30, 2015
Expected term
6 years, 1 month

 
6 years, 1 month

Interest rate
1.40
%
 
1.56
%
Dividend yield
—

 
—

Volatility (1)
92.4
%
 
103.3
%
(1)
For the six months ended June 30, 2016, the Company estimated expected volatility based on the historical volatility of its own common stock on a stand-alone basis. Prior to January 1, 2016, including the six months ended June 30, 2015, the Company estimated expected volatility based on the historical volatility of a peer group.
Summary of Stock Option Activity
The following table summarizes stock option activity for the six months ended June 30, 2016:
($ in thousands except share and per share data)
Number of
shares
 
Weighted-
average
exercise
price
 
Weighted- average
remaining
contractual
term
 
Aggregate
intrinsic
value
Outstanding at December 31, 2015
3,134,094

 
$
6.23

 
8 years
 
$
1,630

Granted
1,091,000

 
2.01

 
 
 
 
Exercised
—

 
—

 
 
 
 
Forfeited
(29,256
)
 
4.61

 
 
 
 
Expired
(188
)
 
4.24

 
 
 
 
Outstanding at June 30, 2016 (1)
4,195,650

 
$
5.15

 
8 years
 
$
43

Exercisable at June 30, 2016
1,954,190

 
$
7.50

 
6 years, 11 months
 
$
—


(1)
Includes both vested stock options as well as unvested stock options for which the requisite service period has not been rendered but that are expected to vest based on achievement of a service condition.
XML 38 R23.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Costs (Tables)
 6 Months Ended
Jun. 30, 2016
Restructuring and Related Activities [Abstract]  
Restructuring and Related Costs
Restructuring-related charges for both the three and six months ended June 30, 2016 totaled approximately $0.3 million and were comprised of approximately $0.3 million of employee severance and benefit related charges and less than $0.1 million of asset impairments.

The restructuring and asset impairment activity for the six months ended June 30, 2016 was as follows:
($ in thousands)
 
Employee Severance and Benefits
 
Asset Impairments
 
Total
Accrued restructuring balance as of December 31, 2015
 
$
—

 
$
—

 
$
—

Additional accruals
 
258

 
34

 
292

Cash payments
 
—

 
—

 
—

Non-cash settlements
 
—

 
(34
)
 
(34
)
Accrued restructuring balance as of June 30, 2016
 
$
258

 
$
—

 
$
258
XML 39 R24.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loss Per Share (Tables)
 6 Months Ended
Jun. 30, 2016
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Details in the computation of basic and diluted loss per share are as follows:
 
Three months ended  June 30,
 
Six months ended  June 30,
($ in thousands, except share and per share data)
2016
 
2015
 
2016
 
2015
Loss per share - basic:
 

 
 

 
 

 
 

Numerator for basic loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Basic loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.22
)
 
$
(0.37
)
Loss per share - diluted:
 

 
 

 
 

 
 

Numerator for diluted loss per share
$
(8,092
)
 
$
(6,756
)
 
$
(9,499
)
 
$
(15,281
)
Adjust: Warrant revaluation income (expense) for dilutive warrants
—

 
—

 
1,958

 
—

Net loss attributable to common share
$
(8,092
)
 
$
(6,756
)
 
$
(11,457
)
 
$
(15,281
)
Denominator for basic loss per share
43,898,785

 
40,889,732

 
43,898,785

 
40,875,704

Plus: Incremental shares underlying dilutive warrants outstanding
—

 
—

 
36,034

 
—

Denominator for diluted loss per share
43,898,785

 
40,889,732

 
43,934,819

 
40,875,704

Diluted net loss per common share
$
(0.18
)
 
$
(0.17
)
 
$
(0.26
)
 
$
(0.37
)
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding, as their effect would be anti-dilutive: 
 
Three months ended  June 30,
 
Six months ended  June 30,
 
2016
 
2015
 
2016
 
2015
“In the money” stock options
216,000

 
1,482,614

 
545,500

 
1,518,957

“Out of the money” stock options
3,979,650

 
1,654,200

 
3,556,497

 
1,442,200

“In the money” warrants
—

 
1,201,698

 
—

 
1,201,698

“Out of the money” warrants
5,340,877

 
4,831,352

 
4,751,145

 
4,831,352

 
 
 
 
 
 
 
 
Other securities excluded from the calculation of diluted loss per share:
 
 
 
 
 
 
 
Stock options with performance condition
—

 
100,000

 
—

 
100,000
XML 40 R25.htm IDEA: XBRL DOCUMENT v3.5.0.2
Business and Organization (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Jun. 30, 2015
Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 8,161 $ 29,268 $ 26,850 $ 37,495
Working capital $ 5,800      
XML 41 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
Summary of Significant Accounting Policies (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jan. 01, 2012
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Sep. 03, 2009
New Accounting Pronouncement, Early Adoption [Line Items]              
Intangible assets   $ 0   $ 0   $ 4,136 $ 6,300
Useful life 12 years            
Intangible asset impairment   3,905 $ 0 3,905 $ 0    
Income tax expense (benefit)   $ 0 $ 0 $ 0 $ 0    
Accumulated deficit              
New Accounting Pronouncement, Early Adoption [Line Items]              
Cumulative effect from adoption of new accounting standard           (100)  
Additional paid-in capital              
New Accounting Pronouncement, Early Adoption [Line Items]              
Cumulative effect from adoption of new accounting standard           100  
Accounting Standards Update 2016-09 | Accumulated deficit | New Accounting Pronouncement, Early Adoption, Effect              
New Accounting Pronouncement, Early Adoption [Line Items]              
Cumulative effect from adoption of new accounting standard           (100)  
Accounting Standards Update 2016-09 | Additional paid-in capital | New Accounting Pronouncement, Early Adoption, Effect              
New Accounting Pronouncement, Early Adoption [Line Items]              
Cumulative effect from adoption of new accounting standard           $ 100  
XML 42 R27.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory (Details) - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Inventory Disclosure [Abstract]    
Raw materials (LAVIV and product candidates) $ 71 $ 338
Work in process (LAVIV) 189 144
Total inventory, gross 260 482
Reserve for work in process expiration (151) 0
Total inventory, net $ 109 $ 482
XML 43 R28.htm IDEA: XBRL DOCUMENT v3.5.0.2
Inventory - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Inventory [Line Items]    
Reserve for work in process expiration $ 151 $ 0
Cost of Sales    
Inventory [Line Items]    
Inventory write-down $ 200  
XML 44 R29.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants - Liability-Classified Warrants Outstanding (Details) - $ / shares
Jun. 30, 2016
Dec. 31, 2015
Warrants    
Warrants issued to purchase common stock (shares) 5,340,877 5,666,779
Warrant exercise price (in dollars per share) $ 7.18 $ 7.14
Issued in March 2010 financing    
Warrants    
Warrants issued to purchase common stock (shares) 0 319,789
Warrant exercise price (in dollars per share) $ 6.25  
Issued in June 2011 financing    
Warrants    
Warrants issued to purchase common stock (shares) 0 6,113
Warrant exercise price (in dollars per share) $ 22.50  
Issued in Series B and D Preferred Stock offerings    
Warrants    
Warrants issued to purchase common stock (shares) 1,970,594 1,970,594
Warrant exercise price (in dollars per share) $ 6.25  
Issued in August 2011 financing    
Warrants    
Warrants issued to purchase common stock (shares) 565,759 565,759
Warrant exercise price (in dollars per share) $ 18.75  
Issued to placement agents in August 2011 financing    
Warrants    
Warrants issued to purchase common stock (shares) 50,123 50,123
Warrant exercise price (in dollars per share) $ 13.635  
Issued in Series E Preferred Stock offering    
Warrants    
Warrants issued to purchase common stock (shares) 60,000 60,000
Warrant exercise price (in dollars per share) $ 2.50  
Issued with Convertible Notes    
Warrants    
Warrants issued to purchase common stock (shares) 1,125,578 1,125,578
Warrant exercise price (in dollars per share) $ 2.50  
Issued in Series E Preferred Stock offering    
Warrants    
Warrants issued to purchase common stock (shares) 1,568,823 1,568,823
Warrant exercise price (in dollars per share) $ 7.50  
XML 45 R30.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants - Warrant Activity (Details)
 6 Months Ended
Jun. 30, 2016
$ / shares
shares
Increase (Decrease) in Warrants Outstanding [Roll Forward]  
Beginning balance, number of warrants outstanding (shares) | shares 5,666,779
Number of warrants granted during the period (shares) | shares 0
Number of warrants exercised during the period (shares) | shares 0
Number of warrants expired during the period (shares) | shares (325,902)
Ending balance, number of warrants outstanding (shares) | shares 5,340,877
Beginning balance, weighted-average exercise price (usd per share) | $ / shares $ 7.14
Weighted-average exercise price, warrants granted during the period (usd per share) | $ / shares 0.00
Weighted-average exercise price, warrants exercised during the period (usd per share) | $ / shares 0.00
Weighted-average exercise price, warrants expired during the period (usd per share) | $ / shares 6.55
Ending balance, weighted-average exercise price (usd per share) | $ / shares $ 7.18
XML 46 R31.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants - Narrative (Details) - USD ($)
$ in Millions
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Warrant | Level 3        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Non-cash expense (income) $ (2.3) $ (0.6) $ (7.5) $ 1.1
XML 47 R32.htm IDEA: XBRL DOCUMENT v3.5.0.2
Warrants - Aggregate Fair Values, Inputs and Assumptions (Details) - Warrant Liability - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Fair value assumptions    
Calculated aggregate value $ 764 $ 8,275
Weighted average exercise price per share (usd per share) $ 7.18 $ 7.14
Closing price per share of common stock (usd per share) $ 1.15 $ 4.55
Volatility (as a percent) 97.20% 85.20%
Weighted average remaining expected life 1 year 3 months 1 year 8 months
Risk-free interest rate (as a percent) 0.49% 0.98%
Dividend yield 0.00% 0.00%
XML 48 R33.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements - Fair Value Hierarchy (Details) - Recurring - Measured at fair value - USD ($)
$ in Thousands
Jun. 30, 2016
Dec. 31, 2015
Assets    
Cash and cash equivalents $ 8,161 $ 29,268
Liabilities    
Warrant liability 764 8,275
Level 1    
Assets    
Cash and cash equivalents 8,161 29,268
Liabilities    
Warrant liability 0 0
Level 2    
Assets    
Cash and cash equivalents 0 0
Liabilities    
Warrant liability 0 0
Level 3    
Assets    
Cash and cash equivalents 0 0
Liabilities    
Warrant liability $ 764 $ 8,275
XML 49 R34.htm IDEA: XBRL DOCUMENT v3.5.0.2
Fair Value Measurements - Warrant Liability Reconciliation (Details) - Warrant
$ in Thousands
 6 Months Ended
Jun. 30, 2016
USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
December 31, 2015 $ 8,275
Expiration of warrants (62)
Change in fair value of warrant liability (7,449)
June 30, 2016 $ 764
XML 50 R35.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Narrative (Details) - USD ($)
$ / shares in Units, $ in Millions
 3 Months Ended 6 Months Ended
Sep. 03, 2009
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Dec. 31, 2015
Dec. 31, 2013
Equity-based compensation              
Options issued (in shares)   4,195,650   4,195,650   3,134,094  
Weighted average fair market value of options granted (in dollars per share)       $ 1.53 $ 3.57    
Stock-based compensation expense   $ 0.6 $ 0.8 $ 1.1 $ 1.0    
Fair value of options vested       1.6      
Service Based Stock Options              
Equity-based compensation              
Unrecognized compensation cost   $ 4.7   $ 4.7      
Recognition period (years)       2 years 9 months      
The Plan              
Equity-based compensation              
Number of shares allowed for issuance (in shares) 7,600,000            
The Plan | Options              
Equity-based compensation              
Terms of options, not to exceed (in years) 10 years            
Vesting percentage per year 25.00%            
Vesting period (in years) 4 years            
Options available for grant (in shares)   3,365,103   3,365,103      
Equity incentive outside of the Plan | Options              
Equity-based compensation              
Options issued (in shares)             25,000
Director | The Plan | Options              
Equity-based compensation              
Vesting period (in years) 1 year            
XML 51 R36.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Weighted Average Assumptions (Details)
 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]    
Expected life 6 years 1 month 6 years 1 month
Interest rate 1.40% 1.56%
Dividend yield 0.00% 0.00%
Volatility 92.40% 103.30%
XML 52 R37.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation - Stock Option Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
 6 Months Ended 12 Months Ended
Jun. 30, 2016
Dec. 31, 2015
Number of shares    
Outstanding at beginning of period (in shares) 3,134,094  
Granted (in shares) 1,091,000  
Exercised (shares) 0  
Forfeited (in shares) (29,256)  
Expired (in shares) (188)  
Outstanding at end of period (in shares) 4,195,650 3,134,094
Exercisable at end of period (in shares) 1,954,190  
Weighted-average exercise price    
Outstanding at beginning of period (in dollars per share) $ 6.23  
Granted (in dollars per share) 2.01  
Exercised (in dollars per share) 0.00  
Forfeited (in dollars per share) 4.61  
Expired (in dollars per share) 4.24  
Outstanding at end of period (in dollars per share) 5.15 $ 6.23
Exercisable at end of period (in dollars per share) $ 7.50  
Additional disclosures    
Weighted-average remaining contractual term (in years), outstanding 8 years 8 years
Weighted-average remaining contractual term (in years), exercisable 6 years 11 months  
Aggregate intrinsic value, outstanding $ 43 $ 1,630
Aggregate intrinsic value, exercisable $ 0  
XML 53 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2
Related Party Transactions (Details)
 1 Months Ended 3 Months Ended 6 Months Ended
Jan. 31, 2016
USD ($)
Jun. 30, 2016
USD ($)
agreement
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
director
agreement
Jun. 30, 2015
USD ($)
Dec. 31, 2015
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Number of exclusive channel collaboration agreements (agreement) | agreement   2   2    
Technology Access Fee            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Fees to Intrexon $ 10,000,000          
Affiliated Entity            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expenses for work performed   $ 900,000 $ 1,100,000 $ 2,200,000 $ 2,900,000  
Outstanding payables to Intrexon   $ 900,000   $ 900,000   $ 10,700,000
Shareholder ownership percentage of related party in affiliate, more than   50.00%   50.00%    
Shareholder ownership percentage   38.00%   38.00%    
Affiliated Entity | 2015 ECC            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expenses for work performed       $ 0 0  
Affiliated Entity | Direct Expenses for Work Performed            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expenses for work performed   $ 300,000 800,000 800,000 1,700,000  
Affiliated Entity | Pass-through Costs            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Expenses for work performed   $ 600,000 $ 300,000 $ 1,400,000 $ 1,200,000  
Director            
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]            
Number of directors (director) | director       2    
XML 54 R39.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Costs (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
USD ($)
Jun. 30, 2015
USD ($)
Jun. 30, 2016
USD ($)
employee
Jun. 30, 2015
USD ($)
Restructuring Cost and Reserve [Line Items]        
Restructuring costs $ 292 $ 0 $ 292 $ 0
Number of employees impacted by reduction-in-force (employee) | employee     25  
Percent of employee base impacted     50.00%  
Employee Severance and Benefits        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs     $ 258  
Asset Impairments        
Restructuring Cost and Reserve [Line Items]        
Restructuring costs $ 34   $ 34  
XML 55 R40.htm IDEA: XBRL DOCUMENT v3.5.0.2
Restructuring Costs - Changes in Restructuring Balance (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Restructuring Reserve [Roll Forward]        
Accrued restructuring, beginning balance     $ 0  
Additional accruals $ 292 $ 0 292 $ 0
Cash payments     0  
Non-cash settlements     (34)  
Accrued restructuring, ending balance 258   258  
Employee Severance and Benefits        
Restructuring Reserve [Roll Forward]        
Accrued restructuring, beginning balance     0  
Additional accruals     258  
Cash payments     0  
Non-cash settlements     0  
Accrued restructuring, ending balance 258   258  
Asset Impairments        
Restructuring Reserve [Roll Forward]        
Accrued restructuring, beginning balance     0  
Additional accruals 34   34  
Cash payments     0  
Non-cash settlements     (34)  
Accrued restructuring, ending balance $ 0   $ 0  
XML 56 R41.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loss Per Share - Earnings Per Share (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Loss per share - basic:        
Numerator for basic loss per share $ (8,092) $ (6,756) $ (9,499) $ (15,281)
Denominator for basic loss per share (shares) 43,898,785 40,889,732 43,898,785 40,875,704
Basic loss per common share (usd per share) $ (0.18) $ (0.17) $ (0.22) $ (0.37)
Loss per share - diluted:        
Numerator for diluted loss per share $ (8,092) $ (6,756) $ (9,499) $ (15,281)
Adjust: Warrant revaluation income (expense) for dilutive warrants 0 0 1,958 0
Net loss attributable to common share $ (8,092) $ (6,756) $ (11,457) $ (15,281)
Denominator for basic loss per share (shares) 43,898,785 40,889,732 43,898,785 40,875,704
Plus: Incremental shares underlying dilutive warrants outstanding (shares) 0 0 36,034 0
Denominator for diluted loss per share (shares) 43,898,785 40,889,732 43,934,819 40,875,704
Diluted net loss per common share (usd per share) $ (0.18) $ (0.17) $ (0.26) $ (0.37)
XML 57 R42.htm IDEA: XBRL DOCUMENT v3.5.0.2
Loss Per Share - Antidilutive Securities (Details) - shares
 3 Months Ended 6 Months Ended
Jun. 30, 2016
Jun. 30, 2015
Jun. 30, 2016
Jun. 30, 2015
Performance based options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from EPS (shares) 0 100,000 0 100,000
“In the money” stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from EPS (shares) 216,000 1,482,614 545,500 1,518,957
“Out of the money” stock options        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from EPS (shares) 3,979,650 1,654,200 3,556,497 1,442,200
“In the money” warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from EPS (shares) 0 1,201,698 0 1,201,698
“Out of the money” warrants        
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]        
Antidilutive securities excluded from EPS (shares) 5,340,877 4,831,352 4,751,145 4,831,352
XML 58 R43.htm IDEA: XBRL DOCUMENT v3.5.0.2
Equity (Details) - USD ($)
 1 Months Ended 6 Months Ended
Jan. 31, 2016
Jun. 30, 2016
Mar. 31, 2016
Dec. 31, 2015
Class of Stock [Line Items]        
Common stock, shares authorized (shares)   150,000,000 100,000,000 100,000,000
Cantor Fitzgerald & Co.        
Class of Stock [Line Items]        
Stock issued during the period (shares)   0    
Cantor Fitzgerald & Co. | Common Stock        
Class of Stock [Line Items]        
Aggregate offering price $ 50,000,000.0      
Cantor Fitzgerald & Co.        
Class of Stock [Line Items]        
Fixed commission (percent) 3.00%      
EXCEL 59 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 60 Show.js IDEA: XBRL DOCUMENT /** * Rivet Software Inc. * * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved. * Version 2.4.0.3 * */ var Show = {}; Show.LastAR = null, Show.hideAR = function(){ Show.LastAR.style.display = 'none'; }; Show.showAR = function ( link, id, win ){ if( Show.LastAR ){ Show.hideAR(); } var ref = link; do { ref = ref.nextSibling; } while (ref && ref.nodeName != 'TABLE'); if (!ref || ref.nodeName != 'TABLE') { var tmp = win ? win.document.getElementById(id) : document.getElementById(id); if( tmp ){ ref = tmp.cloneNode(true); ref.id = ''; link.parentNode.appendChild(ref); } } if( ref ){ ref.style.display = 'block'; Show.LastAR = ref; } }; Show.toggleNext = function( link ){ var ref = link; do{ ref = ref.nextSibling; }while( ref.nodeName != 'DIV' ); if( ref.style && ref.style.display && ref.style.display == 'none' ){ ref.style.display = 'block'; if( link.textContent ){ link.textContent = link.textContent.replace( '+', '-' ); }else{ link.innerText = link.innerText.replace( '+', '-' ); } }else{ ref.style.display = 'none'; if( link.textContent ){ link.textContent = link.textContent.replace( '-', '+' ); }else{ link.innerText = link.innerText.replace( '-', '+' ); } } }; XML 61 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 63 FilingSummary.xml IDEA: XBRL DOCUMENT 3.5.0.2 html 114 198 1 false 42 0 false 7 false false R1.htm 0001000 - Document - Document and Entity Information Sheet http://www.fibrocell.com/role/DocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 1001000 - Statement - Condensed Consolidated Balance Sheets (unaudited) Sheet http://www.fibrocell.com/role/CondensedConsolidatedBalanceSheetsUnaudited Condensed Consolidated Balance Sheets (unaudited) Statements 2 false false R3.htm 1001501 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Sheet http://www.fibrocell.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) Statements 3 false false R4.htm 1002000 - Statement - Condensed Consolidated Statements of Operations (unaudited) Sheet http://www.fibrocell.com/role/CondensedConsolidatedStatementsOfOperationsUnaudited Condensed Consolidated Statements of Operations (unaudited) Statements 4 false false R5.htm 1003000 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) Sheet http://www.fibrocell.com/role/CondensedConsolidatedStatementsOfStockholdersEquityUnaudited Condensed Consolidated Statements of Stockholders' Equity (unaudited) Statements 5 false false R6.htm 1004000 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) Sheet http://www.fibrocell.com/role/CondensedConsolidatedStatementsOfCashFlowsUnaudited Condensed Consolidated Statements of Cash Flows (unaudited) Statements 6 false false R7.htm 2101100 - Disclosure - Business and Organization Sheet http://www.fibrocell.com/role/BusinessAndOrganization Business and Organization Notes 7 false false R8.htm 2102100 - Disclosure - Basis of Presentation Sheet http://www.fibrocell.com/role/BasisOfPresentation Basis of Presentation Notes 8 false false R9.htm 2103100 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.fibrocell.com/role/SummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 2104100 - Disclosure - Inventory Sheet http://www.fibrocell.com/role/Inventory Inventory Notes 10 false false R11.htm 2105100 - Disclosure - Warrants Sheet http://www.fibrocell.com/role/Warrants Warrants Notes 11 false false R12.htm 2106100 - Disclosure - Fair Value Measurements Sheet http://www.fibrocell.com/role/FairValueMeasurements Fair Value Measurements Notes 12 false false R13.htm 2107100 - Disclosure - Stock-Based Compensation Sheet http://www.fibrocell.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 2108100 - Disclosure - Related Party Transactions Sheet http://www.fibrocell.com/role/RelatedPartyTransactions Related Party Transactions Notes 14 false false R15.htm 2109100 - Disclosure - Restructuring Costs Sheet http://www.fibrocell.com/role/RestructuringCosts Restructuring Costs Notes 15 false false R16.htm 2111100 - Disclosure - Loss Per Share Sheet http://www.fibrocell.com/role/LossPerShare Loss Per Share Notes 16 false false R17.htm 2112100 - Disclosure - Equity Sheet http://www.fibrocell.com/role/Equity Equity Notes 17 false false R18.htm 2203201 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.fibrocell.com/role/SummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://www.fibrocell.com/role/SummaryOfSignificantAccountingPolicies 18 false false R19.htm 2304301 - Disclosure - Inventory (Tables) Sheet http://www.fibrocell.com/role/InventoryTables Inventory (Tables) Tables http://www.fibrocell.com/role/Inventory 19 false false R20.htm 2305301 - Disclosure - Warrants (Tables) Sheet http://www.fibrocell.com/role/WarrantsTables Warrants (Tables) Tables http://www.fibrocell.com/role/Warrants 20 false false R21.htm 2306301 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.fibrocell.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.fibrocell.com/role/FairValueMeasurements 21 false false R22.htm 2307301 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.fibrocell.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.fibrocell.com/role/StockBasedCompensation 22 false false R23.htm 2309301 - Disclosure - Restructuring Costs (Tables) Sheet http://www.fibrocell.com/role/RestructuringCostsTables Restructuring Costs (Tables) Tables http://www.fibrocell.com/role/RestructuringCosts 23 false false R24.htm 2311301 - Disclosure - Loss Per Share (Tables) Sheet http://www.fibrocell.com/role/LossPerShareTables Loss Per Share (Tables) Tables http://www.fibrocell.com/role/LossPerShare 24 false false R25.htm 2401401 - Disclosure - Business and Organization (Details) Sheet http://www.fibrocell.com/role/BusinessAndOrganizationDetails Business and Organization (Details) Details http://www.fibrocell.com/role/BusinessAndOrganization 25 false false R26.htm 2403402 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.fibrocell.com/role/SummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://www.fibrocell.com/role/SummaryOfSignificantAccountingPoliciesPolicies 26 false false R27.htm 2404402 - Disclosure - Inventory (Details) Sheet http://www.fibrocell.com/role/InventoryDetails Inventory (Details) Details http://www.fibrocell.com/role/InventoryTables 27 false false R28.htm 2404403 - Disclosure - Inventory - Narrative (Details) Sheet http://www.fibrocell.com/role/InventoryNarrativeDetails Inventory - Narrative (Details) Details 28 false false R29.htm 2405402 - Disclosure - Warrants - Liability-Classified Warrants Outstanding (Details) Sheet http://www.fibrocell.com/role/WarrantsLiabilityClassifiedWarrantsOutstandingDetails Warrants - Liability-Classified Warrants Outstanding (Details) Details 29 false false R30.htm 2405403 - Disclosure - Warrants - Warrant Activity (Details) Sheet http://www.fibrocell.com/role/WarrantsWarrantActivityDetails Warrants - Warrant Activity (Details) Details 30 false false R31.htm 2405404 - Disclosure - Warrants - Narrative (Details) Sheet http://www.fibrocell.com/role/WarrantsNarrativeDetails Warrants - Narrative (Details) Details 31 false false R32.htm 2405405 - Disclosure - Warrants - Aggregate Fair Values, Inputs and Assumptions (Details) Sheet http://www.fibrocell.com/role/WarrantsAggregateFairValuesInputsAndAssumptionsDetails Warrants - Aggregate Fair Values, Inputs and Assumptions (Details) Details 32 false false R33.htm 2406402 - Disclosure - Fair Value Measurements - Fair Value Hierarchy (Details) Sheet http://www.fibrocell.com/role/FairValueMeasurementsFairValueHierarchyDetails Fair Value Measurements - Fair Value Hierarchy (Details) Details 33 false false R34.htm 2406403 - Disclosure - Fair Value Measurements - Warrant Liability Reconciliation (Details) Sheet http://www.fibrocell.com/role/FairValueMeasurementsWarrantLiabilityReconciliationDetails Fair Value Measurements - Warrant Liability Reconciliation (Details) Details 34 false false R35.htm 2407402 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.fibrocell.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 35 false false R36.htm 2407403 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details) Sheet http://www.fibrocell.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails Stock-Based Compensation - Weighted Average Assumptions (Details) Details 36 false false R37.htm 2407404 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details) Sheet http://www.fibrocell.com/role/StockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock Option Activity (Details) Details 37 false false R38.htm 2408401 - Disclosure - Related Party Transactions (Details) Sheet http://www.fibrocell.com/role/RelatedPartyTransactionsDetails Related Party Transactions (Details) Details http://www.fibrocell.com/role/RelatedPartyTransactions 38 false false R39.htm 2409402 - Disclosure - Restructuring Costs (Details) Sheet http://www.fibrocell.com/role/RestructuringCostsDetails Restructuring Costs (Details) Details http://www.fibrocell.com/role/RestructuringCostsTables 39 false false R40.htm 2409403 - Disclosure - Restructuring Costs - Changes in Restructuring Balance (Details) Sheet http://www.fibrocell.com/role/RestructuringCostsChangesInRestructuringBalanceDetails Restructuring Costs - Changes in Restructuring Balance (Details) Details 40 false false R41.htm 2411402 - Disclosure - Loss Per Share - Earnings Per Share (Details) Sheet http://www.fibrocell.com/role/LossPerShareEarningsPerShareDetails Loss Per Share - Earnings Per Share (Details) Details 41 false false R42.htm 2411403 - Disclosure - Loss Per Share - Antidilutive Securities (Details) Sheet http://www.fibrocell.com/role/LossPerShareAntidilutiveSecuritiesDetails Loss Per Share - Antidilutive Securities (Details) Details 42 false false R43.htm 2412401 - Disclosure - Equity (Details) Sheet http://www.fibrocell.com/role/EquityDetails Equity (Details) Details http://www.fibrocell.com/role/Equity 43 false false All Reports Book All Reports fcsc-20160630.xml fcsc-20160630.xsd fcsc-20160630_cal.xml fcsc-20160630_def.xml fcsc-20160630_lab.xml fcsc-20160630_pre.xml true true ZIP 65 0000357097-16-000179-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000357097-16-000179-xbrl.zip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